



Leading European Nephrology

ERA-EDTA Registry

Annual
Report
2013

ISBN 978-90-817480-5-6

Suggested Citation ERA-EDTA Registry: ERA-EDTA Registry Annual Report 2013. Academic Medical Center, Department of Medical Informatics, Amsterdam, The Netherlands, 2015

Disclaimer ERA-EDTA, its Registry Committee, AMC and its department of Medical Informatics disclaim any express or implied warranty of fitness for the use of ERA-EDTA Registry products and shall not be liable for any direct, indirect or consequential loss; personal injury; special or punitive damages; loss of profits, loss of savings and loss of revenue; loss of business, loss of reputation and loss of goodwill; and loss of data arising from the use of ERA-EDTA Registry products.

ERA-EDTA Registry
Annual Report 2013

ERA-EDTA Registry

Academic Medical Center
Department of Medical Informatics
PO Box 22700
1100 DE Amsterdam
The Netherlands

Telephone +31 20 566 7637
E-mail erareg@amc.uva.nl
Website www.era-edta-reg.org

ERA-EDTA Registry Committee

A Więcek, Poland (ERA-EDTA President)

C Wanner, Germany (Chairman)

FJ Caskey, United Kingdom

F Collart, Belgium

C Couchoud, France

D Fouque, France

JW Groothoff, The Netherlands

JG Heaf, Denmark

P Ravani, Italy

I Rychlik, Czech Republic

F Schaefer, Germany

S Schön, Sweden

Registry Office Staff

KJ Jager, epidemiologist (Managing Director)

M Bonthuis, epidemiologist (for paediatric section)

R Cornet, medical informatician

FW Dekker, epidemiologist

G Guggenheim, secretary

A Kramer, medical informatician

M Noordzij, epidemiologist

M Pippias, medical doctor

VS Stel, epidemiologist

AJ Weerstra, data manager

Acknowledgements

The ERA-EDTA Registry would like to thank the patients and staff of all the dialysis and transplant units who have contributed data via their national and regional renal registries. In addition, we would like to thank the following persons and organizations for their contribution to the work of the ERA-EDTA Registry.

For contribution to Section A

Registry	Contributors
Austria	R Kramar
Belgium, Dutch-speaking	B De Moor, F Schroven, and J De Meester
Belgium, French-speaking	JM des Grottes and F Collart
Bosnia and Herzegovina	H Resić, B Prnjavorac, and N Petković
Denmark	JG Heaf
Estonia	Ü Pechter, M Rosenberg and K Lilienthal
Finland	P Finne and C Grönhagen-Riska
France	M Lassalle and C Couchoud
Greece	N Afentakis
Iceland	R Palsson
Norway	T Leivestad
Romania	G Mircescu, L Garneata, and E Podgoreanu
Serbia	Working group of Serbian RRT Registry and all of the Serbian renal units
Slovenia	J Buturović-Ponikvar, J Gubenšek, M Arnot
Spain, Andalusia	P Castro de la Nuez
Spain, Aragon	JJ Sanchez Miret and JM Abad Diez
Spain, Asturias	R Alonso de la Torre, JR Quirós, and RERCA Working Group
Spain, Basque country	Á Magaz, J Aranzabal, M Rodrigo, and I Moina
Spain, Cantabria	M Arias Rodríguez and O García Ruiz
Spain, Castile and León	R González and C Fernández-Renedo
Spain, Castile-La Mancha	G Gutiérrez Ávila and I Moreno Alía
Spain, Catalonia	E Arcos, J Comas, and J Tort
Spain, Extremadura	JM Ramos Aceitero and MA García Bazaga
Spain, Galicia	E Bouzas-Caamaño and J Sánchez-Ibáñez
Spain, Community of Madrid	M I Aparicio Madre and C Chamorro Jambrina
Spain, Region of Murcia	C Santiuste de Pablos and I Marín Sánchez
Spain, Valencian region	O Zurriaga Llorens, M Ferrer Alamar, and N Fuster Camarena
Sweden	KG Prütz, M Stendahl, M Evans, S Schön, L Bäckman, and M Segelmark
The Netherlands	M Hemmeler and A Hemke
United Kingdom, England/Northern Ireland/Wales	All the staff of the UK Renal Registry and of the renal units submitting data
United Kingdom, Scotland	All of the Scottish renal units

For contribution to Section B

Registry	Contributors
Albania	N Thereska, A Strakosha, and N Pasko
Bulgaria	E Vazelov and V Mushekov
Croatia	I Bubić, S Rački, and N Janković
Cyprus	K Ioannou and all of the renal units providing data
Czech Republic	I Rychlík, J Potucek, and F Lopot
Georgia	N Kantaria and Dialysis Nephrology and Transplantation Union of Georgia
Israel	R Dichtiar, T Shohat, and E Golan
Latvia	H Cerneviskis and V Kuzema
Lithuania	V Kuzminskis, IA Bumblytė, and E Žiginskienė
Montenegro	M Ratkovic, D Radunovic, and S Ivanovic
Poland	B Rutkowski, G Korejwo, and P Jagodziński
Portugal	F Macário, F Nolasco, and R Filipe
Russia	B Bikbov and N Tomilina
Slovakia	V Spustová, I Lajdová, and M Karolyova
Spain (18 of 19 regions)	Spanish RRT National Registry at ONT, Spanish Regional Registries, and Spanish Society of Nephrology (SEN)
Switzerland	P Ambühl and R Winzeler
Turkey	G Süleymanlar, N Seyahi, and MR Altıparmak
Ukraine	M Kolesnyk, M Kulyzkyi, and S Nikolaenko

The ERA-EDTA Registry is funded by the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA).

List of abbreviations

Abbreviation	Term
APD	Automated peritoneal dialysis
CAKUT	Congenital anomalies of the kidney and urinary tract
CAPD	Continuous ambulatory peritoneal dialysis
CI	Confidence interval
COD	Cause of death
DM	Diabetes mellitus
ERA-EDTA	European Renal Association - European Dialysis and Transplant Association
ESPN	European Society for Paediatric Nephrology
ESRD	End-stage renal disease
ESRF	End-stage renal failure
EU27	The 27 Member States of the European Union as of 2007 (Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, The Netherlands, United Kingdom)
GN	Glomerulonephritis / sclerosis
HD	Haemodialysis
HDF	Haemodiafiltration
HF	Haemofiltration
HT	Hypertension
HUS	Haemolytic uraemic syndrome
ISO	International Standards Organization
Misc	Miscellaneous
N	Count
ODBC	Open database connectivity
Oth	Other
PD	Peritoneal dialysis
PGP	Pretty good privacy
PKD	Polycystic kidneys, adult type
Pmarp	Per million age-related population
Pmp	Per million population
PN	Pyelonephritis
PRD	Primary renal disease
RRT	Renal replacement therapy
RVD	Renal vascular disease
SD	Standard deviation
SOPs	Standard Operating Procedures
Tx	Transplant
Unkn	Unknown
USRDS	United States Renal Data System

Table of Contents

I	Introduction	13
	Chapter overview.....	15
	New to this edition.....	15
	ERA-EDTA Registry website	15
	ESPN/ERA-EDTA Registry website	15
II	Reference Tables - Section A	17
A1	AFFILIATED REGISTRY INFORMATION FOR 2013	
	Table A.1.1.....	18
	General population of the country/region and percent coverage of general population	
	Table A.1.2.....	19
	Renal centres: total number of centres and number of collaborating centres	
A2	INCIDENT PATIENTS ACCEPTED FOR RRT IN 2013, AT DAY 1	
	Table A.2.1.....	20
	Incident counts and percentages <i>at day 1, by age and gender</i>	
	Table A.2.2.....	21
	Gender, mean age, and median age of incident patients <i>at day 1</i>	
	Table A.2.3.....	22
	Incident rates per million (age-related) population, unadjusted <i>at day 1, by age and gender</i>	
	Table A.2.4.....	23
	Incident rates per million population, unadjusted <i>at day 1, by cause of renal failure</i>	
	Table A.2.5.....	24
	Incident rates per million population, adjusted <i>at day 1, by cause of renal failure, adjusted for age and gender</i>	
A3	INCIDENT PATIENTS ACCEPTED FOR RRT IN 2013, AT DAY 91	
	Table A.3.1.....	25
	Incident counts and percentages <i>at day 91, by age and gender</i>	
	Table A.3.2.....	26
	Gender, mean age, and median age of incident patients <i>at day 91</i>	
	Table A.3.3.....	27
	Incident rates per million (age-related) population, unadjusted <i>at day 91, by age and gender</i>	
	Table A.3.4.....	28
	Incident rates per million population, unadjusted <i>at day 91, by cause of renal failure</i>	

Table A.3.5	29
Incident rates per million population, adjusted <i>at day 91, by cause of renal failure, adjusted for age and gender</i>	
Table A.3.6	30
Incident counts <i>at day 91, by established therapy</i>	
Table A.3.7	31
Incident rates per million population, unadjusted <i>at day 91, by established therapy</i>	
Table A.3.8	32
Incident rates per million population, adjusted <i>at day 91, by established therapy, adjusted for age and gender</i>	
Table A.3.9	33
Percentages of established therapy, unadjusted <i>at day 91</i>	
Table A.3.10	34
Percentages of established therapy, unadjusted <i>at day 91, by age, gender, and primary diagnosis</i>	

A4 PREVALENT PATIENTS ON RRT IN 2013

Table A.4.1	35
Prevalent counts and percentages <i>prevalent patients on December 31, by age and gender</i>	
Table A.4.2	36
Gender, mean age, and median age <i>prevalent patients on December 31</i>	
Table A.4.3	37
Prevalence per million (age-related) population, unadjusted <i>prevalent patients on December 31, by age and gender</i>	
Table A.4.4	38
Prevalence per million population and percentages, unadjusted <i>prevalent patients on December 31, by cause of renal failure</i>	
Table A.4.5	39
Prevalence per million population, adjusted <i>prevalent patients on December 31, by cause of renal failure, adjusted for age and gender</i>	
Table A.4.6	40
Prevalent counts <i>prevalent patients on December 31, by established therapy</i>	
Table A.4.7	41
Prevalence per million population, unadjusted <i>prevalent patients on December 31, by established therapy</i>	
Table A.4.8	42
Prevalence per million population, adjusted <i>prevalent patients on December 31, by established therapy, adjusted for age and gender</i>	
Table A.4.9	43
Percentages of established therapy, unadjusted <i>prevalent patients on December 31</i>	
Table A.4.10	44
Percentages of established therapy, unadjusted <i>prevalent patients on December 31, by age, gender, and primary diagnosis</i>	

A5 RENAL TRANSPLANTS IN 2013

Table A.5.1	45
Renal transplants performed in 2013, counts and percentages <i>by donor type</i>	
Table A.5.2	46
Renal transplants performed in 2013, per million population <i>by donor type</i>	

A6 SURVIVAL PROBABILITY

Patient Survival on RRT

Table A.6.1	48
90-day, one-, two- and five-year survival probabilities (cohort 2004-2008): Incident RRT patients, unadjusted from day 1 to 90 days, one, two, and five years, by age, gender, and primary diagnosis	
Table A.6.2	49
90-day, one-, two- and five-year survival probabilities (cohort 2004-2008): Incident RRT patients, adjusted from day 1 to 90 days, one, two, and five years, adjusted for age, gender, and primary diagnosis	
Table A.6.3	50
One-, two- and five-year survival probabilities (cohort 2004-2008): Incident RRT patients, unadjusted from day 91 to one, two, and five years + 90 days, by age, gender, and primary diagnosis	
Table A.6.4	51
One-, two- and five-year survival probabilities (cohort 2004-2008): Incident RRT patients, adjusted from day 91 to one, two, and five years + 90 days, adjusted for age, gender, and primary diagnosis	
Table A.6.5	52
90-day, one- and two-year survival probabilities (cohort 2007-2011): Incident RRT patients, unadjusted from day 1 to 90 days, one, and two years, by age, gender, and primary diagnosis	
Table A.6.6	53
90-day, one- and two-year survival probabilities (cohort 2007-2011): Incident RRT patients, adjusted from day 1 to 90 days, one, and two years, adjusted for age, gender, and primary diagnosis	
Table A.6.7	54
One- and two-year survival probabilities (cohort 2007-2011): Incident RRT patients, unadjusted from day 91 to one and two years + 90 days, by age, gender, and primary diagnosis	
Table A.6.8	55
One- and two-year survival probabilities (cohort 2007-2011): Incident RRT patients, adjusted from day 91 to one and two years + 90 days, adjusted for age, gender, and primary diagnosis	

Patient Survival on Dialysis

Table A.6.9.a	56
90-day, one-, two- and five-year survival probabilities (cohort 2004-2008): Incident dialysis patients, unadjusted from day 1 to 90 days, one, two, and five years, by age, gender, and primary diagnosis, with transplantation as censored observation	
Table A.6.9.b (competing risks survival data)	57
90-day, one-, two- and five-year survival probabilities (cohort 2004-2008): Incident dialysis patients, unadjusted from day 1 to 90 days, one, two, and five years, by age, gender, and primary diagnosis, with transplantation as competing event	
Table A.6.10.a	58
90-day, one-, two- and five-year survival probabilities (cohort 2004-2008): Incident dialysis patients, adjusted from day 1 to 90 days, one, two, and five years, adjusted for age, gender, and primary diagnosis, with transplantation as censored observation	
Table A.6.10.b (competing risks survival data)	59
90-day, one-, two- and five-year survival probabilities (cohort 2004-2008): Incident dialysis patients, adjusted from day 1 to 90 days, one, two, and five years, adjusted for age, gender, and primary diagnosis, with transplantation as competing event	
Table A.6.11.a	60
One-, two- and five-year survival probabilities (cohort 2004-2008): Incident dialysis patients, unadjusted from day 91 to one, two, and five years + 90 days, by age, gender, and primary diagnosis, with transplantation as censored observation	
Table A.6.11.b (competing risks survival data)	61
One-, two- and five-year survival probabilities (cohort 2004-2008): Incident dialysis patients, unadjusted from day 91 to one, two, and five years + 90 days, by age, gender, and primary diagnosis, with transplantation as competing event	
Table A.6.12.a	62
One-, two- and five-year survival probabilities (cohort 2004-2008): Incident dialysis patients, adjusted from day 91 to one, two, and five years + 90 days, adjusted for age, gender, and primary diagnosis, with transplantation as censored observation	
Table A.6.12.b (competing risks survival data)	63
One-, two- and five-year survival probabilities (cohort 2004-2008): Incident dialysis patients, adjusted from day 91 to one, two, and five years + 90 days, adjusted for age, gender, and primary diagnosis, with transplantation as competing event	
Table A.6.13.a	64
90-day, one- and two-year survival probabilities (cohort 2007-2011): Incident dialysis patients, unadjusted from day 1 to 90 days, one, and two years, by age, gender, and primary diagnosis, with transplantation as censored observation	
Table A.6.13.b (competing risks survival data)	65
90-day, one- and two-year survival probabilities (cohort 2007-2011): Incident dialysis patients, unadjusted from day 1 to 90 days, one, and two years, by age, gender, and primary diagnosis, with transplantation as competing event	
Table A.6.14.a	66
90-day, one- and two-year survival probabilities (cohort 2007-2011): Incident dialysis patients, adjusted from day 1 to 90 days, one, and two years, adjusted for age, gender, and primary diagnosis, with transplantation as censored observation	

Table A.6.14.b (competing risks survival data)	67
90-day, one- and two-year survival probabilities (cohort 2007-2011): Incident dialysis patients, adjusted from day 1 to 90 days, one, and two years, adjusted for age, gender, and primary diagnosis, with transplantation as competing event	
Table A.6.15.a	68
One- and two-year survival probabilities (cohort 2007-2011): Incident dialysis patients, unadjusted from day 91 to one and two years + 90 days, by age, gender, and primary diagnosis, with transplantation as censored observation	
Table A.6.15.b (competing risks survival data)	69
One- and two-year survival probabilities (cohort 2007-2011): Incident dialysis patients, unadjusted from day 91 to one and two years + 90 days, by age, gender, and primary diagnosis, with transplantation as competing event	
Table A.6.16.a	70
One- and two-year survival probabilities (cohort 2007-2011): Incident dialysis patients, adjusted from day 91 to one and two years + 90 days, adjusted for age, gender, and primary diagnosis, with transplantation as censored observation	
Table A.6.16.b (competing risks survival data)	71
One- and two-year survival probabilities (cohort 2007-2011): Incident dialysis patients, adjusted from day 91 to one and two years + 90 days, adjusted for age, gender, and primary diagnosis, with transplantation as competing event	
<u>Patient Survival after First Transplant (deceased donor)</u>	
Table A.6.17	72
One-, two- and five-year survival probabilities (cohort 2004-2008): First transplant patients (deceased donor), unadjusted from day of transplant to one, two, and five years, by age, gender, and primary diagnosis	
Table A.6.18	73
One-, two- and five-year survival probabilities (cohort 2004-2008): First transplant patients (deceased donor), adjusted from day of transplant to one, two, and five years, adjusted for age, gender, and primary diagnosis	
Table A.6.19	74
One- and two-year survival probabilities (cohort 2007-2011): First transplant patients (deceased donor), unadjusted from day of transplant to one and two years, by age, gender, and primary diagnosis	
Table A.6.20	75
One- and two-year survival probabilities (cohort 2007-2011): First transplant patients (deceased donor), adjusted from day of transplant to one and two years, adjusted for age, gender, and primary diagnosis	
<u>Patient Survival after First Transplant (living donor)</u>	
Table A.6.21	76
One-, two- and five-year survival probabilities (cohort 2004-2008): First transplant patients (living donor), unadjusted from day of transplant to one, two, and five years, by age, gender, and primary diagnosis	
Table A.6.22	77
One-, two- and five-year survival probabilities (cohort 2004-2008): First transplant patients (living donor), adjusted from day of transplant to one, two, and five years, adjusted for age, gender, and primary diagnosis	
Table A.6.23	78
One- and two-year survival probabilities (cohort 2007-2011): First transplant patients (living donor), unadjusted from day of transplant to one and two years, by age, gender, and primary diagnosis	
Table A.6.24	79
One- and two-year survival probabilities (cohort 2007-2011): First transplant patients (living donor), adjusted from day of transplant to one and two years, adjusted for age, gender, and primary diagnosis	
<u>Graft Survival after First Transplant (deceased donor)</u>	
Table A.6.25	80
One-, two- and five-year survival probabilities (cohort 2004-2008): First graft (deceased donor), unadjusted from day of transplant to one, two, and five years, by age, gender, and primary diagnosis	
Table A.6.26	81
One-, two- and five-year survival probabilities (cohort 2004-2008): First graft (deceased donor), adjusted from day of transplant to one, two, and five years, adjusted for age, gender, and primary diagnosis	
Table A.6.27	82
One- and two-year survival probabilities (cohort 2007-2011): First graft (deceased donor), unadjusted from day of transplant to one and two years, by age, gender, and primary diagnosis	
Table A.6.28	83
One- and two-year survival probabilities (cohort 2007-2011): First graft (deceased donor), adjusted from day of transplant to one and two years, adjusted for age, gender, and primary diagnosis	
<u>Graft Survival after First Transplant (living donor)</u>	
Table A.6.29	84
One-, two- and five-year survival probabilities (cohort 2004-2008): First graft (living donor), unadjusted from day of transplant to one, two, and five years, by age, gender, and primary diagnosis	
Table A.6.30	85
One-, two- and five-year survival probabilities (cohort 2004-2008): First graft (living donor), adjusted from day of transplant to one, two, and five years, adjusted for age, gender, and primary diagnosis	

Table A.6.31	86
One- and two-year survival probabilities (cohort 2007-2011): First graft (living donor), unadjusted <i>from day of transplant to one and two years, by age, gender, and primary diagnosis</i>	
Table A.6.32	87
One- and two-year survival probabilities (cohort 2007-2011): First graft (living donor), adjusted <i>from day of transplant to one and two years, adjusted for age, gender, and primary diagnosis</i>	
<u>Patient Survival by Modality and Primary Diagnosis (transplantation as censored observation in dialysis survival)</u>	
Figure A.6.1	88
Adjusted survival (cohort 2004-2008): Incident dialysis patients and patients receiving a first transplant (between 2004 and 2008) <i>from day 91, by modality, adjusted for age, gender, and primary diagnosis</i>	
Figure A.6.2	88
Adjusted survival (cohort 2004-2008): Incident haemodialysis patients <i>from day 91, by primary diagnosis, adjusted for age and gender</i>	
Figure A.6.3	88
Adjusted survival (cohort 2004-2008): Incident peritoneal dialysis patients <i>from day 91, by primary diagnosis, adjusted for age and gender</i>	
<u>Patient Survival by Modality and Primary Diagnosis (transplantation as competing event in dialysis survival)</u>	
Figure A.6.4	89
Adjusted survival (cohort 2004-2008): Incident dialysis patients and patients receiving a first transplant (between 2004 and 2008) <i>from day 91, by modality, adjusted for age, gender, and primary diagnosis</i>	
Figure A.6.5	89
Adjusted survival (cohort 2004-2008): Incident haemodialysis patients <i>from day 91, by primary diagnosis, adjusted for age and gender</i>	
Figure A.6.6	89
Adjusted survival (cohort 2004-2008): Incident peritoneal dialysis patients <i>from day 91, by primary diagnosis, adjusted for age and gender</i>	
A7 EXPECTED REMAINING LIFETIMES	
Table A.7.1	90
Expected remaining lifetimes (years) of the general population in 2010, and of prevalent dialysis and transplant pa- tients in 2012 and 2013 (includes mortality in the first 90 days) <i>by age and gender</i>	
 III Reference Tables - Section B	
91	
B1 AFFILIATED REGISTRY INFORMATION FOR 2013	
Table B.1.1	92
General population of the country/region and percent coverage of general population	
Table B.1.2	93
Renal centres: total number of centres and number of collaborating centres	
B2 INCIDENT PATIENTS ACCEPTED FOR RRT IN 2013, AT DAY 1	
Table B.2.1	94
Incident counts and incident rates per million population, unadjusted <i>at day 1</i>	
Table B.2.2	95
Gender, mean age, and median age of incident patients <i>at day 1</i>	
Table B.2.3	96
Incident rates per million population, adjusted <i>at day 1, adjusted for age and gender</i>	
Table B.2.4	97
Incident rates per million population and percentages, unadjusted <i>at day 1, by cause of renal failure</i>	

B3 INCIDENT PATIENTS ACCEPTED FOR RRT IN 2013, AT DAY 91

Table B.3.1	98
Incident counts and incident rates per million population, unadjusted <i>at day 91</i>	
Table B.3.2	99
Gender, mean age, and median age of incident patients <i>at day 91</i>	
Table B.3.3	100
Incident rates per million population, adjusted <i>at day 91, adjusted for age and gender</i>	
Table B.3.4	101
Incident rates per million population and percentages, unadjusted <i>at day 91, by cause of renal failure</i>	
Table B.3.5	102
Incident counts <i>at day 91, by established therapy</i>	
Table B.3.6	103
Incident rates per million population, unadjusted <i>at day 91, by established therapy</i>	
Table B.3.7	104
Percentages of established therapy, unadjusted <i>at day 91</i>	

B4 PREVALENT PATIENTS ON RRT IN 2013

Table B.4.1	105
Prevalent counts and prevalence per million population, unadjusted <i>prevalent patients on December 31</i>	
Table B.4.2	106
Gender, mean age, and median age <i>prevalent patients on December 31</i>	
Table B.4.3	107
Prevalence per million population, adjusted <i>prevalent patients on December 31, adjusted for age and gender</i>	
Table B.4.4	108
Prevalence per million population and percentages, unadjusted <i>prevalent patients on December 31, by cause of renal failure</i>	
Table B.4.5	109
Prevalent counts <i>prevalent patients on December 31, by established therapy</i>	
Table B.4.6	110
Prevalence per million population, unadjusted <i>prevalent patients on December 31, by established therapy</i>	
Table B.4.7	111
Percentages of established therapy, unadjusted <i>prevalent patients on December 31</i>	

B5 RENAL TRANSPLANTS IN 2013

Table B.5.1	112
Renal transplants performed in 2013, counts and percentages <i>by donor type</i>	
Table B.5.2	113
Renal transplants performed in 2013, per million population <i>by donor type</i>	

IV Summary Data

115

Table S.1.1	117
Section A - Summary data from registries providing individual patient data	
Table S.1.2	118
Section B - Summary data from registries providing aggregated data	

P1 GENERAL CHARACTERISTICS

Table P.1.1 121
 Population covered (in thousands)
by age and year

Table P.1.2 121
 Grouping of primary renal diseases for paediatric patients
groups and codes included

P2 INCIDENT PATIENTS ACCEPTED FOR RRT, AT DAY 1

Table P.2.1 122
 Incident counts
at day 1, by age and cohort

Table P.2.2 122
 Incident counts
at day 1, by age, treatment modality, and cohort

Table P.2.3 122
 Incident counts
between 2004 and 2013, at day 1, by age and cause of renal failure

Table P.2.4 123
 Incident rates per million age-related population (per year)
at day 1, by age and cohort

Table P.2.5 123
 Incident rates per million age-related population (per year)
at day 1, by age, treatment modality, and cohort

Table P.2.6 123
 Incident rates per million age-related population
between 2004 and 2013, at day 1, by age and cause of renal failure

P3 PREVALENT PATIENTS ON RRT

Table P.3.1 124
 Prevalent counts
prevalent patients on December 31, by age and year

Table P.3.2 124
 Prevalent counts
prevalent patients on December 31, by age and year

Table P.3.3 124
 Prevalent counts
prevalent patients on December 31, 2013, by age and cause of renal failure

Table P.3.4 125
 Prevalence per million age-related population (per year)
prevalent patients on December 31, by age and year

Table P.3.5 125
 Prevalence per million age-related population (per year)
prevalent patients on December 31, by age and year

Table P.3.6 125
 Prevalence per million age-related population
prevalent patients on December 31, 2013, by age and cause of renal failure

VI Methods

Data collection and preparation 129

Definitions and coding systems 132

Statistical analyses 133

Bibliography 137

VII Appendices

Appendix 1 - Grouping of primary renal diseases 140

Appendix 2 - Grouping of primary renal disease codes 2012 141



Appendix 3 - Grouping of causes of death 146

Appendix 4 - Treatment modalities 147

Appendix 5 - Renal registries contributing data for the different types of analyses 148

I Introduction

Figure 1: National and regional renal registries that contributed data to this annual report



I Introduction

The ERA-EDTA Registry collects data on renal replacement therapy (RRT) via the national and regional renal registries in Europe. For this Annual Report 2013 it used 49 data sets from national or regional renal registries in 34 countries. The reference tables are presented in two parts: Section A (chapter II) and Section B (chapter III). Section A relates to individual patient data from 31 national and regional registries from 17 countries (shown in red in Figure 1), whereas section B relates to 18 national registries from 18 countries providing aggregated data based on individual patient data, centre questionnaire data or information from health authorities (shown in orange in Figure 1).

Chapter overview

Chapter II (Section A) contains data on the incidence and prevalence of RRT and data on survival and expected remaining lifetimes from those registries providing individual patient data. Chapter III (Section B) contains data on the incidence and prevalence from the countries providing aggregated data. Chapter IV describes summary data from all participating registries. The incidence and prevalence of RRT in paediatric patients are described in chapter V, based on data from registries providing individual paediatric data. Chapter VI describes the methods used, including data collection and preparation, definitions, and coding systems. In addition, it describes the statistical methods to calculate incidence and prevalence, patient and graft survival, and expected remaining lifetimes.

New to this edition

This year, Estonia provided individual patient data for the A-section of this annual report for the first time, while Cyprus, Lithuania and Switzerland provided aggregated data for the B-section of the report for the first time.

In addition, for the first time also competing risks analyses are used for the calculation of survival probabilities for patients treated with dialysis (with transplantation as competing event). This new method is described in detail in Chapter VI.

ERA-EDTA Registry website

PDF files of the ERA-EDTA annual reports and other information on the Registry can be downloaded from the website of the ERA-EDTA Registry: www.era-edta-reg.org. This website also includes a repository of educational publications and the 2012 version of the ERA-EDTA Coding System for PRD.

ESPN/ERA-EDTA Registry website

Information on the activities of the European Society for Paediatric Nephrology (ESPN)/ERA-EDTA Registry and on paediatric registries in general is provided at the ESPN/ERA-EDTA Registry website: www.espn-reg.org. In addition, PDF files of the ESPN/ERA-EDTA Registry annual reports can be downloaded from this website.

II Reference Tables - Section A

Table A.1.1
General population of the country/region and percent coverage of general population

	General population of whole country/region in thousands	% Coverage of general population by the registry for individual patient data
Austria	8452	100
Belgium, Dutch-speaking	6396	100
Belgium, French-speaking	4729	100
Bosnia and Herzegovina	3508	100
Denmark	5671	100
Estonia	1318	100
Finland	5439	100
France	65698	100
Greece	10948	100
Iceland	324	100
Norway	5080	100
Romania	19984	99.0
Serbia	7164	94.0
Slovenia	2060	100
Spain, Andalusia	8391	100
Spain, Aragon	1335	100
Spain, Asturias	1068	100
Spain, Basque country	2172	100
Spain, Cantabria	589	100
Spain, Castile and León	2507	100
Spain, Castile-La Mancha	2085	100
Spain, Catalonia	7554	100
Spain, Extremadura	1104	100
Spain, Galicia	2755	100
Spain, Community of Madrid	6496	100
Spain, Region of Murcia	1472	100
Spain, Valencian region	5114	100
Sweden	9600	100
The Netherlands	16804	100
United Kingdom, All countries	64106	100
United Kingdom, England	53866	100
United Kingdom, Northern Ireland	1830	100
United Kingdom, Scotland	5328	100
United Kingdom, Wales	3082	100

Table A.1.2
Renal centres: total number of centres and number of collaborating centres

	Total number of renal centres of whole country/region	Number of renal centres collaborating with the registry for individual patient data
Austria	79	79
Belgium, Dutch-speaking	25	25
Belgium, French-speaking	23	23
Bosnia and Herzegovina	27	27
Denmark	15	15
Estonia	3	3
Finland	31	31
France	1225	1225
Greece	168	168
Iceland	1	1
Norway	25	25
Romania	139	138
Serbia	67	63
Slovenia	24	24
Spain, Andalusia	62	62
Spain, Aragon	10	10
Spain, Asturias	10	10
Spain, Basque country	11	11
Spain, Cantabria	2	2
Spain, Castile and León	23	23
Spain, Castile-La Mancha	12	12
Spain, Catalonia	45	45
Spain, Extremadura	12	12
Spain, Galicia	25	25
Spain, Community of Madrid	37	37
Spain, Region of Murcia	13	13
Spain, Valencian region	48	48
Sweden	66	66
The Netherlands	76	76
United Kingdom, All countries	72	72
United Kingdom, England	52	52
United Kingdom, Northern Ireland	5	5
United Kingdom, Scotland	10	10
United Kingdom, Wales	5	5

A2 INCIDENT PATIENTS ACCEPTED FOR RRT IN 2013, AT DAY 1

Table A.2.1
Incident counts and percentages
at day 1, by age and gender

	All			0-19						20-44						45-64						65-74						75+					
	All	Men	Women	All	Men	Women	All	Men	Women	All	Men	Women	All	Men	Women	All	Men	Women	All	Men	Women	All	Men	Women									
	N (100%)	N (100%)	N (100%)	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%								
Austria	1198	774	424	8	1	6	1	2	0	113	9	63	8	50	12	399	33	275	36	124	29	369	31	249	32	120	28	309	26	181	23	128	30
Belgium, Dutch-speaking *	1193	730	463							84	7	47	6	37	8	275	23	175	24	100	22	299	25	194	27	105	23	535	45	314	43	221	48
Belgium, French-speaking *	864	586	278							70	8	44	8	26	9	255	30	186	32	69	25	220	25	153	26	67	24	319	37	203	35	116	42
Bosnia and Herzegovina	407	245	162	6	1	5	2	1	1	51	13	24	10	27	17	158	39	99	40	59	36	118	29	77	31	41	25	74	18	40	16	34	21
Denmark	663	456	207	11	2	5	1	6	3	90	14	61	13	29	14	188	28	135	30	53	26	197	30	136	30	61	29	177	27	119	26	58	28
Estonia	84	50	34	0	0	0	0	0	0	10	12	7	14	3	9	33	39	18	36	15	44	25	30	16	32	9	26	16	19	9	18	7	21
Finland	485	328	157	14	3	12	4	2	1	65	13	42	13	23	15	183	38	125	38	58	37	135	28	88	27	47	30	88	18	61	19	27	17
France	10470	6573	3897	122	1	74	1	48	1	893	9	528	8	365	9	2954	28	1854	28	1100	28	2432	23	1579	24	853	22	4069	39	2538	39	1531	39
Greece	2362	1476	886	6	0	3	0	3	0	151	6	92	6	59	7	590	25	389	26	201	23	584	25	392	27	192	22	1031	44	600	41	431	49
Iceland	25	17	8	1	4	1	6	0	0	6	24	3	18	3	38	7	28	5	29	2	25	4	16	4	24	0	0	7	28	4	24	3	38
Norway	513	345	168	9	2	5	1	4	2	70	14	48	14	22	13	153	30	103	30	50	30	143	28	91	26	52	31	138	27	98	28	40	24
Romania	2862	1621	1241	28	1	14	1	14	1	384	13	221	14	163	13	1266	44	730	45	536	43	710	25	391	24	319	26	474	17	265	16	209	17
Serbia	992	630	362	7	1	3	0	4	1	101	10	55	9	46	13	437	44	285	45	152	42	270	27	177	28	93	26	177	18	110	17	67	19
Slovenia	260	152	108	4	2	1	1	3	3	25	10	17	11	8	7	77	30	48	32	29	27	61	23	40	26	21	19	93	36	46	30	47	44
Spain, Andalusia	1061	667	394	18	2	8	1	10	3	137	13	99	15	38	10	379	36	236	35	143	36	271	26	168	25	103	26	256	24	156	23	100	25
Spain, Aragon	176	119	57	2	1	1	1	1	2	10	6	4	3	6	11	53	30	40	34	13	23	42	24	29	24	13	23	69	39	45	38	24	42
Spain, Asturias	170	122	48	0	0	0	0	0	0	16	9	9	7	7	15	62	36	43	35	19	40	42	25	36	30	6	13	50	29	34	28	16	33
Spain, Basque country	264	183	81	2	1	2	1	0	0	35	13	20	11	15	19	76	29	58	32	18	22	68	26	45	25	23	28	83	31	58	32	25	31
Spain, Cantabria *	52	39	13							8	15	5	13	3	23	18	35	12	31	6	46	16	31	16	41	0	0	10	19	6	15	4	31
Spain, Castile and León *	270	197	73							22	8	17	9	5	7	78	29	55	28	23	32	79	29	62	31	17	23	91	34	63	32	28	38
Spain, Castile-La Mancha *	215	136	79							23	11	15	11	8	10	73	34	50	37	23	29	39	18	28	21	11	14	80	37	43	32	37	47
Spain, Catalonia	1095	719	376	20	2	13	2	7	2	100	9	64	9	36	10	315	29	222	31	93	25	294	27	198	28	96	26	366	33	222	31	144	38
Spain, Extremadura	136	97	39	1	1	1	1	0	0	12	9	7	7	5	13	48	35	37	38	11	28	29	21	18	19	11	28	46	34	34	35	12	31
Spain, Galicia	392	261	131	1	0	0	0	1	1	42	11	30	11	12	9	129	33	84	32	45	34	104	27	66	25	38	29	116	30	81	31	35	27
Spain, Community of Madrid	793	516	277	9	1	6	1	3	1	110	14	59	11	51	18	256	32	173	34	83	30	184	23	119	23	65	23	234	30	159	31	75	27
Spain, Region of Murcia	160	107	53	2	1	1	1	1	2	24	15	15	14	9	17	54	34	42	39	12	23	44	28	31	29	13	25	36	23	18	17	18	34
Spain, Valencian region	686	439	247	3	0	2	0	1	0	76	11	48	11	28	11	200	29	129	29	71	29	192	28	126	29	66	27	215	31	134	31	81	33
Sweden	1111	754	357	20	2	14	2	6	2	102	9	59	8	43	12	366	33	249	33	117	33	332	30	231	31	101	28	291	26	201	27	90	25
The Netherlands	1939	1150	789	33	2	16	1	17	2	235	12	133	12	102	13	578	30	313	27	265	34	581	30	360	31	221	28	512	26	328	29	184	23
United Kingdom, All countries *	6928	4391	2537							1049	15	677	15	372	15	2483	36	1513	34	970	38	1716	25	1095	25	621	24	1680	24	1106	25	574	23
United Kingdom, England *	5904	3755	2149							892	15	574	15	318	15	2161	37	1330	35	831	39	1432	24	922	25	510	24	1419	24	929	25	490	23
United Kingdom, Northern Ireland *	178	119	59							33	19	22	18	11	19	50	28	30	25	20	34	51	29	35	29	16	27	44	25	32	27	12	20
United Kingdom, Scotland	510	285	225	9	2	6	2	3	1	88	17	56	20	32	14	168	33	85	30	83	37	135	26	73	26	62	28	110	22	65	23	45	20
United Kingdom, Wales *	345	238	107							36	10	25	11	11	10	104	30	68	29	36	34	98	28	65	27	33	31	107	31	80	34	27	25

Categories may not add up because of missing values or rounding off; Percentages are row percentages
* Patients younger than 20 years of age are not reported

Table A.2.2
Gender, mean age, and median age of incident patients
at day 1

	All				Men				Women			
	%	Mean (years)	SD	Median (years)	%	Mean (years)	SD	Median (years)	%	Mean (years)	SD	Median (years)
Austria	100	65.0	14.8	67.8	64.6	64.8	14.1	67.5	35.4	65.3	15.8	69.0
Belgium, Dutch-speaking *	100	69.8	14.4	73.3	61.2	69.5	14.0	72.8	38.8	70.2	15.0	74.2
Belgium, French-speaking *	100	67.7	14.6	69.1	67.8	67.3	13.9	68.5	32.2	68.6	15.9	70.0
Bosnia and Herzegovina	100	60.9	15.8	63.7	60.2	61.3	15.4	64.4	39.8	60.3	16.4	63.2
Denmark	100	63.3	16.6	67.3	68.8	63.5	16.1	67.1	31.2	63.1	17.7	67.9
Estonia	100	62.3	13.6	64.6	59.5	62.0	14.1	64.5	40.5	62.7	13.0	64.6
Finland	100	60.3	16.8	64.3	67.6	59.9	17.3	63.6	32.4	61.1	15.7	64.7
France	100	67.4	16.2	70.0	62.8	67.5	15.8	70.0	37.2	67.1	16.8	70.0
Greece	100	69.5	14.0	72.9	62.5	69.1	13.7	72.3	37.5	70.3	14.5	74.6
Iceland	100	57.0	21.0	62.3	68.0	57.0	21.9	62.3	32.0	57.1	20.4	55.3
Norway	100	63.3	16.7	66.6	67.3	63.7	16.5	66.4	32.7	62.6	17.1	67.0
Romania	100	60.6	14.7	62.4	56.6	60.5	14.5	62.0	43.4	60.7	14.9	62.8
Serbia	100	62.0	13.8	63.6	63.5	62.5	13.0	63.6	36.5	61.2	15.1	63.7
Slovenia	100	65.7	16.6	69.1	58.5	64.8	16.1	67.5	41.5	66.9	17.4	71.6
Spain, Andalusia	100	62.2	16.1	64.7	62.9	61.8	16.2	64.3	37.1	62.9	16.1	65.3
Spain, Aragon	100	67.2	14.6	71.6	67.6	67.6	13.1	71.6	32.4	66.3	17.4	72.4
Spain, Asturias	100	65.3	14.1	66.6	71.8	66.2	12.9	66.8	28.2	63.1	16.6	64.0
Spain, Basque country	100	63.8	16.1	67.9	69.3	64.0	15.6	67.4	30.7	63.3	17.3	68.0
Spain, Cantabria *	100	62.1	13.8	65.1	75.0	62.9	12.6	66.4	25.0	59.9	17.2	59.0
Spain, Castile and León *	100	67.1	14.0	69.2	73.0	66.8	14.0	68.8	27.0	67.8	14.0	70.2
Spain, Castile-La Mancha *	100	64.7	14.9	66.9	63.3	63.5	14.9	65.7	36.7	66.9	14.7	73.3
Spain, Catalonia	100	65.5	16.3	68.7	65.7	65.0	16.1	68.0	34.3	66.3	16.7	70.7
Spain, Extremadura	100	64.8	14.8	67.2	71.3	65.4	14.1	67.9	28.7	63.5	16.6	67.1
Spain, Galicia	100	64.8	14.7	67.2	66.6	65.1	14.4	67.1	33.4	64.2	15.4	67.2
Spain, Community of Madrid	100	63.3	16.4	66.2	65.1	64.1	15.8	66.6	34.9	61.7	17.6	65.4
Spain, Region of Murcia	100	62.3	15.3	65.1	66.9	61.7	14.5	64.1	33.1	63.7	17.0	68.8
Spain, Valencian region	100	65.6	14.9	68.4	64.0	65.6	15.0	67.5	36.0	65.5	15.0	69.2
Sweden	100	64.0	15.8	67.2	67.9	64.4	15.4	67.3	32.1	63.3	16.6	67.0
The Netherlands	100	63.6	16.1	66.9	59.3	64.6	15.7	68.1	40.7	62.3	16.5	65.4
United Kingdom, All countries *	100	62.2	15.6	64.6	63.4	62.4	15.7	65.1	36.6	61.6	15.5	63.6
United Kingdom, England *	100	62.0	15.7	64.3	63.6	62.3	15.7	64.7	36.4	61.5	15.6	63.4
United Kingdom, Northern Ireland *	100	62.6	15.5	66.7	66.9	63.4	15.5	67.5	33.1	61.1	15.5	64.7
United Kingdom, Scotland	100	60.4	16.9	63.7	55.9	60.0	17.7	64.5	44.1	60.8	15.8	63.1
United Kingdom, Wales *	100	65.8	14.6	69.3	69.0	66.0	14.9	69.3	31.0	65.3	13.9	67.8

Categories may not add up because of missing values or rounding off; Percentages are row percentages

* Patients younger than 20 years of age are not reported

Table A.2.3
Incident rates per million (age-related) population, unadjusted
at day 1, by age and gender

	All			0-19			20-44			45-64			65-74			75+		
	All	Men	Women	All	Men	Women	All	Men	Women	All	Men	Women	All	Men	Women	All	Men	Women
	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp
Austria	141.7	187.7	98.0	4.7	6.9	2.4	39.6	44.0	35.2	168.1	233.7	103.6	437.0	635.3	265.2	452.5	716.9	297.4
Belgium, Dutch-speaking *	186.5	231.1	143.0				41.6	46.2	37.0	154.7	195.0	113.5	492.8	663.9	333.9	884.4	1298.9	608.5
Belgium, French-speaking *	182.7	254.5	114.6				43.5	54.6	32.4	208.2	307.6	111.3	574.9	869.7	324.0	834.8	1470.7	475.2
Bosnia and Herzegovina	116.0	142.5	90.6	6.9	11.4	2.3	40.8	38.0	43.6	177.3	227.1	129.7	331.7	489.1	206.8	549.8	718.0	431.1
Denmark	116.9	162.0	72.5	8.2	7.2	9.1	50.2	67.4	32.6	124.2	177.8	70.3	325.1	461.7	195.9	430.0	713.8	236.8
Estonia	63.7	81.2	48.4	0	0	0	21.8	29.8	13.4	94.7	111.6	80.2	199.7	332.7	116.7	139.5	280.4	84.7
Finland	89.2	122.7	56.8	11.6	19.4	3.4	38.6	48.6	28.0	121.5	166.7	76.7	233.3	323.3	153.3	191.9	359.9	93.4
France	159.4	206.6	115.0	7.6	9.0	6.1	43.2	51.5	35.1	171.6	221.2	124.5	424.2	587.5	280.1	684.4	1132.9	413.2
Greece	215.8	276.9	157.7	2.8	2.7	2.9	40.7	49.2	32.0	205.9	281.6	135.4	537.4	774.0	330.9	908.5	1262.1	653.5
Iceland	77.2	104.7	49.6	11.2	21.9	0	53.4	52.5	54.3	87.7	125.4	50.1	173.6	350.2	0	362.4	478.0	274.0
Norway	101.0	135.2	66.5	7.2	7.8	6.5	40.3	53.9	26.0	118.9	156.7	79.4	319.2	414.8	227.5	390.1	698.2	187.4
Romania	144.7	167.9	122.5	6.7	6.5	6.9	53.8	60.3	47.0	241.7	286.7	199.1	406.6	522.1	319.9	316.3	476.9	221.7
Serbia	147.3	192.1	104.8	5.3	4.4	6.2	45.3	48.6	41.8	221.6	298.4	149.5	405.6	595.8	252.3	331.4	524.8	206.5
Slovenia	126.2	149.0	103.8	10.1	4.9	15.6	35.3	46.0	23.6	128.8	158.7	98.2	324.3	463.9	206.1	553.6	797.5	426.0
Spain, Andalusia	126.4	160.6	93.0	9.9	8.5	11.3	44.4	63.1	25.1	175.6	220.1	131.7	397.6	524.9	284.9	400.2	620.7	257.5
Spain, Aragon	131.9	179.4	84.9	8.1	7.8	8.3	21.9	16.9	27.3	148.1	221.0	73.5	346.7	503.3	204.7	453.7	736.7	263.7
Spain, Asturias	159.2	238.3	86.4	0	0	0	46.0	51.1	40.7	194.0	276.1	115.9	387.2	723.0	102.3	364.2	665.4	185.6
Spain, Basque country	121.5	173.2	72.6	5.1	10.0	0	49.3	55.5	42.9	122.0	189.4	56.8	315.2	446.3	200.2	357.1	658.8	173.2
Spain, Cantabria *	88.3	135.4	43.2				39.7	48.9	30.3	106.8	143.4	70.7	303.4	646.2	0	159.4	252.3	102.6
Spain, Castile and León *	107.7	158.7	57.7				27.4	41.2	12.9	110.0	151.8	66.3	315.0	511.5	131.2	269.6	465.1	138.6
Spain, Castile-La Mancha *	103.1	129.5	76.4				30.4	38.1	22.0	139.4	185.7	90.5	240.3	362.8	129.3	379.5	489.5	300.9
Spain, Catalonia	145.0	193.0	98.2	13.1	16.5	9.5	36.0	44.9	26.5	162.7	231.8	95.0	469.0	675.0	287.8	536.5	846.2	343.0
Spain, Extremadura	123.2	177.0	70.2	4.6	9.0	0	31.4	35.8	26.9	163.9	246.9	76.9	304.9	401.9	218.6	387.4	723.4	167.3
Spain, Galicia	142.3	195.9	92.1	2.3	0	4.8	45.6	64.6	26.3	170.6	225.9	117.1	353.2	480.8	241.8	333.1	604.3	163.4
Spain, Community of Madrid	122.1	165.2	82.2	6.9	9.0	4.7	43.9	47.5	40.4	153.7	218.3	95.1	361.1	517.5	232.4	455.8	836.2	232.0
Spain, Region of Murcia	108.7	144.6	72.4	5.9	5.7	6.1	42.3	50.8	33.2	153.1	237.5	68.2	408.9	614.4	227.5	338.6	419.5	283.9
Spain, Valencian region	134.1	173.2	95.8	3.0	3.9	2.1	41.0	50.4	31.1	149.2	194.4	104.9	406.1	564.8	264.3	486.1	750.8	307.0
Sweden	115.7	157.4	74.2	9.2	12.5	5.7	32.5	36.9	28.0	150.8	203.4	97.2	320.7	453.5	192.0	357.1	603.5	186.8
The Netherlands	115.4	138.2	93.0	8.6	8.1	9.0	43.8	49.3	38.1	122.9	132.5	113.1	353.8	448.0	263.6	416.4	675.5	247.3
United Kingdom, All countries *	108.1	139.3	77.9				48.9	63.2	34.6	152.1	188.0	117.2	284.5	377.7	198.3	329.3	527.5	191.0
United Kingdom, England *	109.6	141.5	78.6				49.2	63.4	35.1	158.9	198.1	120.7	285.1	381.2	195.8	331.4	525.7	194.9
United Kingdom, Northern Ireland *	97.3	132.6	63.3				53.8	72.9	35.3	109.6	132.9	86.7	328.4	473.7	196.5	355.3	651.9	160.5
United Kingdom, Scotland	95.7	110.2	82.1	7.7	10.1	5.3	50.3	65.1	36.0	114.8	119.0	110.7	258.5	295.6	225.2	259.1	386.3	175.5
United Kingdom, Wales *	111.9	157.1	68.3				37.5	52.0	22.9	128.3	171.1	87.1	297.4	406.3	194.7	394.6	715.2	169.5

* Patients younger than 20 years of age are not reported

Table A.2.4
Incident rates per million population, unadjusted
at day 1, by cause of renal failure

	Total		GN		PN		PKD		DM						HT		RVD		Misc		Unkn		Missing	
									Type I		Type II		Both											
	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%
Austria	141.7	100	15.7	11.1	5.1	3.6	7.3	5.2	4.3	3.0	32.4	22.9	36.7	25.9	17.0	12.0	18.1	12.8	27.6	19.4	14.2	10.0	0	0
Belgium, Dutch-speaking *	186.5	100	16.1	8.6	8.1	4.4	9.7	5.2	4.8	2.6	31.7	17.0	36.6	19.6	22.5	12.1	9.5	5.1	69.6	37.3	14.4	7.7	0	0
Belgium, French-speaking *	182.7	100	18.0	9.8	7.6	4.2	8.5	4.6	1.7	0.9	35.7	19.6	37.4	20.5	45.3	24.8	5.1	2.8	48.6	26.6	12.3	6.7	0	0
Bosnia and Herzegovina	116.0	100	16.2	14.0	14.8	12.8	4.0	3.4	26.8	23.1	4.8	4.2	31.6	27.3	17.1	14.7	1.1	1.0	20.2	17.4	10.8	9.3	0	0
Denmark	116.9	100	10.2	8.7	4.4	3.8	6.7	5.7	9.0	7.7	17.8	15.2	26.8	22.9	15.2	13.0	1.1	0.9	25.9	22.2	26.6	22.8	0	0
Estonia	63.7	100	10.6	16.7	3.0	4.8	4.6	7.1	9.9	15.5	3.0	4.8	12.9	20.2	4.6	7.1	17.5	27.4	10.6	16.7	0	0	0	0
Finland	89.2	100	10.8	12.2	4.2	4.7	10.7	12.0	12.7	14.2	15.6	17.5	28.3	31.8	5.3	6.0	0.6	0.6	15.1	16.9	14.2	15.9	0	0
France	159.4	100	17.9	11.2	7.4	4.7	10.4	6.5			35.6	22.4	40.1	25.2	1.6	1.0	24.0	15.1	21.9	13.7	0.3	0.2		
Greece	215.8	100	16.5	7.7	11.9	5.5	9.2	4.3	2.5	1.1	55.5	25.7	58.0	26.9	20.9	9.7	3.7	1.7	22.8	10.6	72.6	33.7	0	0
Iceland	77.2	100	18.5	24.0	3.1	4.0	6.2	8.0	3.1	4.0	9.3	12.0	12.4	16.0	15.4	20.0	6.2	8.0	9.3	12.0	6.2	8.0	0	0
Norway	101.0	100	16.1	16.0	5.3	5.3	5.7	5.7	5.5	5.5	13.6	13.5	19.1	18.9	30.1	29.8	1.8	1.8	20.1	19.9	2.8	2.7	0	0
Romania	144.7	100	19.7	13.6	8.4	5.8	4.6	3.2			21.9	15.2	10.1	7.0	0.8	0.6	27.3	18.9	51.9	35.9	0	0		
Serbia	147.3	100	14.3	9.7	14.7	10.0	6.2	4.2	12.6	8.6	21.4	14.5	34.0	23.1	39.6	26.9	1.9	1.3	18.1	12.3	18.4	12.5	0	0
Slovenia	126.2	100	14.1	11.2	5.8	4.6	8.3	6.5	9.2	7.3	23.3	18.5	32.5	25.8	19.4	15.4	0.5	0.4	20.9	16.5	24.8	19.6	0	0
Spain, Andalusia	126.4	100	15.3	12.1	11.6	9.1	8.6	6.8			31.7	25.1	10.8	8.6	5.7	4.5	13.5	10.7	29.3	23.2	0	0		
Spain, Aragon	131.9	100	17.2	13.1	1.5	1.1	9.0	6.8	5.2	4.0	36.7	27.8	42.0	31.8	24.0	18.2	3.0	2.3	17.2	13.1	18.0	13.6	0	0
Spain, Asturias	159.2	100	27.2	17.1	7.5	4.7	10.3	6.5	3.7	2.4	34.7	21.8	38.4	24.1	30.0	18.8	2.8	1.8	21.5	13.5	21.5	13.5	0	0
Spain, Basque country	121.5	100	12.9	10.6	7.8	6.4	10.6	8.7	4.1	3.4	16.6	13.6	20.7	17.0	23.5	19.3	4.6	3.8	21.6	17.8	19.8	16.3	0	0
Spain, Cantabria *	88.3	100	11.9	13.5	8.5	9.6	8.5	9.6	5.1	5.8	17.0	19.2	22.1	25.0	20.4	23.1	6.8	7.7	8.5	9.6	1.7	1.9	0	0
Spain, Castile and León ‡	107.7	100	14.8	13.7	3.6	3.3	6.4	5.9	3.2	3.0	29.9	27.8	33.1	30.7	22.3	20.7	0	0	17.6	16.3	10.0	9.3	0	0
Spain, Castile-La Mancha *	103.1	100	15.8	15.3	9.1	8.8	7.7	7.4			27.8	27.0	10.6	10.2	3.4	3.3	12.0	11.6	16.8	16.3	0	0		
Spain, Catalonia	145.0	100	16.3	11.2	8.7	6.0	10.5	7.2	4.2	2.9	28.5	19.6	32.7	22.6	15.8	10.9	5.2	3.6	13.8	9.5	42.1	29.0	0	0
Spain, Extremadura	123.2	100	7.2	5.9	9.1	7.4	10.0	8.1			41.7	33.8	11.8	9.6	3.6	2.9	7.2	5.9	31.7	25.7	0.9	0.7		
Spain, Galicia	142.3	100	13.8	9.7	8.3	5.9	14.5	10.2	4.7	3.3	29.8	20.9	34.5	24.2	12.7	8.9	5.8	4.1	18.5	13.0	34.1	24.0	0	0
Spain, Community of Madrid	122.1	100	18.5	15.1	4.9	4.0	7.4	6.1	4.9	4.0	29.3	24.0	34.2	28.0	14.9	12.2	2.8	2.3	18.9	15.5	20.5	16.8	0	0
Spain, Region of Murcia	108.7	100	27.9	25.6	6.1	5.6	8.2	7.5			25.1	23.1	10.9	10.0	6.1	5.6	10.2	9.4	14.3	13.1	0	0		
Spain, Valencian region	134.1	100	11.3	8.5	10.0	7.4	8.4	6.3			26.8	20.0	20.3	15.2	6.6	5.0	15.8	11.8	34.8	25.9	0	0		
Sweden ‡	115.7	100	16.2	14.0	3.1	2.7	10.1	8.7	10.0	8.6	18.6	16.1	28.6	24.8	17.0	14.7	0.5	0.5	24.5	21.2	15.6	13.5	0	0
The Netherlands	115.4	100	7.9	6.8	3.5	3.0	4.9	4.3	3.2	2.7	15.8	13.7	19.0	16.5	14.2	12.3	13.0	11.3	17.6	15.3	10.6	9.2	24.8	21.5
United Kingdom, All countries *	108.1	100	14.0	13.0	6.6	6.1	7.3	6.8			24.5	22.7	7.2	6.7	3.6	3.3	19.3	17.9	15.4	14.2	10.0	9.3		
United Kingdom, England *	109.6	100	13.8	12.6	6.3	5.8	7.2	6.6			24.4	22.3	7.9	7.2	3.1	2.8	19.8	18.1	15.3	14.0	11.7	10.7		
United Kingdom, Northern Ireland *	97.3	100	10.4	10.7	13.1	13.5	9.8	10.1			20.2	20.8	5.5	5.6	7.1	7.3	15.3	15.7	14.2	14.6	1.6	1.7		
United Kingdom, Scotland	95.7	100	16.7	17.5	8.6	9.0	7.3	7.6			22.7	23.7	2.8	2.9	5.8	6.1	18.4	19.2	13.3	13.9	0	0		
United Kingdom, Wales *	111.9	100	16.5	14.8	5.2	4.6	7.8	7.0			31.8	28.4	3.6	3.2	6.8	6.1	16.5	14.8	21.7	19.4	1.9	1.7		

Abbreviations used: GN: glomerulonephritis/sclerosis; PN: pyelonephritis; PKD: polycystic kidneys, adult type; DM: diabetes mellitus; HT: hypertension; RVD: renal vascular disease; Misc: miscellaneous; Unkn: unknown
 Categories may not add up because of rounding off or a limited number of cases (<10%) with diabetes mellitus type unknown; Percentages are row percentages; When cells are left empty, (complete) data are unavailable

* Patients younger than 20 years of age are not reported

‡ Mapping the 2012 Primary Renal Disease (PRD) codes to the old PRD codes results in a different distribution of PRD groups

Table A.2.5
Incident rates per million population, adjusted
at day 1, by cause of renal failure, adjusted for age and gender

	Total	GN	PN	PKD	DM			HT	RVD	Misc	Unkn	Missing
	Pmp	Pmp	Pmp	Pmp	Type I	Type II	Both	Pmp	Pmp	Pmp	Pmp	Pmp
					Pmp	Pmp	Pmp					
Austria	137.7	15.0	5.0	6.9	4.1	31.5	35.6	16.5	17.7	27.1	13.9	0
Belgium, Dutch-speaking *	171.8	15.3	7.3	9.3	4.7	29.3	34.0	20.4	8.2	64.1	13.2	0
Belgium, French-speaking *	192.7	18.8	8.0	8.8	1.8	38.8	40.6	47.9	5.3	50.7	12.6	0
Bosnia and Herzegovina	137.4	16.8	18.4	5.3	30.6	6.2	36.8	20.7	1.3	24.8	13.3	0
Denmark	116.2	10.4	4.4	6.8	8.9	17.1	26.0	15.0	1.1	25.7	26.8	0
Estonia	65.1	10.8	2.9	4.5	10.3	3.0	13.4	4.7	18.3	10.5	0	0
Finland	84.1	10.1	3.9	10.3	13.0	13.7	26.7	5.1	0.6	14.0	13.4	0
France	156.6	18.1	7.5	10.6			35.5	38.1	1.6	23.9	21.1	0.3
Greece	190.3	15.7	10.3	8.8	2.5	49.0	51.4	18.2	3.2	20.3	62.4	0
Iceland	89.7	19.5	4.3	6.6	3.3	9.8	13.1	21.6	7.8	9.6	7.2	0
Norway	108.2	17.0	5.5	5.9	5.6	14.7	20.3	33.0	2.1	21.5	2.9	0
Romania	144.8	19.6	8.5	4.6			21.6	10.1	0.8	27.4	52.2	0
Serbia	136.1	13.7	13.5	5.7	11.7	19.4	31.0	36.6	1.9	16.7	17.0	0
Slovenia	123.4	13.5	5.8	7.7	8.8	22.1	30.9	19.1	0.4	20.9	25.1	0
Spain, Andalusia	134.1	15.8	12.3	9.0			33.9	11.8	6.0	14.2	31.1	0
Spain, Aragon	120.1	16.5	1.4	8.7	4.9	33.9	38.8	20.2	2.4	16.5	15.4	0
Spain, Asturias	130.7	23.5	6.9	8.8	3.3	28.4	31.6	22.3	2.5	18.2	16.8	0
Spain, Basque country	109.5	12.1	7.2	9.4	3.8	14.6	18.4	20.3	3.8	20.4	17.8	0
Spain, Cantabria *	80.8	10.9	7.9	7.5	4.7	16.2	20.9	18.2	6.1	7.7	1.5	0
Spain, Castile and León ‡	88.0	12.4	3.0	5.7	3.0	24.5	27.6	15.9	0	15.1	8.3	0
Spain, Castile-La Mancha *	102.3	16.1	9.4	7.5			28.4	10.5	3.5	11.5	15.5	0
Spain, Catalonia	146.1	16.3	8.9	10.6	4.2	29.5	33.7	15.6	5.3	14.0	41.6	0
Spain, Extremadura	114.6	6.9	8.0	9.3			39.1	11.1	2.9	7.1	29.2	1.0
Spain, Galicia	121.1	12.3	7.7	13.1	4.6	24.4	29.1	10.5	4.4	16.1	27.9	0
Spain, Community of Madrid	131.1	19.4	5.2	7.5	4.7	32.9	37.6	16.0	3.1	20.1	22.2	0
Spain, Region of Murcia	123.5	31.1	6.7	8.1			28.9	12.7	7.2	11.4	17.5	0
Spain, Valencian region	131.0	11.2	9.7	8.2			26.6	19.7	6.4	15.7	33.6	0
Sweden ‡	111.5	15.9	2.9	10.2	10.0	17.4	27.4	16.1	0.4	23.5	15.1	0
The Netherlands	116.0	7.9	3.5	4.8	3.2	15.7	18.9	14.6	13.4	17.5	10.8	24.6
United Kingdom, All countries *	110.5	14.4	6.7	7.6			25.2	7.4	3.6	19.7	15.6	10.3
United Kingdom, England *	112.6	14.2	6.4	7.5			25.3	8.1	3.1	20.3	15.5	12.1
United Kingdom, Northern Ireland *	107.6	11.3	14.2	10.9			21.7	6.4	8.2	16.8	16.0	2.0
United Kingdom, Scotland	95.0	16.7	8.7	7.2			22.5	2.9	5.7	18.0	13.4	0
United Kingdom, Wales *	106.3	16.5	4.7	8.3			29.9	3.5	6.2	15.5	19.9	1.8

Abbreviations used: GN: glomerulonephritis/sclerosis; PN: pyelonephritis; PKD: polycystic kidneys, adult type; DM: diabetes mellitus; HT: hypertension; RVD: renal vascular disease; Misc: miscellaneous; Unkn: unknown
 Categories may not add up because of rounding off or a limited number of cases (<10%) with diabetes mellitus type unknown; When cells are left empty, (complete) data are unavailable

* Patients younger than 20 years of age are not reported

‡ Mapping the 2012 Primary Renal Disease (PRD) codes to the old PRD codes results in a different distribution of PRD groups

Table A.3.1
Incident counts and percentages
at day 91, by age and gender

	All			0-19						20-44						45-64						65-74						75+					
	All	Men	Women	All	Men	Women	All	Men	Women	All	Men	Women	All	Men	Women	All	Men	Women	All	Men	Women	All	Men	Women									
	N (100%)	N (100%)	N (100%)	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%								
Austria †	1117	720	397	9	1	7	1	2	1	108	10	59	8	49	12	381	34	264	37	117	29	333	30	223	31	110	28	286	26	167	23	119	30
Belgium, Dutch-speaking *	1077	664	413							75	7	42	6	33	8	260	24	167	25	93	23	264	25	171	26	93	23	478	44	284	43	194	47
Belgium, French-speaking *	780	530	250							69	9	44	8	25	10	231	30	168	32	63	25	200	26	138	26	62	25	280	36	180	34	100	40
Bosnia and Herzegovina	386	235	151	6	2	5	2	1	1	49	13	24	10	25	17	145	38	91	39	54	36	117	30	77	33	40	26	69	18	38	16	31	21
Denmark	622	425	197	11	2	5	1	6	3	83	13	55	13	28	14	180	29	131	31	49	25	188	30	127	30	61	31	160	26	107	25	53	27
Estonia	79	49	30	0	0	0	0	0	0	10	13	7	14	3	10	30	38	18	37	12	40	26	33	16	33	10	33	13	16	8	16	5	17
Finland	466	312	154	13	3	11	4	2	1	63	14	41	13	22	14	174	37	119	38	55	36	130	28	83	27	47	31	86	18	58	19	28	18
France	9586	5998	3588	117	1	70	1	47	1	844	9	500	8	344	10	2779	29	1726	29	1053	29	2236	23	1452	24	784	22	3610	38	2250	38	1360	38
Greece	2128	1330	798	6	0	3	0	3	0	142	7	86	6	56	7	555	26	368	28	187	23	517	24	343	26	174	22	908	43	530	40	378	47
Iceland	24	17	7	1	4	1	6	0	0	6	25	3	18	3	43	7	29	5	29	2	29	4	17	4	24	0	0	6	25	4	24	2	29
Norway	488	325	163	9	2	5	2	4	2	69	14	47	14	22	13	147	30	98	30	49	30	129	26	80	25	49	30	134	27	95	29	39	24
Romania	2581	1442	1139	27	1	13	1	14	1	368	14	207	14	161	14	1154	45	659	46	495	43	645	25	347	24	298	26	387	15	216	15	171	15
Serbia	922	581	341	6	1	2	0	4	1	96	10	51	9	45	13	416	45	270	46	146	43	255	28	167	29	88	26	149	16	91	16	58	17
Slovenia	236	138	98	3	1	1	1	2	2	24	10	17	12	7	75	32	47	34	28	29	53	22	36	26	17	17	81	34	37	27	44	45	
Spain, Andalusia	1025	643	382	17	2	8	1	9	2	135	13	96	15	39	10	371	36	234	36	137	36	258	25	160	25	98	26	244	24	145	23	99	26
Spain, Aragon	167	114	53	2	1	1	1	1	2	8	5	3	3	5	9	51	31	39	34	12	23	37	22	25	22	12	23	69	41	46	40	23	43
Spain, Asturias †	159	113	47	0	0	0	0	0	0	14	9	8	7	6	13	56	35	37	33	19	40	41	26	35	31	6	13	49	31	33	29	16	34
Spain, Basque country	249	172	77	2	1	2	1	0	0	34	14	20	12	14	18	73	29	56	33	17	22	61	24	39	23	22	29	79	32	55	32	24	31
Spain, Cantabria *	49	36	13							7	14	4	11	3	23	17	35	11	31	6	46	15	31	15	42	0	0	10	20	6	17	4	31
Spain, Castile and León *	267	196	71							22	8	17	9	5	7	76	28	54	28	22	31	77	29	63	32	14	20	92	34	62	32	30	42
Spain, Castile-La Mancha *	216	136	80							23	11	14	10	9	11	72	33	50	37	22	28	42	19	30	22	12	15	79	37	42	31	37	46
Spain, Catalonia †	1052	693	359	20	2	13	2	7	2	96	9	61	9	35	10	300	29	213	31	87	24	275	26	188	27	87	24	361	34	218	31	143	40
Spain, Extremadura †	132	96	36	1	1	1	1	0	0	11	8	7	7	4	10	48	36	37	39	11	30	28	21	18	19	10	27	45	34	33	34	12	33
Spain, Galicia	385	257	128	2	1	1	0	1	1	43	11	30	12	13	10	120	31	79	31	41	32	107	28	69	27	38	30	113	29	78	30	35	27
Spain, Community of Madrid	762	493	269	9	1	6	1	3	1	106	14	55	11	51	19	246	32	167	34	79	29	179	23	117	24	62	23	222	29	148	30	74	28
Spain, Region of Murcia	153	102	51	2	1	1	1	1	2	24	16	15	15	9	18	51	33	40	39	11	22	41	27	28	27	13	25	35	23	18	18	17	33
Spain, Valencian region	665	428	237	3	0	2	0	1	0	73	11	46	11	27	11	192	29	123	29	69	29	183	28	120	28	63	27	214	32	137	32	77	32
Sweden	1000	681	319	18	2	12	2	6	2	99	10	56	8	43	13	343	34	233	34	110	34	287	29	201	30	86	27	253	25	179	26	74	23
The Netherlands	1822	1080	742	31	2	15	1	16	2	220	12	126	12	94	13	554	30	300	28	254	34	528	29	325	30	203	27	489	27	314	29	175	24
United Kingdom, All countries * †	6520	4134	2386							1016	16	658	16	358	15	2393	37	1457	35	936	39	1587	24	1014	25	573	24	1524	23	1005	24	519	22
United Kingdom, England * †	5564	3546	2018							863	16	557	16	306	15	2088	38	1283	36	805	40	1328	24	858	24	470	23	1286	23	848	24	438	22
United Kingdom, Northern Ireland * †	158	104	54							32	20	21	20	11	20	46	29	29	27	18	33	41	26	29	28	12	22	39	24	26	25	13	24
United Kingdom, Scotland	486	269	217	8	2	5	2	3	1	85	17	55	20	30	14	163	34	83	31	80	37	127	26	67	25	60	28	103	21	59	22	44	20
United Kingdom, Wales * †	320	221	99							36	11	25	11	11	11	96	30	63	29	33	34	91	28	60	27	31	31	96	30	72	33	24	24

Categories may not add up because of missing values or rounding off; Percentages are row percentages

* Patients younger than 20 years of age are not reported

† The incident counts at day 91 are estimated (see methods)

Table A.3.2
Gender, mean age, and median age of incident patients
at day 91

	All				Men				Women			
	%	Mean (years)	SD	Median (years)	%	Mean (years)	SD	Median (years)	%	Mean (years)	SD	Median (years)
Austria †	100	64.8	15.0	67.6	64.4	64.5	14.5	67.1	35.6	65.4	15.9	69.8
Belgium, Dutch-speaking *	100	69.6	14.4	73.2	61.7	69.4	14.1	72.9	38.3	70.1	14.9	73.9
Belgium, French-speaking *	100	67.4	14.8	68.9	67.9	67.0	14.1	68.3	32.1	68.1	16.1	69.9
Bosnia and Herzegovina	100	61.0	15.8	64.0	60.9	61.5	15.5	64.7	39.1	60.4	16.3	63.5
Denmark	100	63.1	16.7	66.7	68.3	63.1	16.2	66.6	31.7	63.1	17.8	67.8
Estonia	100	62.0	13.7	64.7	62.0	61.9	14.1	64.0	38.0	62.2	13.2	64.9
Finland	100	60.3	16.9	64.0	67.0	59.8	17.4	63.6	33.0	61.2	15.8	64.8
France	100	66.9	16.3	69.6	62.6	67.1	16.0	69.6	37.4	66.6	16.9	69.5
Greece	100	69.1	14.1	72.4	62.5	68.6	13.9	71.6	37.5	69.8	14.5	73.8
Iceland	100	56.3	20.8	60.0	70.8	57.2	21.9	62.5	29.2	53.9	19.4	46.9
Norway	100	63.3	16.9	66.6	66.6	63.7	16.7	66.3	33.4	62.5	17.2	66.9
Romania	100	60.0	14.7	62.0	55.9	60.0	14.5	61.5	44.1	60.0	15.0	62.4
Serbia	100	61.7	13.7	63.4	63.0	62.2	12.9	63.4	37.0	60.8	15.0	63.5
Slovenia	100	65.3	16.3	67.7	58.5	63.8	16.1	66.1	41.5	67.5	16.4	71.9
Spain, Andalusia	100	62.1	16.2	64.7	62.7	61.6	16.2	64.0	37.3	62.8	16.1	65.5
Spain, Aragon	100	67.5	14.5	71.8	68.3	68.0	13.0	71.5	31.7	66.4	17.5	72.7
Spain, Asturias †	100	66.1	14.6	67.7	70.7	66.7	13.6	67.7	29.3	64.6	16.7	66.3
Spain, Basque country	100	63.6	16.2	67.7	69.1	63.7	15.8	67.5	30.9	63.2	17.3	68.2
Spain, Cantabria *	100	62.9	13.8	66.3	73.5	63.9	12.5	67.6	26.5	60.1	17.2	59.2
Spain, Castile and León *	100	67.3	14.0	69.4	73.4	67.0	14.0	69.0	26.6	68.0	14.2	70.7
Spain, Castile-La Mancha *	100	64.8	15.0	67.3	63.0	63.6	14.9	66.0	37.0	66.8	15.1	73.3
Spain, Catalonia †	100	65.4	16.7	68.8	65.9	65.0	16.5	68.1	34.1	66.2	17.0	70.5
Spain, Extremadura †	100	63.7	15.0	65.1	72.5	64.2	13.9	63.7	27.5	62.4	17.6	66.9
Spain, Galicia	100	64.5	15.1	67.3	66.8	64.8	14.7	67.2	33.2	63.9	15.9	67.4
Spain, Community of Madrid	100	63.2	16.5	66.2	64.7	64.0	15.8	66.6	35.3	61.7	17.7	65.2
Spain, Region of Murcia	100	62.3	15.5	65.0	66.7	61.7	14.6	64.3	33.3	63.5	17.1	69.1
Spain, Valencian region	100	65.7	15.1	68.6	64.4	65.8	15.1	68.0	35.6	65.6	15.0	69.2
Sweden	100	63.5	15.9	66.7	68.1	64.1	15.5	66.9	31.9	62.3	16.8	65.3
The Netherlands	100	63.6	16.2	66.8	59.3	64.5	15.9	67.9	40.7	62.2	16.5	65.4
United Kingdom, All countries * †	100	61.7	15.6	63.7	63.4	62.1	15.7	64.7	36.6	61.0	15.4	62.8
United Kingdom, England * †	100	61.7	15.6	63.6	63.7	62.1	15.6	64.4	36.3	60.9	15.5	62.6
United Kingdom, Northern Ireland * †	100	61.6	16.0	65.6	66.0	62.1	15.8	66.6	34.0	60.5	16.5	61.2
United Kingdom, Scotland	100	60.2	16.5	62.8	55.3	59.5	17.3	62.8	44.7	61.1	15.6	62.8
United Kingdom, Wales * †	100	65.2	15.0	68.6	69.0	65.2	15.4	69.0	31.0	65.3	14.3	66.7

Categories may not add up because of missing values or rounding off; Percentages are row percentages

* Patients younger than 20 years of age are not reported

† The incident counts at day 91, on which the data presented in this table are based, are estimated (see methods)

Table A.3.3
Incident rates per million (age-related) population, unadjusted
at day 91, by age and gender

	All			0-19			20-44			45-64			65-74			75+		
	All	Men	Women	All	Men	Women	All	Men	Women	All	Men	Women	All	Men	Women	All	Men	Women
	Pmp	Pmp	Pmp	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp
Austria †	132.1	174.4	91.8	5.5	8.4	2.4	37.8	41.2	34.3	160.5	224.1	98.0	394.4	568.1	243.8	418.4	660.1	276.5
Belgium, Dutch-speaking *	168.4	210.2	127.6				37.2	41.3	33.0	146.2	186.1	105.6	435.1	585.2	295.7	790.1	1174.8	534.1
Belgium, French-speaking *	164.9	230.2	103.0				42.9	54.6	31.1	188.6	277.8	101.6	522.6	784.4	299.9	732.7	1304.1	409.6
Bosnia and Herzegovina	110.0	136.7	84.4	6.9	11.4	2.3	39.2	38.0	40.3	162.8	208.7	118.7	328.9	489.1	201.7	512.7	682.1	393.0
Denmark	109.7	151.0	69.0	8.2	7.2	9.1	46.3	60.8	31.5	118.9	172.5	65.0	310.3	431.1	195.9	388.7	641.8	216.4
Estonia	59.9	79.6	42.7	0	0	0	21.8	29.8	13.4	86.1	111.6	64.2	207.7	332.7	129.7	113.3	249.2	60.5
Finland	85.7	116.7	55.7	10.7	17.8	3.4	37.4	47.5	26.8	115.5	158.7	72.7	224.6	304.9	153.3	187.5	342.2	96.8
France	145.9	188.5	105.9	7.2	8.5	6.0	40.9	48.8	33.1	161.4	205.9	119.2	390.0	540.3	257.4	607.2	1004.3	367.1
Greece	194.4	249.5	142.1	2.8	2.7	2.9	38.3	46.0	30.4	193.7	266.4	126.0	475.8	677.2	299.9	800.1	1114.9	573.2
Iceland	74.1	104.7	43.4	11.2	21.9	0	53.4	52.5	54.3	87.7	125.4	50.1	173.6	350.2	0	310.6	478.0	182.7
Norway	96.1	127.4	64.5	7.2	7.8	6.5	39.7	52.8	26.0	114.2	149.1	77.8	288.0	364.7	214.4	378.8	676.9	182.8
Romania	130.5	149.3	112.5	6.5	6.1	6.9	51.6	56.4	46.4	220.3	258.8	183.8	369.4	463.3	298.8	258.3	388.7	181.4
Serbia	136.9	177.2	98.7	4.5	2.9	6.2	43.0	45.1	40.9	211.0	282.7	143.6	383.1	562.2	238.8	279.0	434.1	178.8
Slovenia	114.6	135.3	94.2	7.6	4.9	10.4	33.9	46.0	20.6	125.4	155.4	94.8	281.7	417.5	166.8	482.1	641.4	398.8
Spain, Andalusia	122.2	154.8	90.1	9.3	8.5	10.2	43.8	61.2	25.7	171.9	218.2	126.1	378.5	499.9	271.1	381.4	576.9	254.9
Spain, Aragon	125.1	171.8	78.9	8.1	7.8	8.3	17.5	12.7	22.7	142.5	215.4	67.8	305.4	433.8	188.9	453.7	753.1	252.7
Spain, Asturias †	149.2	220.1	84.0	0	0	0	40.2	45.4	34.9	175.2	239.7	113.9	374.9	696.2	102.3	354.5	639.3	185.6
Spain, Basque country	114.6	162.8	69.0	5.1	10.0	0	47.9	55.5	40.1	117.1	182.8	53.7	282.8	386.8	191.5	339.9	624.7	166.2
Spain, Cantabria *	83.2	125.0	43.2				34.8	39.1	30.3	100.9	131.5	70.7	284.4	605.8	0	159.4	252.3	102.6
Spain, Castile and León *	106.5	157.9	56.1				27.4	41.2	12.9	107.2	149.0	63.4	307.0	519.7	108.0	272.6	457.7	148.5
Spain, Castile-La Mancha *	103.6	129.5	77.3				30.4	35.6	24.8	137.5	185.7	86.5	258.8	388.8	141.0	374.8	478.1	300.9
Spain, Catalonia †	139.3	186.2	93.7	13.1	16.5	9.5	34.4	42.8	25.6	154.9	222.7	88.6	438.7	640.9	260.8	530.2	832.3	341.4
Spain, Extremadura †	119.6	174.6	65.4	4.6	9.0	0	27.9	35.8	19.7	163.9	246.9	76.9	290.9	401.9	192.1	376.2	695.1	167.3
Spain, Galicia	139.8	192.9	90.0	4.6	4.4	4.8	46.7	64.6	28.5	158.7	212.5	106.7	363.4	502.6	241.8	324.5	581.9	163.4
Spain, Community of Madrid	117.3	157.8	79.8	6.9	9.0	4.7	42.3	44.2	40.4	147.7	210.7	90.6	351.2	508.8	221.7	432.4	778.3	228.9
Spain, Region of Murcia	103.9	137.9	69.7	5.9	5.7	6.1	42.3	50.8	33.2	144.6	226.2	62.5	381.1	555.0	227.5	329.2	419.5	268.1
Spain, Valencian region	130.0	168.9	91.9	3.0	3.9	2.1	39.4	48.3	30.0	143.3	185.4	102.0	387.0	537.9	252.2	483.8	767.6	291.8
Sweden	104.2	142.2	66.3	8.2	10.7	5.7	31.5	35.0	28.0	141.3	190.3	91.4	277.2	394.6	163.5	310.5	537.4	153.6
The Netherlands	108.4	129.8	87.5	8.0	7.6	8.5	41.0	46.7	35.2	117.8	127.0	108.4	321.5	404.4	242.1	397.7	646.7	235.2
United Kingdom, All countries * †	101.7	131.1	73.3				47.4	61.5	33.3	146.6	181.0	113.0	263.1	349.6	183.0	298.8	479.2	172.8
United Kingdom, England * †	103.3	133.6	73.8				47.6	61.5	33.7	153.6	191.1	116.9	264.3	354.6	180.4	300.3	479.8	174.1
United Kingdom, Northern Ireland * †	86.4	116.3	57.5				52.2	69.6	35.3	101.5	127.0	76.6	264.0	392.5	147.4	312.2	522.9	173.9
United Kingdom, Scotland	91.2	104.0	79.2	6.9	8.4	5.3	48.6	63.9	33.7	111.3	116.2	106.7	243.2	271.3	218.0	242.6	350.6	171.6
United Kingdom, Wales * †	103.7	145.6	63.2				37.5	52.0	22.9	118.8	158.5	80.7	276.2	377.1	180.9	355.3	646.6	150.7

* Patients younger than 20 years of age are not reported

† The incident counts at day 91, on which the data presented in this table are based, are estimated (see methods)

Table A.3.4
Incident rates per million population, unadjusted
at day 91, by cause of renal failure

	Total		GN		PN		PKD		DM						HT		RVD		Misc		Unkn		Missing	
									Type I		Type II		Both											
	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%
Austria †	132.1	100	15.6	11.8	4.6	3.5	7.5	5.7	4.1	3.1	30.1	22.7	34.2	25.9	16.4	12.4	16.4	12.4	23.6	17.9	13.9	10.5	0	0
Belgium, Dutch-speaking *	168.4	100	15.5	9.2	7.5	4.5	9.7	5.8	4.5	2.7	29.1	17.3	33.6	20.0	21.4	12.7	8.6	5.1	58.8	34.9	13.3	7.9	0	0
Belgium, French-speaking *	164.9	100	17.8	10.8	7.2	4.4	8.5	5.1	1.3	0.8	31.7	19.2	33.0	20.0	40.6	24.6	4.0	2.4	42.3	25.6	11.6	7.1	0	0
Bosnia and Herzegovina	110.0	100	15.7	14.2	14.5	13.2	4.0	3.6	26.5	24.1	4.6	4.1	31.1	28.2	16.8	15.3	1.1	1.0	17.7	16.1	9.1	8.3	0	0
Denmark	109.7	100	9.7	8.8	3.9	3.5	6.7	6.1	8.6	7.9	16.8	15.3	25.4	23.2	14.6	13.3	1.1	1.0	23.5	21.4	24.9	22.7	0	0
Estonia	59.9	100	10.6	17.7	3.0	5.1	4.6	7.6	9.1	15.2	3.0	5.1	12.1	20.3	3.0	5.1	17.5	29.1	9.1	15.2	0	0	0	0
Finland	85.7	100	10.7	12.4	4.2	4.9	10.5	12.2	12.7	14.8	14.7	17.2	27.4	32.0	5.3	6.2	0.6	0.6	14.0	16.3	13.1	15.2	0	0
France	145.9	100	17.0	11.7	6.9	4.7	10.2	7.0					33.1	22.7	36.9	25.3	1.4	1.0	21.3	14.6	18.8	12.9	0.3	0.2
Greece	194.4	100	16.0	8.2	10.2	5.3	9.0	4.7	2.4	1.2	51.2	26.4	53.6	27.6	18.9	9.7	3.3	1.7	19.2	9.9	64.1	33.0	0	0
Iceland	74.1	100	18.5	25.0	3.1	4.2	6.2	8.3	3.1	4.2	9.3	12.5	12.4	16.7	12.4	16.7	6.2	8.3	9.3	12.5	6.2	8.3	0	0
Norway	96.1	100	15.9	16.6	5.1	5.3	5.7	5.9	5.1	5.3	13.2	13.7	18.3	19.1	28.2	29.3	1.8	1.8	18.3	19.1	2.8	2.9	0	0
Romania	130.5	100	18.1	13.9	7.7	5.9	4.3	3.3					20.0	15.3	8.5	6.5	0.7	0.5	23.6	18.1	47.4	36.3	0	0
Serbia	136.9	100	13.5	9.9	13.7	10.0	6.1	4.4	12.3	9.0	19.9	14.5	32.2	23.5	37.4	27.3	1.8	1.3	16.5	12.0	15.7	11.5	0	0
Slovenia	114.6	100	13.6	11.9	4.4	3.8	8.3	7.2	9.2	8.1	21.4	18.6	30.6	26.7	17.5	15.3	0.5	0.4	18.9	16.5	20.9	18.2	0	0
Spain, Andalusia	122.2	100	15.1	12.4	11.2	9.2	8.5	6.9					30.5	25.0	10.2	8.4	5.5	4.5	12.6	10.3	28.5	23.3	0	0
Spain, Aragon	125.1	100	16.5	13.2	1.5	1.2	9.0	7.2	4.5	3.6	36.0	28.7	40.5	32.3	23.2	18.6	2.2	1.8	15.0	12.0	17.2	13.8	0	0
Spain, Asturias †	149.2	100	27.2	18.2	7.5	5.0	10.3	6.9	2.5	1.7	32.2	21.5	34.7	23.2	28.7	19.2	1.6	1.0	20.3	13.6	19.0	12.8	0	0
Spain, Basque country	114.6	100	12.9	11.2	6.9	6.0	10.6	9.2	4.1	3.6	15.7	13.7	19.8	17.3	21.6	18.9	4.6	4.0	18.4	16.1	19.8	17.3	0	0
Spain, Cantabria *	83.2	100	11.9	14.3	8.5	10.2	6.8	8.2	5.1	6.1	17.0	20.4	22.1	26.5	20.4	24.5	5.1	6.1	8.5	10.2	0	0	0	0
Spain, Castile and León ‡	106.5	100	14.8	13.9	3.6	3.4	6.4	6.0	3.2	3.0	29.5	27.7	32.7	30.7	21.9	20.6	0	0	17.2	16.1	10.0	9.4	0	0
Spain, Castile-La Mancha *	103.6	100	16.3	15.7	9.1	8.8	7.7	7.4					27.3	26.4	10.1	9.7	3.4	3.2	12.0	11.6	17.7	17.1	0	0
Spain, Catalonia †	139.3	100	15.8	11.3	8.7	6.3	10.3	7.4	4.1	2.9	27.8	19.9	31.8	22.8	15.2	10.9	4.5	3.2	12.2	8.7	40.9	29.3	0	0
Spain, Extremadura †	119.6	100	7.2	6.1	9.1	7.6	10.0	8.3					39.3	32.8	10.6	8.8	3.6	3.0	7.2	6.1	31.7	26.5	0.9	0.8
Spain, Galicia	139.8	100	13.4	9.6	7.6	5.5	14.9	10.6	4.7	3.4	28.7	20.5	33.4	23.9	12.7	9.1	6.2	4.4	18.5	13.2	33.0	23.6	0	0
Spain, Community of Madrid	117.3	100	18.3	15.6	4.8	4.1	7.1	6.0	4.9	4.2	27.9	23.8	32.8	28.0	14.8	12.6	2.6	2.2	17.4	14.8	19.6	16.7	0	0
Spain, Region of Murcia	103.9	100	26.5	25.5	6.1	5.9	8.2	7.8					23.1	22.2	10.9	10.5	6.1	5.9	8.8	8.5	14.3	13.7	0	0
Spain, Valencian region	130.0	100	10.8	8.3	9.6	7.4	8.4	6.5					25.8	19.8	19.6	15.0	6.5	5.0	15.4	11.9	34.0	26.2	0	0
Sweden ‡	104.2	100	15.5	14.9	3.0	2.9	10.1	9.7	9.6	9.2	16.7	16.0	26.2	25.2	15.2	14.6	0.2	0.2	20.2	19.4	13.6	13.1	0	0
The Netherlands	108.4	100	7.6	7.0	3.4	3.1	4.9	4.6	3.1	2.9	15.4	14.2	18.4	17.0	13.9	12.8	12.0	11.1	14.8	13.6	10.0	9.2	23.3	21.5
United Kingdom, All countries * †	101.7	100	13.5	13.3	6.4	6.2	7.2	7.1					23.5	23.1	6.8	6.7	3.2	3.1	17.9	17.6	14.3	14.1	8.9	8.7
United Kingdom, England * †	103.3	100	13.3	12.9	6.0	5.8	7.1	6.9					23.5	22.8	7.5	7.2	2.8	2.7	18.3	17.7	14.3	13.8	10.5	10.2
United Kingdom, Northern Ireland * †	86.4	100	8.9	10.3	12.4	14.3	9.1	10.5					17.3	20.0	5.5	6.3	5.6	6.5	13.8	16.0	12.0	13.9	1.6	1.9
United Kingdom, Scotland	91.2	100	16.1	17.7	8.1	8.8	7.3	8.0					22.1	24.3	2.6	2.9	4.5	4.9	17.5	19.1	13.0	14.2	0	0
United Kingdom, Wales * †	103.7	100	16.5	16.0	5.2	5.0	7.8	7.5					29.6	28.6	3.6	3.4	6.4	6.2	15.2	14.7	18.7	18.0	0.6	0.6

Abbreviations used: GN: glomerulonephritis/sclerosis; PN: pyelonephritis; PKD: polycystic kidneys, adult type; DM: diabetes mellitus; HT: hypertension; RVD: renal vascular disease; Misc: miscellaneous; Unkn: unknown
 Categories may not add up because of rounding off or a limited number of cases (<10%) with diabetes mellitus type unknown; Percentages are row percentages; When cells are left empty, (complete) data are unavailable

* Patients younger than 20 years of age are not reported

† The incident counts at day 91, on which the data presented in this table are based, are estimated (see methods)

‡ Mapping the 2012 Primary Renal Disease (PRD) codes to the old PRD codes results in a different distribution of PRD groups

Table A.3.5
Incident rates per million population, adjusted
at day 91, by cause of renal failure, adjusted for age and gender

	Total	GN	PN	PKD	DM			HT	RVD	Misc	Unkn	Missing
	Pmp	Pmp	Pmp	Pmp	Type I	Type II	Both	Pmp	Pmp	Pmp	Pmp	Pmp
					Pmp	Pmp	Pmp					
Austria †	128.3	14.9	4.6	7.1	4.0	29.2	33.1	15.8	16.0	23.3	13.5	0
Belgium, Dutch-speaking *	155.4	14.8	6.8	9.3	4.4	26.8	31.2	19.4	7.4	54.2	12.3	0
Belgium, French-speaking *	173.6	18.6	7.5	8.8	1.3	34.6	35.9	42.7	4.2	44.0	11.9	0
Bosnia and Herzegovina	129.9	16.2	18.0	5.3	30.2	5.8	36.0	20.0	1.4	22.0	11.0	0
Denmark	108.7	9.8	3.8	6.7	8.5	16.1	24.6	14.4	1.1	23.2	25.0	0
Estonia	61.7	10.8	2.9	4.5	9.5	3.0	12.5	3.5	18.3	9.2	0	0
Finland	81.0	9.9	3.9	10.1	13.0	13.0	26.0	5.1	0.6	13.0	12.4	0
France	143.7	17.3	6.9	10.4			33.0	34.9	1.4	21.2	18.2	0.3
Greece	171.9	15.1	8.9	8.7	2.4	45.1	47.5	16.5	2.8	17.2	55.3	0
Iceland	85.0	19.5	4.3	6.6	3.3	9.8	13.1	17.0	7.8	9.6	7.2	0
Norway	103.1	16.8	5.4	6.0	5.2	14.4	19.6	30.7	2.1	19.8	2.9	0
Romania	130.5	18.1	7.9	4.3			19.6	8.5	0.7	23.7	47.6	0
Serbia	126.4	13.0	12.6	5.6	11.4	17.9	29.4	34.5	1.7	15.1	14.7	0
Slovenia	111.0	12.9	4.3	7.7	8.9	20.1	29.0	17.0	0.4	18.7	21.0	0
Spain, Andalusia	129.4	15.6	11.9	8.9			32.6	11.2	5.8	13.4	30.1	0
Spain, Aragon	113.2	15.6	1.4	8.7	4.3	33.1	37.4	19.0	2.0	14.3	14.8	0
Spain, Asturias †	122.0	23.5	6.9	8.8	2.4	26.4	28.5	20.8	1.6	17.3	15.1	0
Spain, Basque country	103.3	12.1	6.4	9.4	3.8	13.8	17.6	18.9	3.7	17.4	17.7	0
Spain, Cantabria *	76.6	11.3	7.9	5.9	4.7	16.2	20.9	18.2	4.6	7.7	0	0
Spain, Castile and León ‡	86.5	12.3	2.9	5.7	3.0	24.1	27.1	15.6	0	14.6	8.3	0
Spain, Castile-La Mancha *	102.6	16.5	9.4	7.5			27.9	9.8	3.5	11.6	16.5	0
Spain, Catalonia †	139.9	15.7	8.9	10.4	4.0	28.6	32.6	15.1	4.5	12.4	40.4	0
Spain, Extremadura †	111.2	6.9	8.1	9.3			37.0	10.1	2.9	7.1	29.1	1.0
Spain, Galicia	119.0	11.9	7.1	13.4	4.6	23.3	27.9	10.4	4.7	16.5	26.9	0
Spain, Community of Madrid	126.0	19.3	5.1	7.2	4.7	31.3	36.0	15.9	2.9	18.4	21.1	0
Spain, Region of Murcia	118.2	29.8	6.7	8.1			26.3	12.7	7.2	9.8	17.6	0
Spain, Valencian region	126.8	10.6	9.3	8.2			25.6	18.8	6.2	15.2	32.7	0
Sweden ‡	100.5	15.2	2.8	10.2	9.6	15.4	25.1	14.3	0.2	19.5	13.1	0
The Netherlands	109.1	7.7	3.4	4.8	3.1	15.3	18.4	14.3	12.4	14.8	10.2	23.1
United Kingdom, All countries * †	104.0	13.8	6.4	7.5			24.2	7.0	3.2	18.2	14.5	9.2
United Kingdom, England * †	106.1	13.6	6.1	7.5			24.3	7.6	2.8	18.8	14.4	10.9
United Kingdom, Northern Ireland * †	95.0	10.0	13.3	10.3			18.9	6.4	6.4	15.5	13.7	2.0
United Kingdom, Scotland	90.7	16.3	8.1	7.2			21.9	2.7	4.4	17.2	13.0	0
United Kingdom, Wales * †	98.8	16.4	4.7	8.2			27.9	3.5	5.9	14.3	17.2	1.0

Abbreviations used: GN: glomerulonephritis/sclerosis; PN: pyelonephritis; PKD: polycystic kidneys, adult type; DM: diabetes mellitus; HT: hypertension; RVD: renal vascular disease; Misc: miscellaneous; Unkn: unknown
 Categories may not add up because of rounding off or a limited number of cases (<10%) with diabetes mellitus type unknown; When cells are left empty, (complete) data are unavailable

* Patients younger than 20 years of age are not reported

† The incident counts at day 91, on which the data presented in this table are based, are estimated (see methods)

‡ Mapping the 2012 Primary Renal Disease (PRD) codes to the old PRD codes results in a different distribution of PRD groups

Table A.3.6
Incident counts
at day 91, by established therapy

	Total	Haemodialysis						Peritoneal dialysis				Transplant				Unkn	Missing
		HD hospital/ centre	HD home	HD type Unkn	HF	HDF	Total HD/ HF/HDF	APD	CAPD	PD type Unkn	Total PD	Living	Deceased	Tx type Unkn	Total Tx		
Austria †	1117	866	1	0	2	86	955	42	68	5	115	32	15	0	47	0	0
Belgium, Dutch-speaking *	1077	595	64	0	1	275	935	75	43	0	118	10	14	0	24	0	0
Belgium, French-speaking *	780	495	6	0	8	154	663	44	48	0	92	4	21	0	25	0	0
Bosnia and Herzegovina	386	361	0	0	0	12	373	1	12	0	13	0	0	0	0	0	0
Denmark	622	375	0	0		375	122	73	0	195	26	24	0	50	2	0	
Estonia	79	52	0	0	0	6	58	14	2	0	16	1	4	0	5	0	0
Finland	466	281	17	0	0	15	313	87	62	0	149	3	1	0	4	0	0
France	9586	6673	5	8	20	1265	7971	399	748	0	1147	155	271	0	426	2	40
Greece	2128	1894	0	0	0	76	1970	67	85	0	152	6	0	0	6	0	0
Iceland	24	10	0	0		10				11	11	3	0	0	3	0	0
Norway	488	302	0	0		302				112	112	33	41	0	74	0	0
Romania	2581	2410	0	0	1	3	2414	3	134	0	137	11	15	4	30	0	0
Serbia	922	736	1	10	5	36	788	10	106	0	116	12	6	0	18	0	0
Slovenia	236	0	0	120	0	89	209	0	20	3	23	0	4	0	4	0	0
Spain, Andalusia	1025	803	0	0		803				177	177	30	15	0	45	0	0
Spain, Aragon	167	125	0	0		3	128	6	29	0	35	3	1	0	4	0	0
Spain, Asturias †	159	107	0	0		107	23	26	0	49	1	2	0	3	0	0	
Spain, Basque country	249	155	1	0		156	0	70	0	70	19	4	0	23	0	0	
Spain, Cantabria *	49	32	0	0		32	1	12	0	13	1	3	0	4	0	0	
Spain, Castile and León *	267	213	0	0		213	10	36	0	46	0	8	0	8	0	0	
Spain, Castile-La Mancha *	216	160	0	0		160	12	37	0	49		7	7	0	0	0	
Spain, Catalonia †	1052	540	0	0		265	805	42	109	0	151	64	32	0	96	0	0
Spain, Extremadura †	132	111	1	0	0	0	113	8	11	0	19	0	0	0	0	0	0
Spain, Galicia	385	275	0	0		275	13	74	0	87	18	2	3	23	0	0	
Spain, Community of Madrid	762	591	1	8	0	0	600	24	73	16	113	13	36	0	49	0	0
Spain, Region of Murcia	153	116	0	0	0	0	116	2	33	0	35	1	1	0	2	0	0
Spain, Valencian region	665	509	2	0		511	4	142	0	146	1	7	0	8	0	0	
Sweden	1000	0	7	545		552				362	362	62	24	0	86	0	0
The Netherlands	1822	1241	0	0		1241	109	189	0	298	258	25	0	283	0	0	
United Kingdom, All countries * † §	6520	4111	22	8	7	391	4538	617	660	24	1301	366	310	5	681	0	0
United Kingdom, England * †	5564	3418	19	8	6	381	3832	548	565	22	1135	309	284	5	597	0	0
United Kingdom, Northern Ireland * †	158	110	0	0	0	0	110	25	4	1	30	15	3	0	18	0	0
United Kingdom, Scotland	486	368	1	0		369	45	31	0	76	27	14	0	41	0	0	
United Kingdom, Wales * †	320	219	3	0	1	10	233	2	56	1	59	17	10	0	27	0	0

Abbreviations used: HD: haemodialysis; Unkn: unknown; HF: haemofiltration; HDF: haemodiafiltration; APD: automated peritoneal dialysis; CAPD: continuous ambulatory peritoneal dialysis; PD: peritoneal dialysis; Tx: transplant
 Categories may not add up because of rounding off; When cells are left empty, (complete) data are unavailable

* Patients younger than 20 years of age are not reported

† The incident counts at day 91 are estimated (see methods)

§ Not all UK centres record whether a patient is on HDF and this is probably an underestimate of HDF usage in the UK

Table A.3.7
Incident rates per million population, unadjusted
at day 91, by established therapy

	Total	Haemodialysis						Peritoneal dialysis				Transplant				Unkn	Missing
		HD hospital/ centre	HD home	HD type Unkn	HF	HDF	Total HD/ HF/HDF	APD	CAPD	PD type Unkn	Total PD	Living	Deceased	Tx type Unkn	Total Tx		
Austria †	132.1	102.5	0.2	0	0.2	10.1	113.0	4.9	8.0	0.6	13.5	3.8	1.8	0	5.6	0	0
Belgium, Dutch-speaking *	168.4	93.0	10.0	0	0.2	43.0	146.2	11.7	6.7	0	18.4	1.6	2.2	0	3.8	0	0
Belgium, French-speaking *	164.9	104.7	1.3	0	1.7	32.6	140.2	9.3	10.2	0	19.5	0.8	4.4	0	5.3	0	0
Bosnia and Herzegovina	110.0	102.9	0	0	0	3.4	106.3	0.3	3.4	0	3.7	0	0	0	0	0	0
Denmark	109.7	66.1	0	0			66.1	21.5	12.9	0	34.4	4.6	4.2	0	8.8	0.4	0
Estonia	59.9	39.5	0	0	0	4.6	44.0	10.6	1.5	0	12.1	0.8	3.0	0	3.8	0	0
Finland	85.7	51.7	3.1	0	0	2.8	57.5	16.0	11.4	0	27.4	0.6	0.2	0	0.7	0	0
France	145.9	101.6	0.1	0.1	0.3	19.3	121.3	6.1	11.4	0	17.5	2.4	4.1	0	6.5	0	0.6
Greece	194.4	173.0	0	0	0	6.9	179.9	6.1	7.8	0	13.9	0.5	0	0	0.5	0	0
Iceland	74.1	30.9	0	0			30.9			34.0	34.0	9.3	0	0	9.3	0	0
Norway	96.1	59.5	0	0			59.5			22.0	22.0	6.5	8.1	0	14.6	0	0
Romania	130.5	121.8	0	0	0.1	0.2	122.0	0.2	6.8	0	6.9	0.6	0.8	0.2	1.5	0	0
Serbia	136.9	109.3	0.1	1.5	0.7	5.3	117.0	1.5	15.7	0	17.2	1.8	0.9	0	2.7	0	0
Slovenia	114.6	0	0	58.3	0	43.2	101.5	0	9.7	1.5	11.2	0	1.9	0	1.9	0	0
Spain, Andalusia	122.2	95.7	0	0			95.7			21.1	21.1	3.6	1.8	0	5.4	0	0
Spain, Aragon	125.1	93.6	0	0		2.2	95.9	4.5	21.7	0	26.2	2.2	0.7	0	3.0	0	0
Spain, Asturias †	149.2	100.5	0	0			100.5	21.2	24.3	0	45.6	0.9	2.2	0	3.1	0	0
Spain, Basque country	114.6	71.4	0.5	0	0		71.8	0	32.2	0	32.2	8.7	1.8	0	10.6	0	0
Spain, Cantabria *	83.2	54.3	0	0			54.3	1.7	20.4	0	22.1	1.7	5.1	0	6.8	0	0
Spain, Castile and León *	106.5	85.0	0	0			85.0	4.0	14.4	0	18.3	0	3.2	0	3.2	0	0
Spain, Castile-La Mancha *	103.6	76.7	0	0			76.7	5.8	17.7	0	23.5			3.4	3.4	0	0
Spain, Catalonia †	139.3	71.5	0	0		35.1	106.6	5.6	14.4	0	20.0	8.5	4.2	0	12.8	0	0
Spain, Extremadura †	119.6	100.8	1.2	0	0	0	102.1	7.2	10.3	0	17.5	0	0	0	0	0	0
Spain, Galicia	139.8	99.8	0	0			99.8	4.7	26.9	0	31.6	6.5	0.7	1.1	8.3	0	0
Spain, Community of Madrid	117.3	91.0	0.2	1.2	0	0	92.4	3.7	11.2	2.5	17.4	2.0	5.5	0	7.5	0	0
Spain, Region of Murcia	103.9	78.8	0	0	0	0	78.8	1.4	22.4	0	23.8	0.7	0.7	0	1.4	0	0
Spain, Valencian region	130.0	99.5	0.4	0			99.9	0.8	27.8	0	28.6	0.2	1.4	0	1.6	0	0
Sweden	104.2	0	0.7	56.8			57.5			37.7	37.7	6.5	2.5	0	9.0	0	0
The Netherlands	108.4	73.8	0	0			73.8	6.5	11.2	0	17.7	15.4	1.5	0	16.8	0	0
United Kingdom, All countries * † §	101.7	64.1	0.3	0.1	0.1	6.1	70.8	9.6	10.3	0.4	20.3	5.7	4.8	0.1	10.6	0	0
United Kingdom, England * †	103.3	63.5	0.4	0.2	0.1	7.1	71.1	10.2	10.5	0.4	21.1	5.7	5.3	0.1	11.1	0	0
United Kingdom, Northern Ireland * †	86.4	60.1	0	0	0	0	59.9	13.8	2.0	0.7	16.6	8.2	1.6	0	9.8	0	0
United Kingdom, Scotland	91.2	69.1	0.2	0			69.3	8.4	5.8	0	14.3	5.1	2.6	0	7.7	0	0
United Kingdom, Wales * †	103.7	71.0	1.0	0	0.3	3.2	75.6	0.6	18.3	0.3	19.2	5.5	3.4	0	8.9	0	0

Abbreviations used: HD: haemodialysis; Unkn: unknown; HF: haemofiltration; HDF: haemodiafiltration; APD: automated peritoneal dialysis; CAPD: continuous ambulatory peritoneal dialysis; PD: peritoneal dialysis; Tx: transplant
 Categories may not add up because of rounding off; When cells are left empty, (complete) data are unavailable

* Patients younger than 20 years of age are not reported

† The incident counts at day 91, on which the data presented in this table are based, are estimated (see methods)

§ Not all UK centres record whether a patient is on HDF and this is probably an underestimate of HDF usage in the UK

Table A.3.8

Incident rates per million population, adjusted*at day 91, by established therapy, adjusted for age and gender*

	Total	Haemodialysis						Peritoneal dialysis				Transplant				Unkn	Missing
		HD hospital/ centre	HD home	HD type Unkn	HF	HDF	Total HD/ HF/HDF	APD	CAPD	PD type Unkn	Total PD	Living	Deceased	Tx type Unkn	Total Tx		
Austria †	128.3	99.6	0.2	0.4	0.3	9.9	109.7	4.9	7.9	0.7	13.3	3.6	1.8	0	5.4	0	0
Belgium, Dutch-speaking *	155.4	85.6	9.2	0	0.1	39.2	134.1	11.3	6.3	0	17.6	1.5	2.1	0	3.6	0	0
Belgium, French-speaking *	173.6	110.1	1.3	0	1.8	34.5	147.7	9.8	10.8	0	20.6	0.8	4.5	0	5.3	0	0
Bosnia and Herzegovina	129.9	121.9	0	0	0	4.3	126.2	0.2	3.5	0	3.7	0	0	0	0	0	0
Denmark	108.7	65.5	0	0			65.5	21.5	12.7	0	34.2	4.6	4.1	0	8.7	0.3	0
Estonia	61.7	40.5	0	0	0	4.3	44.8	11.2	1.7	0	12.9	0.8	3.3	0	4.0	0	0
Finland	81.0	48.1	3.3	0	0	2.8	54.1	15.6	10.6	0	26.2	0.5	0.2	0	0.7	0	0
France	143.7	100.0	0.1	0.1	0.3	18.8	119.3	6.1	10.9	0	17.0	2.5	4.3	0	6.8	0	0.6
Greece	171.9	152.0	0	0	0	6.7	158.7	5.7	7.0	0	12.7	0.5	0	0	0.5	0	0
Iceland	85.0	36.9	0	0			36.9			37.9	37.9	10.2	0	0	10.2	0	0
Norway	103.1	64.6	0	0			64.6			23.7	23.7	6.5	8.4	0	14.9	0	0
Romania	130.5	121.9	0	0	0.1	0.2	122.1	0.1	6.7	0	6.9	0.5	0.7	0.2	1.5	0	0
Serbia	126.4	100.4	0.2	1.4	0.7	5.0	107.6	1.4	14.6	0	16.0	1.9	0.9	0	2.8	0	0
Slovenia	111.0	0	0	57.1	0	41.6	98.7	0	9.2	1.4	10.6	0	1.7	0	1.7	0	0
Spain, Andalusia	129.4	101.9	0	0			101.9			22.1	22.1	3.6	1.7	0	5.4	0	0
Spain, Aragon	113.2	84.1	0	0		2.3	86.5	4.3	19.3	0	23.7	2.4	0.7	0	3.1	0	0
Spain, Asturias †	122.0	81.0	0	0			81.0	18.2	20.6	0	38.8	0.8	2.0	0	2.8	0	0
Spain, Basque country	103.3	63.8	0.4	0			64.3	0	28.9	0	28.9	8.4	1.7	0	10.1	0	0
Spain, Cantabria *	76.6	48.8	0	0			48.8	1.5	20.0	0	21.5	1.6	4.7	0	6.3	0	0
Spain, Castile and León *	86.5	67.7	0	0			67.7	3.4	12.3	0	15.7	0	3.1	0	3.1	0	0
Spain, Castile-La Mancha *	102.6	75.5	0	0			75.5	5.5	18.0	0	23.6			3.6	3.6	0	0
Spain, Catalonia †	139.9	71.4	0	0		35.4	106.7	5.8	14.7	0	20.4	8.5	4.5	0	13.0	0	0
Spain, Extremadura †	111.2	92.9	1.3	0	0	0	94.2	7.7	9.5	0	17.2	0	0	0	0	0	0.6
Spain, Galicia	119.0	83.0	0	0			83.0	4.2	23.3	0	27.5	6.5	0.6	1.3	8.4	0	0
Spain, Community of Madrid	126.0	98.6	0.2	1.3	0	0	100.1	3.9	11.9	2.6	18.4	1.9	5.6	0	7.5	0	0
Spain, Region of Murcia	118.2	90.5	0	0	0	0	90.5	1.4	25.2	0	26.6	0.6	0.5	0	1.1	0	0
Spain, Valencian region	126.8	97.0	0.4	0			97.4	0.8	27.2	0	27.9	0.2	1.3	0	1.5	0	0
Sweden	100.5	0	0.8	54.6			55.3			36.2	36.2	6.5	2.4	0	9.0	0	0
The Netherlands	109.1	74.9	0	0			74.9	6.3	11.3	0	17.6	15.1	1.4	0	16.6	0	0
United Kingdom, All countries * † §	104.0	65.5	0.4	0.1	0.1	6.2	72.3	9.9	10.5	0.4	20.8	5.9	5.0	0.1	10.9	0	0
United Kingdom, England * †	106.1	65.1	0.4	0.2	0.1	7.3	73.0	10.4	10.8	0.4	21.6	5.9	5.4	0.1	11.4	0	0
United Kingdom, Northern Ireland * †	95.0	66.3	0	0	0	0	66.1	15.6	2.5	0.8	18.5	8.6	1.8	0	10.4	0	0
United Kingdom, Scotland	90.7	68.4	0.2	0			68.6	8.5	5.8	0	14.2	5.1	2.8	0	7.9	0	0
United Kingdom, Wales * †	98.8	66.3	1.3	0	0.3	3.1	70.7	0.7	17.8	0.3	18.8	6.0	3.7	0	9.6	0	0

Abbreviations used: HD: haemodialysis; Unkn: unknown; HF: haemofiltration; HDF: haemodiafiltration; APD: automated peritoneal dialysis; CAPD: continuous ambulatory peritoneal dialysis; PD: peritoneal dialysis; Tx: transplant
 Categories may not add up because of rounding off; When cells are left empty, (complete) data are unavailable

* Patients younger than 20 years of age are not reported

† The incident counts at day 91, on which the data presented in this table are based, are estimated (see methods)

§ Not all UK centres record whether a patient is on HDF and this is probably an underestimate of HDF usage in the UK

Table A.3.9
Percentages of established therapy, unadjusted
at day 91

	Total	Haemodialysis						Peritoneal dialysis				Transplant				Unkn	Missing
		HD hospital/ centre	HD home	HD type Unkn	HF	HDF	Total HD/ HF/HDF	APD	CAPD	PD type Unkn	Total PD	Living	Deceased	Tx type Unkn	Total Tx		
		%	%	%	%	%	%	%	%	%	%	%	%	%	%		
Austria †	100	77.6	0.1	0	0.1	7.7	85.5	3.7	6.1	0.4	10.2	2.9	1.4	0	4.2	0	0
Belgium, Dutch-speaking *	100	55.2	5.9	0	0.1	25.5	86.8	7.0	4.0	0	11.0	0.9	1.3	0	2.2	0	0
Belgium, French-speaking *	100	63.5	0.8	0	1.0	19.7	85.0	5.6	6.2	0	11.8	0.5	2.7	0	3.2	0	0
Bosnia and Herzegovina	100	93.5	0	0	0	3.1	96.6	0.3	3.1	0	3.4	0	0	0	0	0	0
Denmark	100	60.3	0	0	0	0	60.3	19.6	11.7	0	31.4	4.2	3.9	0	8.0	0.3	0
Estonia	100	65.8	0	0	0	7.6	73.4	17.7	2.5	0	20.3	1.3	5.1	0	6.3	0	0
Finland	100	60.3	3.6	0	0	3.2	67.2	18.7	13.3	0	32.0	0.6	0.2	0	0.9	0	0
France	100	69.6	0.1	0.1	0.2	13.2	83.2	4.2	7.8	0	12.0	1.6	2.8	0	4.4	0	0.4
Greece	100	89.0	0	0	0	3.6	92.6	3.1	4.0	0	7.1	0.3	0	0	0.3	0	0
Iceland	100	41.7	0	0	0	0	41.7	0	0	45.8	45.8	12.5	0	0	12.5	0	0
Norway	100	61.9	0	0	0	0	61.9	0	0	23.0	23.0	6.8	8.4	0	15.2	0	0
Romania	100	93.4	0	0	0	0.1	93.5	0.1	5.2	0	5.3	0.4	0.6	0.2	1.2	0	0
Serbia	100	79.8	0.1	1.1	0.5	3.9	85.5	1.1	11.5	0	12.6	1.3	0.7	0	2.0	0	0
Slovenia	100	0	0	50.8	0	37.7	88.6	0	8.5	1.3	9.7	0	1.7	0	1.7	0	0
Spain, Andalusia	100	78.3	0	0	0	0	78.3	0	0	17.3	17.3	2.9	1.5	0	4.4	0	0
Spain, Aragon	100	74.9	0	0	0	1.8	76.6	3.6	17.4	0	21.0	1.8	0.6	0	2.4	0	0
Spain, Asturias †	100	67.4	0	0	0	0	67.4	14.2	16.3	0	30.5	0.6	1.5	0	2.1	0	0
Spain, Basque country	100	62.2	0.4	0	0	0	62.7	0	28.1	0	28.1	7.6	1.6	0	9.2	0	0
Spain, Cantabria *	100	65.3	0	0	0	0	65.3	2.0	24.5	0	26.5	2.0	6.1	0	8.2	0	0
Spain, Castile and León *	100	79.8	0	0	0	0	79.8	3.7	13.5	0	17.2	0	3.0	0	3.0	0	0
Spain, Castile-La Mancha *	100	74.1	0	0	0	0	74.1	5.6	17.1	0	22.7	0	0	3.2	3.2	0	0
Spain, Catalonia †	100	51.3	0	0	0	25.2	76.5	4.0	10.3	0	14.3	6.1	3.0	0	9.2	0	0
Spain, Extremadura †	100	84.3	1.0	0	0	0	85.4	6.1	8.6	0	14.6	0	0	0	0	0	0
Spain, Galicia	100	71.4	0	0	0	0	71.4	3.4	19.2	0	22.6	4.7	0.5	0.8	6.0	0	0
Spain, Community of Madrid	100	77.6	0.1	1.0	0	0	78.7	3.1	9.6	2.1	14.8	1.7	4.7	0	6.4	0	0
Spain, Region of Murcia	100	75.8	0	0	0	0	75.8	1.3	21.6	0	22.9	0.7	0.7	0	1.3	0	0
Spain, Valencian region	100	76.5	0.3	0	0	0	76.8	0.6	21.4	0	22.0	0.2	1.1	0	1.2	0	0
Sweden	100	0	0.7	54.5	0	0	55.2	0	0	36.2	36.2	6.2	2.4	0	8.6	0	0
The Netherlands	100	68.1	0	0	0	0	68.1	6.0	10.4	0	16.4	14.2	1.4	0	15.5	0	0
United Kingdom, All countries * † §	100	63.0	0.3	0.1	0.1	6.0	69.6	9.5	10.1	0.4	20.0	5.6	4.7	0.1	10.4	0	0
United Kingdom, England * †	100	61.4	0.3	0.1	0.1	6.8	68.9	9.8	10.2	0.4	20.4	5.5	5.1	0.1	10.7	0	0
United Kingdom, Northern Ireland * †	100	69.6	0	0	0	0	69.4	16.0	2.3	0.8	19.2	9.5	1.9	0	11.4	0	0
United Kingdom, Scotland	100	75.7	0.2	0	0	0	75.9	9.3	6.4	0	15.6	5.6	2.9	0	8.4	0	0
United Kingdom, Wales * †	100	68.5	0.9	0	0.3	3.1	72.9	0.6	17.6	0.3	18.6	5.3	3.2	0	8.6	0	0

Abbreviations used: HD: haemodialysis; Unkn: unknown; HF: haemofiltration; HDF: haemodiafiltration; APD: automated peritoneal dialysis; CAPD: continuous ambulatory peritoneal dialysis; PD: peritoneal dialysis; Tx: transplant
 Categories may not add up because of rounding off; Percentages are row percentages; When cells are left empty, (complete) data are unavailable

* Patients younger than 20 years of age are not reported

† The incident counts at day 91, on which the data presented in this table are based, are estimated (see methods)

§ Not all UK centres record whether a patient is on HDF and this is probably an underestimate of HDF usage in the UK

Table A.4.2
Gender, mean age, and median age
prevalent patients on December 31

	All				Men				Women			
	%	Mean (years)	SD	Median (years)	%	Mean (years)	SD	Median (years)	%	Mean (years)	SD	Median (years)
Austria	100	60.6	15.4	62.3	63.0	60.5	15.1	62.4	37.0	60.6	16.0	62.1
Belgium, Dutch-speaking *	100	65.4	15.3	67.1	59.5	65.0	15.0	66.7	40.5	66.0	15.6	67.9
Belgium, French-speaking *	100	64.4	15.4	65.7	63.1	64.3	15.3	65.8	36.9	64.6	15.6	65.6
Bosnia and Herzegovina	100	59.1	15.3	61.0	57.8	58.2	15.3	60.1	42.2	60.2	15.3	62.7
Denmark	100	58.2	16.5	59.9	62.1	58.5	16.3	60.2	37.9	57.7	16.8	59.5
Estonia	100	56.7	15.1	57.4	56.6	56.1	14.6	55.4	43.4	57.4	15.9	58.7
Finland	100	58.6	16.2	61.1	63.5	58.9	16.1	61.6	36.5	58.1	16.4	60.2
France	100	61.8	16.6	63.3	60.7	61.7	16.4	63.2	39.3	62.0	16.8	63.4
Greece	100	63.6	15.7	65.8	63.7	63.3	15.6	65.3	36.3	64.1	16.0	66.6
Iceland	100	55.8	18.2	57.3	57.7	56.4	18.3	60.4	42.3	54.9	18.1	56.0
Norway	100	58.9	16.1	60.7	65.1	59.2	16.0	61.2	34.9	58.2	16.2	60.0
Romania //	100	59.1	15.2	60.8	56.0	58.6	15.1	60.3	44.0	59.9	15.2	61.6
Serbia	100	58.1	14.3	60.0	59.7	58.2	14.2	60.1	40.3	57.9	14.5	59.8
Slovenia	100	61.8	15.1	62.8	59.8	61.1	14.8	62.1	40.2	62.7	15.4	63.8
Spain, Andalusia	100	59.7	15.8	61.1	60.6	59.0	15.6	60.1	39.4	60.7	16.1	62.6
Spain, Aragon	100	62.2	15.4	63.6	64.8	62.5	14.9	63.6	35.2	61.8	16.4	63.5
Spain, Asturias	100	62.3	14.9	63.2	64.7	62.4	14.7	63.0	35.3	62.3	15.3	63.9
Spain, Basque country	100	60.9	15.8	63.1	63.7	61.4	15.6	63.4	36.3	60.2	16.0	62.5
Spain, Cantabria *	100	60.9	14.8	61.8	68.9	61.6	14.6	63.0	31.1	59.3	15.2	59.5
Spain, Castile and León *	100	63.6	15.2	64.4	65.1	63.2	15.0	64.3	34.9	64.3	15.7	65.0
Spain, Castile-La Mancha *	100	61.6	15.0	63.0	61.6	61.0	14.8	61.5	38.4	62.7	15.2	64.8
Spain, Catalonia	100	62.0	15.9	64.0	62.7	61.7	15.7	63.7	37.3	62.3	16.2	64.3
Spain, Extremadura	100	60.7	15.4	61.2	61.6	60.2	14.9	60.3	38.4	61.7	16.1	62.8
Spain, Galicia	100	61.6	15.1	63.1	62.7	61.6	14.7	63.0	37.3	61.6	15.7	63.3
Spain, Community of Madrid	100	60.9	15.8	62.3	61.5	61.0	15.5	62.4	38.5	60.8	16.4	62.0
Spain, Region of Murcia	100	61.3	15.6	62.8	62.9	61.1	15.4	62.7	37.1	61.8	16.0	62.9
Spain, Valencian region	100	62.2	15.9	64.2	61.8	61.9	15.8	64.0	38.2	62.7	16.0	64.4
Sweden	100	59.5	16.1	61.5	64.3	60.0	15.9	62.1	35.7	58.6	16.4	60.4
The Netherlands	100	59.6	16.1	61.5	59.8	59.6	16.1	61.6	40.2	59.6	16.2	61.5
United Kingdom, All countries *	100	58.1	15.6	58.5	60.9	58.4	15.6	58.8	39.1	57.7	15.5	58.0
United Kingdom, England *	100	58.1	15.6	58.6	60.9	58.4	15.7	58.8	39.1	57.7	15.5	58.1
United Kingdom, Northern Ireland *	100	57.9	15.9	58.0	62.1	58.0	15.5	58.0	37.9	57.7	16.4	57.9
United Kingdom, Scotland	100	56.5	16.0	56.8	58.5	56.4	16.1	57.3	41.5	56.6	16.0	56.5
United Kingdom, Wales *	100	59.3	15.7	60.4	63.1	59.6	15.9	60.7	36.9	58.7	15.4	59.7

Categories may not add up because of missing values or rounding off; Percentages are row percentages

* Patients younger than 20 years of age are not reported

|| The overall prevalence of RRT is underestimated by approximately 3% due to an estimated 30% underreporting of patients living on a functioning graft

Table A.4.3
Prevalence per million (age-related) population, unadjusted
prevalent patients on December 31, by age and gender

	All			0-19			20-44			45-64			65-74			75+		
	All	Men	Women	All	Men	Women	All	Men	Women	All	Men	Women	All	Men	Women	All	Men	Women
	Pmp	Pmp	Pmp	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp
Austria	1053.7	1359.7	762.2	61.2	78.0	43.5	453.2	539.7	366.1	1548.2	1994.7	1109.3	2729.7	3873.2	1739.2	2240.7	3572.4	1459.3
Belgium, Dutch-speaking *	1223.1	1472.8	979.4				429.7	497.4	360.9	1479.7	1793.3	1160.4	3050.9	3949.0	2216.3	4089.6	5720.9	3003.8
Belgium, French-speaking *	1269.9	1646.2	912.9				456.0	575.4	336.2	1761.5	2253.7	1281.1	3710.6	5178.3	2461.8	4433.0	7621.8	2630.0
Bosnia and Herzegovina	746.9	881.2	617.8	29.7	41.1	18.3	358.8	443.3	272.7	1279.6	1559.7	1011.2	1678.4	2070.7	1366.8	3031.5	3787.5	2497.6
Denmark	876.9	1096.8	660.0	66.8	75.3	57.9	524.2	625.7	420.8	1331.3	1643.6	1016.8	1911.3	2508.8	1345.9	1870.7	2897.3	1171.9
Estonia	572.1	693.7	465.5	25.9	21.6	30.5	376.4	425.2	325.3	947.2	1202.4	727.1	1198.0	1767.6	842.9	819.4	1401.8	593.1
Finland	825.9	1066.8	593.0	95.0	108.4	81.1	391.6	483.8	294.6	1295.5	1632.8	961.3	1950.8	2703.7	1282.2	1388.9	2401.4	795.4
France	1175.1	1472.5	895.7	54.5	62.7	45.9	561.4	683.7	441.0	1712.6	2157.2	1290.7	2870.1	3796.8	2052.4	3158.2	4926.0	2089.3
Greece	1172.1	1534.3	828.4	44.2	51.0	37.1	436.4	550.2	321.0	1565.3	2145.0	1025.9	2785.5	3778.9	1918.3	3175.7	4665.6	2101.6
Iceland	685.7	788.3	582.5	67.2	87.8	45.8	498.5	490.1	507.2	952.4	1103.4	801.6	2256.7	2714.3	1806.9	1656.6	2509.6	1004.7
Norway	900.5	1166.8	631.7	59.8	68.4	50.7	483.3	593.8	366.8	1439.8	1853.3	1008.2	2399.9	3126.9	1702.0	2069.3	3562.4	1087.2
Romania //	816.9	937.4	702.0	29.5	28.1	31.1	406.0	475.5	332.4	1347.9	1574.1	1133.9	2035.8	2583.7	1624.4	1685.8	2348.3	1295.2
Serbia	839.1	1028.9	659.0	28.5	24.8	32.5	454.0	534.5	371.1	1371.8	1694.9	1068.2	1843.3	2457.4	1348.4	1250.8	1922.6	816.8
Slovenia	1008.3	1217.7	802.9	42.8	48.9	36.3	383.8	457.7	303.4	1450.1	1762.0	1130.7	2567.5	3572.2	1717.4	2607.1	3848.7	1957.9
Spain, Andalusia	1107.7	1357.2	863.2	54.7	62.7	46.3	522.4	648.3	392.0	1742.5	2204.8	1286.2	3090.0	3970.8	2310.0	2683.9	3684.4	2036.5
Spain, Aragon	1131.2	1475.8	790.9	44.4	54.9	33.3	453.8	516.7	386.3	1659.6	2215.2	1091.0	2633.4	3713.7	1653.2	2491.9	3847.2	1582.3
Spain, Asturias	1131.3	1527.5	766.4	51.8	63.1	40.0	448.1	551.0	342.8	1545.6	2106.4	1012.9	2351.1	3434.3	1431.8	2148.7	3542.3	1322.6
Spain, Basque country	1175.4	1539.0	831.0	74.2	84.7	63.2	554.8	662.9	443.4	1579.0	2027.4	1145.6	2837.1	3897.5	1906.3	2297.5	4043.4	1232.9
Spain, Cantabria *	998.5	1405.7	608.5				437.0	547.4	323.0	1495.0	2031.8	965.9	2578.5	3957.7	1358.0	1784.8	3405.9	795.5
Spain, Castile and León *	1123.6	1477.2	776.7				446.6	564.7	321.4	1539.6	1998.3	1060.6	2424.3	3390.6	1520.3	2248.6	3440.1	1450.0
Spain, Castile-La Mancha *	1025.5	1253.0	794.6				427.1	511.2	336.1	1618.0	2053.8	1156.4	2939.6	3745.0	2209.3	2329.3	3107.9	1773.0
Spain, Catalonia	1262.2	1604.2	929.4	75.3	80.0	70.3	486.5	591.0	376.8	1846.3	2409.7	1294.8	3586.0	4881.6	2446.6	3288.1	5073.6	2172.4
Spain, Extremadura	1081.5	1341.1	825.6	13.9	18.1	9.5	484.5	592.5	370.9	1741.4	2215.8	1244.4	2502.5	3215.1	1868.2	2173.1	3000.1	1631.1
Spain, Galicia	1220.9	1583.1	881.6	41.4	35.6	47.5	526.8	633.3	418.5	1757.4	2275.2	1256.4	2805.4	3839.1	1902.5	2024.7	3237.8	1265.5
Spain, Community of Madrid	999.3	1277.6	741.4	49.1	56.9	40.9	410.9	485.0	337.8	1529.7	2019.9	1084.3	2843.3	4048.9	1852.1	2730.8	4301.8	1806.6
Spain, Region of Murcia	1200.4	1501.7	895.9	38.4	57.4	18.3	467.6	548.6	379.5	1981.2	2566.9	1392.5	3633.9	4974.9	2450.0	3753.0	5453.4	2602.3
Spain, Valencian region	1232.5	1536.0	934.4	65.7	85.2	45.1	476.2	573.9	372.8	1734.2	2182.5	1294.6	3214.6	4375.0	2178.1	3413.7	4919.4	2395.3
Sweden	939.5	1211.0	669.2	74.7	85.5	63.2	456.8	549.6	360.2	1521.5	1925.6	1110.7	2158.7	2921.3	1420.2	1833.4	2942.3	1066.8
The Netherlands	945.4	1142.4	752.2	62.2	70.9	53.1	497.6	593.1	401.2	1357.3	1609.7	1103.0	2275.8	2812.2	1761.7	2320.2	3513.5	1541.5
United Kingdom, All countries *	885.7	1095.9	682.3				558.2	667.6	449.1	1480.5	1819.0	1151.4	1932.3	2447.1	1455.7	1760.4	2706.4	1100.3
United Kingdom, England *	890.4	1101.3	685.6				555.5	664.0	447.1	1502.7	1844.9	1169.0	1958.8	2472.5	1481.8	1779.2	2740.9	1103.3
United Kingdom, Northern Ireland *	846.0	1071.2	629.4				570.9	692.5	453.0	1373.9	1776.9	979.7	2054.1	2666.4	1498.4	2035.0	3137.4	1311.1
United Kingdom, Scotland	866.0	1042.7	699.3	62.5	78.7	45.6	583.1	682.5	487.0	1373.7	1656.4	1104.4	1694.6	2134.1	1300.5	1471.9	2097.7	1061.1
United Kingdom, Wales *	886.0	1137.1	643.2				555.0	694.4	415.1	1361.7	1698.1	1038.1	1848.3	2444.2	1286.0	1788.8	2887.4	1017.1

* Patients younger than 20 years of age are not reported

|| The overall prevalence of RRT is underestimated by approximately 3% due to an estimated 30% underreporting of patients living on a functioning graft

Table A.4.4
Prevalence per million population and percentages, unadjusted
prevalent patients on December 31, by cause of renal failure

	Total		GN		PN		PKD		DM						HT		RVD		Misc		Unkn		Missing	
									Type I		Type II		Both											
	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%
Austria	1053.7	100	242.2	23.0	78.0	7.4	71.5	6.8	57.4	5.4	154.9	14.7	212.3	20.1	83.9	8.0	77.3	7.3	189.8	18.0	98.9	9.4	0	0
Belgium, Dutch-speaking *	1223.1	100	213.6	17.5	90.1	7.4	120.2	9.8	53.5	4.4	163.5	13.4	217.0	17.7	92.9	7.6	72.4	5.9	308.0	25.2	109.0	8.9	0	0
Belgium, French-speaking *	1269.9	100	218.5	17.2	115.0	9.1	98.8	7.8	37.2	2.9	178.9	14.1	216.1	17.0	194.3	15.3	44.0	3.5	309.6	24.4	73.6	5.8	0	0
Bosnia and Herzegovina	746.9	100	153.4	20.5	126.3	16.9	37.9	5.1	112.0	15.0	20.8	2.8	132.8	17.8	75.5	10.1	8.3	1.1	147.4	19.7	65.3	8.7	0	0
Denmark	876.9	100	177.2	20.2	64.9	7.4	79.7	9.1	80.1	9.1	66.8	7.6	146.9	16.8	86.9	9.9	4.4	0.5	159.9	18.2	156.9	17.9	0	0
Estonia	572.1	100	158.6	27.7	94.1	16.4	54.6	9.5	83.5	14.6	25.0	4.4	108.5	19.0	0	0	103.2	18.0	53.1	9.3	0	0	0	0
Finland	825.9	100	175.6	21.3	72.6	8.8	109.4	13.2	130.7	15.8	82.6	10.0	213.3	25.8	27.6	3.3	4.4	0.5	142.9	17.3	80.2	9.7	0	0
France	1175.1	100	247.3	21.0	87.5	7.4	114.7	9.8					182.1	15.5	185.9	15.8	11.6	1.0	215.0	18.3	102.3	8.7	28.6	2.4
Greece	1172.1	100	213.7	18.2	78.8	6.7	92.7	7.9	24.0	2.0	195.4	16.7	219.4	18.7	107.6	9.2	19.5	1.7	110.1	9.4	330.2	28.2	0	0
Iceland	685.7	100	173.0	25.2	61.8	9.0	58.7	8.6	43.2	6.3	30.9	4.5	74.1	10.8	108.1	15.8	12.4	1.8	154.4	22.5	43.2	6.3	0	0
Norway	900.5	100	261.4	29.0	74.8	8.3	96.3	10.7					115.2	12.8	154.3	17.1	6.9	0.8	170.3	18.9	21.3	2.4	0	0
Romania	816.9	100	175.7	21.5	89.4	10.9	46.5	5.7					86.5	10.6	43.7	5.4	5.2	0.6	111.5	13.6	258.4	31.6	0	0
Serbia	839.1	100	173.1	20.6	92.1	11.0	57.6	6.9	44.4	5.3	80.0	9.5	124.4	14.8	202.1	24.1	9.5	1.1	122.2	14.6	58.1	6.9	0	0
Slovenia	1008.3	100	226.7	22.5	97.1	9.6	97.6	9.7	45.6	4.5	114.1	11.3	159.7	15.8	105.3	10.4	7.8	0.8	156.8	15.6	157.3	15.6	0	0
Spain, Andalusia	1107.7	100	230.2	20.8	125.4	11.3	107.5	9.7					159.9	14.4	87.8	7.9	31.2	2.8	134.0	12.1	231.7	20.9	0	0
Spain, Aragon	1131.2	100	218.8	19.3	68.2	6.0	96.6	8.5	72.7	6.4	124.4	11.0	197.0	17.4	109.4	9.7	34.5	3.0	145.3	12.8	261.5	23.1	0	0
Spain, Asturias	1131.3	100	220.1	19.5	82.4	7.3	126.4	11.2	58.1	5.1	124.6	11.0	182.6	16.1	155.5	13.7	15.0	1.3	173.3	15.3	176.1	15.6	0	0
Spain, Basque country	1175.4	100	273.5	23.3	126.6	10.8	137.7	11.7	41.0	3.5	83.8	7.1	124.8	10.6	116.9	9.9	45.6	3.9	175.4	14.9	174.0	14.8	0.9	0.1
Spain, Cantabria *	998.5	100	314.2	31.5	76.4	7.7	98.5	9.9	57.7	5.8	88.3	8.8	146.0	14.6	113.8	11.4	81.5	8.2	125.7	12.6	37.4	3.7	5.1	0.5
Spain, Castile and León ‡	1123.6	100	197.4	17.6	51.9	4.6	94.9	8.4	74.2	6.6	112.5	10.0	186.7	16.6	138.4	12.3	0	0	158.0	14.1	296.4	26.4	0	0
Spain, Castile-La Mancha *	1025.5	100	210.6	20.5	125.7	12.3	110.3	10.8					155.4	15.2	68.1	6.6	13.9	1.4	117.0	11.4	220.6	21.5	3.8	0.4
Spain, Catalonia	1262.2	100	263.3	20.9	132.5	10.5	130.4	10.3	38.0	3.0	139.8	11.1	177.8	14.1	115.4	9.1	37.6	3.0	132.5	10.5	272.6	21.6	0	0
Spain, Extremadura	1081.5	100	212.9	19.7	85.1	7.9	111.4	10.3					172.1	15.9	65.2	6.0	17.2	1.6	106.9	9.9	298.9	27.6	11.8	1.1
Spain, Galicia	1220.9	100	224.4	18.4	87.5	7.2	133.2	10.9	49.4	4.0	153.6	12.6	202.9	16.6	96.2	7.9	31.9	2.6	172.4	14.1	272.3	22.3	0	0
Spain, Community of Madrid	999.3	100	215.4	21.6	83.4	8.4	104.4	10.4	52.5	5.3	120.9	12.1	173.3	17.3	98.7	9.9	16.6	1.7	156.7	15.7	150.7	15.1	0	0
Spain, Region of Murcia	1200.4	100	315.9	26.3	101.2	8.4	54.3	4.5					155.6	13.0	64.5	5.4	64.5	5.4	182.7	15.2	261.5	21.8	0	0
Spain, Valencian region	1232.5	100	234.1	19.0	122.6	9.9	106.2	8.6					154.9	12.6	160.9	13.1	43.6	3.5	143.1	11.6	267.1	21.7	0	0
Sweden ‡	939.5	100	237.4	25.3	51.9	5.5	97.7	10.4					168.5	17.9	79.5	8.5	0.2	0	199.3	21.2	104.8	11.2	0.3	0
The Netherlands	945.4	100	154.2	16.3	71.6	7.6	76.6	8.1	37.4	4.0	75.9	8.0	113.2	12.0	102.2	10.8	61.0	6.5	181.4	19.2	111.4	11.8	73.7	7.8
United Kingdom, All countries *	885.7	100	168.5	19.0	96.8	10.9	84.9	9.6					141.3	16.0	53.8	6.1	18.0	2.0	154.5	17.4	142.4	16.1	25.4	2.9
United Kingdom, England *	890.4	100	164.4	18.5	92.7	10.4	82.9	9.3					142.3	16.0	57.3	6.4	17.1	1.9	157.1	17.6	146.5	16.5	30.0	3.4
United Kingdom, Northern Ireland *	846.0	100	164.5	19.4	136.1	16.1	104.4	12.3					129.0	15.2	33.9	4.0	16.9	2.0	158.5	18.7	98.9	11.7	3.8	0.5
United Kingdom, Scotland	866.0	100	191.1	22.1	125.2	14.5	97.0	11.2					126.7	14.6	33.8	3.9	21.0	2.4	153.3	17.7	117.9	13.6	0	0
United Kingdom, Wales *	886.0	100	206.3	23.3	98.3	11.1	87.6	9.9					157.7	17.8	38.3	4.3	29.5	3.3	125.9	14.2	140.5	15.9	1.9	0.2

Abbreviations used: GN: glomerulonephritis/sclerosis; PN: pyelonephritis; PKD: polycystic kidneys, adult type; DM: diabetes mellitus; HT: hypertension; RVD: renal vascular disease; Misc: miscellaneous; Unkn: unknown
 Categories may not add up because of rounding off or a limited number of cases (<10%) with diabetes mellitus type unknown; Percentages are row percentages; When cells are left empty, (complete) data are unavailable

* Patients younger than 20 years of age are not reported

‡ Mapping the 2012 Primary Renal Disease (PRD) codes to the old PRD codes results in a different distribution of PRD groups

|| The overall prevalence of RRT is underestimated by approximately 3% due to an estimated 30% underreporting of patients living on a functioning graft

Table A.4.5

Prevalence per million population, adjusted*prevalent patients on December 31, by cause of renal failure, adjusted for age and gender*

	Total	GN	PN	PKD	DM			HT	RVD	Misc	Unkn	Missing
					Type I	Type II	Both					
					Pmp	Pmp	Pmp					
Austria	1025.5	234.2	76.4	68.8	55.2	150.9	206.1	81.7	75.5	186.3	96.5	0
Belgium, Dutch-speaking *	1146.6	203.7	85.7	113.8	51.0	149.6	200.6	84.4	64.3	291.2	103.0	0
Belgium, French-speaking *	1337.8	229.7	121.2	104.7	38.9	192.1	230.9	203.7	46.4	323.9	77.3	0
Bosnia and Herzegovina	871.4	163.5	148.2	43.4	127.6	24.4	152.0	90.5	11.5	187.7	74.6	0
Denmark	871.6	178.0	65.3	76.8	79.2	64.9	144.1	85.4	4.6	160.2	157.3	0
Estonia	582.5	163.6	94.1	52.9	87.3	24.7	112.0	0	104.8	55.3	0	0
Finland	789.2	167.5	69.9	99.5	132.1	73.5	205.6	26.0	4.2	139.5	77.0	0
France	1182.5	253.9	90.0	115.6			182.4	178.5	11.4	220.1	101.3	29.3
Greece	1078.6	205.9	74.0	88.3	23.9	172.4	196.3	95.1	17.3	104.3	297.4	0
Iceland	779.6	190.3	71.6	69.6	46.5	37.6	84.1	130.6	15.6	163.5	54.3	0
Norway	949.1	272.8	78.8	101.9			120.0	167.6	7.6	177.9	22.4	0
Romania //	816.6	174.8	89.1	45.5			85.5	44.3	5.3	112.3	259.6	0
Serbia	782.3	166.7	86.7	51.6	43.2	71.3	114.5	185.6	8.6	114.5	54.1	0
Slovenia	969.5	213.4	94.6	91.6	43.5	108.6	152.1	103.4	7.4	153.9	152.9	0
Spain, Andalusia	1159.0	235.5	129.9	114.9			169.8	94.2	33.9	137.5	243.2	0
Spain, Aragon	1047.4	206.2	63.9	92.9	69.4	114.0	183.4	92.1	28.4	137.9	242.6	0
Spain, Asturias	959.4	192.6	73.6	107.5	51.2	103.3	154.5	118.2	11.7	154.0	147.3	0
Spain, Basque country	1071.2	252.2	119.1	124.3	37.6	74.0	111.6	101.9	39.7	166.5	155.1	0.8
Spain, Cantabria *	928.4	289.3	72.5	91.9	54.2	85.0	139.2	100.8	74.1	120.9	35.1	4.7
Spain, Castile and León ‡	952.7	174.8	45.5	84.7	65.8	89.2	155.0	103.2	0	136.3	253.2	0
Spain, Castile-La Mancha *	1040.7	217.1	125.0	118.4			158.1	66.7	13.5	118.4	219.5	3.9
Spain, Catalonia	1270.0	265.6	131.3	134.4	37.8	144.2	182.0	115.4	38.1	132.9	270.3	0
Spain, Extremadura	1037.5	207.8	82.2	110.6			163.2	60.8	15.2	103.0	282.5	12.2
Spain, Galicia	1069.6	206.0	79.7	118.3	46.8	125.9	172.7	79.2	24.1	159.4	230.1	0
Spain, Community of Madrid	1057.0	225.4	85.2	112.7	53.3	135.8	189.0	106.6	18.4	161.4	158.2	0
Spain, Region of Murcia	1340.1	347.7	108.8	60.0			177.1	72.7	74.0	201.1	298.6	0
Spain, Valencian region	1203.3	229.7	119.9	105.7			151.5	155.2	42.2	140.0	259.2	0
Sweden ‡	922.3	235.7	51.6	94.8			165.1	74.5	0.2	196.8	103.2	0.3
The Netherlands	940.5	151.4	71.9	73.5	36.7	75.0	111.7	102.4	62.4	181.1	112.3	73.6
United Kingdom, All countries *	910.7	173.5	100.0	87.5			145.4	55.0	18.1	159.1	145.9	26.1
United Kingdom, England *	919.4	170.0	95.9	86.2			147.3	59.0	17.2	162.2	150.7	30.9
United Kingdom, Northern Ireland *	921.8	176.8	146.7	113.1			140.6	38.6	19.5	173.1	109.0	4.3
United Kingdom, Scotland	861.2	190.1	125.6	93.9			126.3	33.0	20.8	153.2	118.4	0
United Kingdom, Wales *	873.0	205.8	101.2	85.8			153.3	36.9	26.7	125.2	136.3	1.8

Abbreviations used: GN: glomerulonephritis/sclerosis; PN: pyelonephritis; PKD: polycystic kidneys, adult type; DM: diabetes mellitus; HT: hypertension; RVD: renal vascular disease; Misc: miscellaneous; Unkn: unknown
 Categories may not add up because of rounding off or a limited number of cases (<10%) with diabetes mellitus type unknown; When cells are left empty, (complete) data are unavailable

* Patients younger than 20 years of age are not reported

‡ Mapping the 2012 Primary Renal Disease (PRD) codes to the old PRD codes results in a different distribution of PRD groups

// The overall prevalence of RRT is underestimated by approximately 3% due to an estimated 30% underreporting of patients living on a functioning graft

Table A.4.6

Prevalent counts*prevalent patients on December 31, by established therapy*

	Total	Haemodialysis						Peritoneal dialysis				Transplant				Unkn	Missing
		HD hospital/ centre	HD home	HD type Unkn	HF	HDF	Total HD/ HF/HDF	APD	CAPD	PD type Unkn	Total PD	Living	Deceased	Tx type Unkn	Total Tx		
Austria	8906	3034	4	2	3	940	3983	218	197	6	421	660	3838	2	4500	2	0
Belgium, Dutch-speaking *	7823	2470	101	0	5	1573	4149	244	119	0	363	178	3125	8	3311	0	0
Belgium, French-speaking *	6005	2348	53	0	27	776	3204	167	105	0	272	162	2010	337	2509	3	17
Bosnia and Herzegovina	2620	2098	0	0	0	240	2338	3	79	3	85	136	57	4	197	0	0
Denmark	4973	1859	149	0	0	2008	2008	348	191	0	539	882	1526	0	2408	18	0
Estonia	754	243	0	0	1	10	254	42	2	0	44	44	412	0	456	0	0
Finland	4492	955	104	0	0	405	1464	218	140	0	358	193	2469	8	2670	0	0
France	77199	30383	245	56	60	8749	39493	1214	1702	0	2916	3005	31173	122	34300	355	135
Greece	12832	7429	1	0	3	2111	9544	390	281	0	671	1072	1545	0	2617	0	0
Iceland	222	48	0	0			48			25	25	104	45	0	149	0	0
Norway	4574	1062	17	2			1081			198	198	1361	1928	6	3295	0	0
Romania	16162	13309	7	2	8	62	13388	69	1430	0	1499	254	316	699	1269	6	0
Serbia	5651	3631	28	18	9	679	4365	34	437	0	471	503	308	0	811	4	0
Slovenia	2077	560	0	0	3	786	1349	6	45	1	52	12	664	0	676	0	0
Spain, Andalusia	9295	4133	8	0			4141			389	389	317	4448	0	4765	0	0
Spain, Aragon	1510	542	2	0		12	556	8	63	0	71	58	825	0	883	0	0
Spain, Asturias	1208	425	0	0	0	5	430	62	51	0	113	29	636	0	665	0	0
Spain, Basque country	2553	809	3	0			812	0	196	0	196	67	1478	0	1545	0	0
Spain, Cantabria *	588	198	0	0			198	8	27	0	35	21	334	0	355	0	0
Spain, Castile and León *	2817	1212	2	0			1214	75	110	0	185	0	1418	0	1418	0	0
Spain, Castile-La Mancha *	2138	810	3	0			813	37	86	0	123		1200	1200	2	0	
Spain, Catalonia	9534	1993	3	0		2024	4020	172	231	0	403	868	4243	0	5111	0	0
Spain, Extremadura	1194	579	8	0	0	0	587	23	50	0	73	8	198	327	533	1	0
Spain, Galicia	3363	1472	9	0			1481	88	191	0	279	133	1429	41	1603	0	0
Spain, Community of Madrid	6491	2201	14	310	0	0	2525	99	186	68	353	166	2992	455	3613	0	0
Spain, Region of Murcia	1767	897	0	0	0	0	897	7	87	0	94	38	738	0	776	0	0
Spain, Valencian region	6303	3321	10	0			3331	45	351	0	396	47	1722	798	2567	9	0
Sweden	9020	0	143	2864			3007			833	833	2221	2958	0	5179	1	0
The Netherlands	15887	5362	217	0			5579	501	426	0	927	4272	5097	12	9381	0	0
United Kingdom, All countries * §	56781	20710	1168	52	12	1723	23665	1836	1784	42	3662	8868	19643	941	29452	2	0
United Kingdom, England *	47961	17366	992	30	11	1687	20086	1576	1566	38	3180	7561	16294	840	24695	0	0
United Kingdom, Northern Ireland *	1548	577	31	22	0	18	648	72	7	2	81	254	497	68	819	0	0
United Kingdom, Scotland	4614	1812	55	0			1867	158	73	0	231	695	1790	29	2514	2	0
United Kingdom, Wales *	2731	964	90	0	1	18	1073	37	138	2	177	385	1091	5	1481	0	0

Abbreviations used: HD: haemodialysis; Unkn: unknown; HF: haemofiltration; HDF: haemodiafiltration; APD: automated peritoneal dialysis; CAPD: continuous ambulatory peritoneal dialysis; PD: peritoneal dialysis; Tx: transplant
When cells are left empty, (complete) data are unavailable

* Patients younger than 20 years of age are not reported

|| The overall prevalence of RRT is underestimated by approximately 3% due to an estimated 30% underreporting of patients living on a functioning graft

§ Not all UK centres record whether a patient is on HDF and this is probably an underestimate of HDF usage in the UK

Table A.4.7

Prevalence per million population, unadjusted*prevalent patients on December 31, by established therapy*

	Total	Haemodialysis						Peritoneal dialysis				Transplant				Unkn	Missing
		HD hospital/ centre	HD home	HD type Unkn	HF	HDF	Total HD/ HF/HDF	APD	CAPD	PD type Unkn	Total PD	Living	Deceased	Tx type Unkn	Total Tx		
Austria	1053.7	359.0	0.5	0.2	0.4	111.2	471.3	25.8	23.3	0.7	49.8	78.1	454.1	0.2	532.4	0.2	0
Belgium, Dutch-speaking *	1223.1	386.2	15.8	0	0.8	245.9	648.7	38.1	18.6	0	56.8	27.8	488.6	1.3	517.6	0	0
Belgium, French-speaking *	1269.9	496.5	11.2	0	5.7	164.1	677.6	35.3	22.2	0	57.5	34.3	425.1	71.3	530.6	0.6	3.6
Bosnia and Herzegovina	746.9	598.1	0	0	0	68.4	666.5	0.9	22.5	0.9	24.2	38.8	16.2	1.1	56.2	0	0
Denmark	876.9	327.8	26.3	0			354.1	61.4	33.7	0	95.0	155.5	269.1	0	424.6	3.2	0
Estonia	572.1	184.4	0	0	0.8	7.6	192.7	31.9	1.5	0	33.4	33.4	312.6	0	346.0	0	0
Finland	825.9	175.6	19.1	0	0	74.5	269.2	40.1	25.7	0	65.8	35.5	453.9	1.5	490.9	0	0
France	1175.1	462.5	3.7	0.9	0.9	133.2	601.1	18.5	25.9	0	44.4	45.7	474.5	1.9	522.1	5.4	2.1
Greece	1172.1	678.6	0.1	0	0.3	192.8	871.8	35.6	25.7	0	61.3	97.9	141.1	0	239.0	0	0
Iceland	685.7	148.3	0	0			148.3			77.2	77.2	321.2	139.0	0	460.2	0	0
Norway	900.5	209.1	3.3	0.4			212.8			39.0	39.0	267.9	379.6	1.2	648.7	0	0
Romania	816.9	672.7	0.4	0.1	0.4	3.1	676.7	3.5	72.3	0	75.8	12.8	16.0	35.3	64.1	0.3	0
Serbia	839.1	539.2	4.2	2.7	1.3	100.8	648.2	5.0	64.9	0	69.9	74.7	45.7	0	120.4	0.6	0
Slovenia	1008.3	271.9	0	0	1.5	381.6	654.9	2.9	21.8	0.5	25.2	5.8	322.3	0	328.2	0	0
Spain, Andalusia	1107.7	492.6	1.0	0			493.5			46.4	46.4	37.8	530.1	0	567.9	0	0
Spain, Aragon	1131.2	406.1	1.5	0		9.0	416.5	6.0	47.2	0	53.2	43.5	618.1	0	661.5	0	0
Spain, Asturias	1131.3	398.0	0	0	0	4.7	402.7	58.1	47.8	0	105.8	27.2	595.6	0	622.8	0	0
Spain, Basque country	1175.4	372.5	1.4	0			373.8	0	90.2	0	90.2	30.8	680.5	0	711.3	0	0
Spain, Cantabria *	998.5	336.2	0	0			336.2	13.6	45.9	0	59.4	35.7	567.2	0	602.9	0	0
Spain, Castile and León *	1123.6	483.4	0.8	0			484.2	29.9	43.9	0	73.8	0	565.6	0	565.6	0	0
Spain, Castile-La Mancha *	1025.5	388.5	1.4	0			390.0	17.7	41.3	0	59.0		575.6	575.6	1.0	0	
Spain, Catalonia	1262.2	263.8	0.4	0		267.9	532.2	22.8	30.6	0	53.4	114.9	561.7	0	676.6	0	0
Spain, Extremadura	1081.5	524.5	7.2	0	0	0	531.7	20.8	45.3	0	66.1	7.2	179.3	296.2	482.8	0.9	0
Spain, Galicia	1220.9	534.4	3.3	0			537.6	31.9	69.3	0	101.3	48.3	518.8	14.9	581.9	0	0
Spain, Community of Madrid	999.3	338.8	2.2	47.7	0	0	388.7	15.2	28.6	10.5	54.3	25.6	460.6	70.0	556.2	0	0
Spain, Region of Murcia	1200.4	609.4	0	0	0	0	609.4	4.8	59.1	0	63.9	25.8	501.3	0	527.2	0	0
Spain, Valencian region	1232.5	649.4	2.0	0			651.4	8.8	68.6	0	77.4	9.2	336.7	156.0	502.0	1.8	0
Sweden	939.5	0	14.9	298.3			313.2			86.8	86.8	231.3	308.1	0	539.5	0.1	0
The Netherlands	945.4	319.1	12.9	0			332.0	29.8	25.4	0	55.2	254.2	303.3	0.7	558.2	0	0
United Kingdom, All countries * §	885.7	323.1	18.2	0.8	0.2	26.9	369.2	28.6	27.8	0.7	57.1	138.3	306.4	14.7	459.4	0	0
United Kingdom, England *	890.4	322.4	18.4	0.6	0.2	31.3	372.9	29.3	29.1	0.7	59.0	140.4	302.5	15.6	458.5	0	0
United Kingdom, Northern Ireland *	846.0	315.3	16.9	12.0	0	9.8	354.2	39.4	3.8	1.1	44.3	138.8	271.6	37.2	447.6	0	0
United Kingdom, Scotland	866.0	340.1	10.3	0			350.4	29.7	13.7	0	43.4	130.5	336.0	5.4	471.9	0.4	0
United Kingdom, Wales *	886.0	312.7	29.2	0	0.3	5.8	348.1	12.0	44.8	0.6	57.4	124.9	353.9	1.6	480.5	0	0

Abbreviations used: HD: haemodialysis; Unkn: unknown; HF: haemofiltration; HDF: haemodiafiltration; APD: automated peritoneal dialysis; CAPD: continuous ambulatory peritoneal dialysis; PD: peritoneal dialysis; Tx: transplant
Categories may not add up because of rounding off; When cells are left empty, (complete) data are unavailable

* Patients younger than 20 years of age are not reported

|| The overall prevalence of RRT is underestimated by approximately 3% due to an estimated 30% underreporting of patients living on a functioning graft

§ Not all UK centres record whether a patient is on HDF and this is probably an underestimate of HDF usage in the UK

Table A.4.8

Prevalence per million population, adjusted*prevalent patients on December 31, by established therapy, adjusted for age and gender*

	Total	Haemodialysis						Peritoneal dialysis				Transplant				Unkn	Missing
		HD hospital/ centre	HD home	HD type Unkn	HF	HDF	Total HD/ HF/HDF	APD	CAPD	PD type Unkn	Total PD	Living	Deceased	Tx type Unkn	Total Tx		
Austria	1025.5	350.7	0.5	0.2	0.4	108.4	460.2	25.0	22.8	0.7	48.5	76.7	439.7	0.2	516.6	0.2	0
Belgium, Dutch-speaking *	1146.6	352.4	14.6	0	0.6	223.8	591.5	36.6	17.7	0	54.3	28.6	471.0	1.2	500.9	0	0
Belgium, French-speaking *	1337.8	520.1	11.6	0	5.9	174.8	712.5	37.6	23.7	0	61.3	35.4	449.0	75.4	559.8	0.6	3.7
Bosnia and Herzegovina	871.4	715.8	0	0	0	74.2	790.0	0.9	23.0	0.9	24.7	38.6	16.9	1.2	56.7	0	0
Denmark	871.6	327.1	26.1	0			353.2	60.5	33.0	0	93.5	157.7	264.0	0	421.7	3.2	0
Estonia	582.5	186.0	0	0	0.6	7.8	194.5	32.5	1.4	0	33.9	34.8	319.3	0	354.1	0	0
Finland	789.2	165.5	18.7	0	0	70.3	254.6	38.7	24.1	0	62.8	34.6	435.7	1.4	471.8	0	0
France	1182.5	456.5	3.9	0.8	0.9	130.6	592.7	18.5	24.5	0	43.0	48.3	488.9	1.9	539.1	5.5	2.1
Greece	1078.6	602.0	0.1	0	0.3	182.6	785.0	33.6	23.2	0	56.8	98.4	138.6	0	236.9	0	0
Iceland	779.6	179.3	0	0			179.3			97.4	97.4	348.9	153.9	0	502.8	0	0
Norway	949.1	224.7	3.6	0.4			228.7			43.4	43.4	275.8	399.9	1.2	676.9	0	0
Romania	816.6	673.0	0.4	0.1	0.4	3.1	677.0	3.6	72.3	0	75.9	12.6	15.8	35.1	63.5	0.3	0
Serbia	782.3	492.9	3.8	2.4	1.2	94.6	595.0	4.8	60.4	0	65.3	77.1	44.4	0	121.5	0.6	0
Slovenia	969.5	265.3	0	0	1.4	368.9	635.6	2.7	20.7	0.5	23.9	5.5	304.4	0	309.9	0	0
Spain, Andalusia	1159.0	524.6	0.9	0			525.5			49.0	49.0	37.1	547.3	0	584.5	0	0
Spain, Aragon	1047.4	353.8	1.4	0		8.5	363.7	5.4	43.8	0	49.1	43.4	591.2	0	634.6	0	0
Spain, Asturias	959.4	319.8	0	0	0	3.6	323.4	50.1	38.3	0	88.4	25.6	522.0	0	547.6	0	0
Spain, Basque country	1071.2	323.9	1.3	0			325.1	0	82.6	0	82.6	30.0	633.5	0	663.5	0	0
Spain, Cantabria *	928.4	299.1	0	0			299.1	13.3	41.8	0	55.1	36.0	538.3	0	574.2	0	0
Spain, Castile and León *	952.7	371.6	0.9	0			372.5	25.7	35.9	0	61.6	0	518.7	0	518.7	0	0
Spain, Castile-La Mancha *	1040.7	377.0	1.3	0			378.3	17.3	42.3	0	59.6		601.8	601.8	1.0	0	
Spain, Catalonia	1270.0	260.9	0.4	0		266.2	527.4	23.6	30.7	0	54.3	113.8	574.5	0	688.3	0	0
Spain, Extremadura	1037.5	486.7	7.3	0	0	0	494.0	20.2	44.6	0	64.7	7.0	180.7	290.0	477.7	1.0	0
Spain, Galicia	1069.6	438.1	3.0	0			441.1	28.4	61.6	0	90.1	47.1	476.0	15.4	538.4	0	0
Spain, Community of Madrid	1057.0	364.0	2.2	51.3	0	0	417.5	15.7	30.2	11.1	57.0	25.7	483.4	73.3	582.5	0	0
Spain, Region of Murcia	1340.1	691.6	0	0	0	0	691.6	5.2	65.1	0	70.3	26.7	551.5	0	578.1	0	0
Spain, Valencian region	1203.3	630.1	1.9	0			632.0	8.7	66.9	0	75.6	9.1	331.0	153.9	494.0	1.7	0
Sweden	922.3	0	15.0	285.7			300.8			83.6	83.6	234.7	303.2	0	537.9	0.1	0
The Netherlands	940.5	325.8	12.7	0			338.5	29.5	25.6	0	55.1	249.9	296.2	0.7	546.8	0	0
United Kingdom, All countries * §	910.7	329.9	18.8	0.8	0.2	27.4	377.2	29.3	28.3	0.7	58.3	143.6	316.5	15.2	475.3	0	0
United Kingdom, England *	919.4	330.9	19.1	0.6	0.2	32.1	382.9	30.0	29.7	0.7	60.5	146.0	313.9	16.2	476.0	0	0
United Kingdom, Northern Ireland *	921.8	351.4	18.1	13.7	0	10.9	394.0	43.5	4.4	1.2	49.0	147.1	292.4	39.2	478.7	0	0
United Kingdom, Scotland	861.2	336.6	10.1	0			346.8	29.3	13.6	0	42.9	131.8	333.9	5.5	471.2	0.4	0
United Kingdom, Wales *	873.0	294.3	29.5	0	0.3	5.7	329.8	11.9	42.5	0.6	55.0	131.0	355.7	1.5	488.3	0	0

Abbreviations used: HD: haemodialysis; Unkn: unknown; HF: haemofiltration; HDF: haemodiafiltration; APD: automated peritoneal dialysis; CAPD: continuous ambulatory peritoneal dialysis; PD: peritoneal dialysis; Tx: transplant
 Categories may not add up because of rounding off; When cells are left empty, (complete) data are unavailable

* Patients younger than 20 years of age are not reported

|| The overall prevalence of RRT is underestimated by approximately 3% due to an estimated 30% underreporting of patients living on a functioning graft

§ Not all UK centres record whether a patient is on HDF and this is probably an underestimate of HDF usage in the UK

Table A.4.9
Percentages of established therapy, unadjusted
prevalent patients on December 31

	Total	Haemodialysis						Peritoneal dialysis				Transplant				Unkn	Missing
		HD hospital/centre	HD home	HD type Unkn	HF	HDF	Total HD/HF/HDF	APD	CAPD	PD type Unkn	Total PD	Living	Deceased	Tx type Unkn	Total Tx		
		%	%	%	%	%	%	%	%	%	%	%	%	%	%		
Austria	100	34.1	0	0	0	10.6	44.7	2.4	2.2	0.1	4.7	7.4	43.1	0	50.5	0	0
Belgium, Dutch-speaking *	100	31.6	1.3	0	0.1	20.1	53.0	3.1	1.5	0	4.6	2.3	39.9	0.1	42.3	0	0
Belgium, French-speaking *	100	39.1	0.9	0	0.4	12.9	53.4	2.8	1.7	0	4.5	2.7	33.5	5.6	41.8	0	0.3
Bosnia and Herzegovina	100	80.1	0	0	0	9.2	89.2	0.1	3.0	0.1	3.2	5.2	2.2	0.2	7.5	0	0
Denmark	100	37.4	3.0	0	0	0	40.4	7.0	3.8	0	10.8	17.7	30.7	0	48.4	0.4	0
Estonia	100	32.2	0	0	0.1	1.3	33.7	5.6	0.3	0	5.8	5.8	54.6	0	60.5	0	0
Finland	100	21.3	2.3	0	0	9.0	32.6	4.9	3.1	0	8.0	4.3	55.0	0.2	59.4	0	0
France	100	39.4	0.3	0.1	0.1	11.3	51.2	1.6	2.2	0	3.8	3.9	40.4	0.2	44.4	0.5	0.2
Greece	100	57.9	0	0	0	16.5	74.4	3.0	2.2	0	5.2	8.4	12.0	0	20.4	0	0
Iceland	100	21.6	0	0	0	0	21.6	0	0	11.3	11.3	46.8	20.3	0	67.1	0	0
Norway	100	23.2	0.4	0	0	0	23.6	0	0	4.3	4.3	29.8	42.2	0.1	72.0	0	0
Romania	100	82.3	0	0	0	0.4	82.8	0.4	8.8	0	9.3	1.6	2.0	4.3	7.9	0	0
Serbia	100	64.3	0.5	0.3	0.2	12.0	77.2	0.6	7.7	0	8.3	8.9	5.5	0	14.4	0.1	0
Slovenia	100	27.0	0	0	0.1	37.8	64.9	0.3	2.2	0	2.5	0.6	32.0	0	32.5	0	0
Spain, Andalusia	100	44.5	0.1	0	0	0	44.6	0	0	4.2	4.2	3.4	47.9	0	51.3	0	0
Spain, Aragon	100	35.9	0.1	0	0	0.8	36.8	0.5	4.2	0	4.7	3.8	54.6	0	58.5	0	0
Spain, Asturias	100	35.2	0	0	0	0.4	35.6	5.1	4.2	0	9.4	2.4	52.6	0	55.0	0	0
Spain, Basque country	100	31.7	0.1	0	0	0	31.8	0	7.7	0	7.7	2.6	57.9	0	60.5	0	0
Spain, Cantabria *	100	33.7	0	0	0	0	33.7	1.4	4.6	0	6.0	3.6	56.8	0	60.4	0	0
Spain, Castile and León *	100	43.0	0.1	0	0	0	43.1	2.7	3.9	0	6.6	0	50.3	0	50.3	0	0
Spain, Castile-La Mancha *	100	37.9	0.1	0	0	0	38.0	1.7	4.0	0	5.8	0	56.1	56.1	56.1	0.1	0
Spain, Catalonia	100	20.9	0	0	0	21.2	42.2	1.8	2.4	0	4.2	9.1	44.5	0	53.6	0	0
Spain, Extremadura	100	48.5	0.7	0	0	0	49.2	1.9	4.2	0	6.1	0.7	16.6	27.4	44.6	0.1	0
Spain, Galicia	100	43.8	0.3	0	0	0	44.0	2.6	5.7	0	8.3	4.0	42.5	1.2	47.7	0	0
Spain, Community of Madrid	100	33.9	0.2	4.8	0	0	38.9	1.5	2.9	1.0	5.4	2.6	46.1	7.0	55.7	0	0
Spain, Region of Murcia	100	50.8	0	0	0	0	50.8	0.4	4.9	0	5.3	2.2	41.8	0	43.9	0	0
Spain, Valencian region	100	52.7	0.2	0	0	0	52.8	0.7	5.6	0	6.3	0.7	27.3	12.7	40.7	0.1	0
Sweden	100	0	1.6	31.8	0	0	33.3	0	0	9.2	9.2	24.6	32.8	0	57.4	0	0
The Netherlands	100	33.8	1.4	0	0	0	35.1	3.2	2.7	0	5.8	26.9	32.1	0.1	59.0	0	0
United Kingdom, All countries * §	100	36.5	2.1	0.1	0	3.0	41.7	3.2	3.1	0.1	6.4	15.6	34.6	1.7	51.9	0	0
United Kingdom, England *	100	36.2	2.1	0.1	0	3.5	41.9	3.3	3.3	0.1	6.6	15.8	34.0	1.8	51.5	0	0
United Kingdom, Northern Ireland *	100	37.3	2.0	1.4	0	1.2	41.9	4.7	0.5	0.1	5.2	16.4	32.1	4.4	52.9	0	0
United Kingdom, Scotland	100	39.3	1.2	0	0	0	40.5	3.4	1.6	0	5.0	15.1	38.8	0.6	54.5	0	0
United Kingdom, Wales *	100	35.3	3.3	0	0	0.7	39.3	1.4	5.1	0.1	6.5	14.1	39.9	0.2	54.2	0	0

Abbreviations used: HD: haemodialysis; Unkn: unknown; HF: haemofiltration; HDF: haemodiafiltration; APD: automated peritoneal dialysis; CAPD: continuous ambulatory peritoneal dialysis; PD: peritoneal dialysis; Tx: transplant
 Categories may not add up because of rounding off; Percentages are row percentages; When cells are left empty, (complete) data are unavailable

* Patients younger than 20 years of age are not reported

|| The overall prevalence of RRT is underestimated by approximately 3% due to an estimated 30% underreporting of patients living on a functioning graft

§ Not all UK centres record whether a patient is on HDF and this is probably an underestimate of HDF usage in the UK

Table A.5.1
Renal transplants performed in 2013, counts and percentages
by donor type

	Total		Living								Deceased		Donor type Unkn	
	N	%	Related		Unrelated		Type Unkn		All		N	%	N	%
			N	%	N	%	N	%	N	%				
Austria §	415	100	42	10.1	28	6.7	0	0	70	16.9	345	83.1	0	0
Belgium, Dutch-speaking *	262	100	22	8.4	3	1.1	0	0	25	9.5	229	87.4	8	3.1
Belgium, French-speaking *	183	100	10	5.5	2	1.1	0	0	12	6.6	171	93.4	0	0
Bosnia and Herzegovina	24	100	16	66.7	3	12.5	0	0	19	79.2	5	20.8	0	0
Denmark	214	100	57	26.6	49	22.9	0	0	106	49.5	108	50.5	0	0
Estonia	47	100	1	2.1	0	0	0	0	1	2.1	46	97.9	0	0
Finland	187	100	12	6.4	0	0	0	0	12	6.4	175	93.6	0	0
France	3072	100	401	13.1	0	0	0	0	401	13.1	2671	86.9	0	0
Greece	161	100	46	28.6	4	2.5	0	0	50	31.1	111	68.9	0	0
Iceland	8	100	5	62.5	0	0	3	37.5	8	100	0	0	0	0
Norway	269	100	43	16.0	24	8.9	0	0	67	24.9	202	75.1	0	0
Romania	176	100	33	18.8	6	3.4	4	2.3	43	24.4	106	60.2	27	15.3
Serbia	112	100	20	17.9	3	2.7	9	8.0	32	28.6	80	71.4	0	0
Slovenia	61	100	0	0	0	0	0	0	0	0	61	100	0	0
Spain, Andalusia	415	100	37	8.9	23	5.5	0	0	60	14.5	355	85.5	0	0
Spain, Aragon	90	100	11	12.2	0	0	1	1.1	12	13.3	78	86.7	0	0
Spain, Asturias	53	100	5	9.4	0	0	0	0	5	9.4	48	90.6	0	0
Spain, Basque country	162	100	0	0	0	0	38	23.5	38	23.5	124	76.5	0	0
Spain, Cantabria *	61	100	5	8.2	1	1.6	0	0	6	9.8	55	90.2	0	0
Spain, Castile and León *	121	100	0	0	0	0	0	0	0	0	121	100	0	0
Spain, Castile-La Mancha *	115	100											115	100
Spain, Catalonia	539	100	164	30.4	0	0	0	0	164	30.4	375	69.6	0	0
Spain, Extremadura	41	100	1	2.4	1	2.4	0	0	2	4.9	37	90.2	2	4.9
Spain, Galicia	132	100					28	21.2	28	21.2	104	78.8	0	0
Spain, Community of Madrid	356	100	23	6.5	2	0.6	0	0	25	7.0	331	93.0	0	0
Spain, Region of Murcia	63	100	0	0	1	1.6	4	6.3	5	7.9	58	92.1	0	0
Spain, Valencian region	236	100	8	3.4	1	0.4	3	1.3	12	5.1	224	94.9	0	0
Sweden	415	100	90	21.7	61	14.7	0	0	151	36.4	264	63.6	0	0
The Netherlands	947	100					515	54.4	515	54.4	428	45.2	4	0.4
United Kingdom, All countries *	3088	100	444	14.4	229	7.4	334	10.8	1007	32.6	2066	66.9	15	0.5
United Kingdom, England *	2624	100	359	13.7	196	7.5	290	11.1	845	32.2	1768	67.4	11	0.4
United Kingdom, Northern Ireland *	87	100	32	36.8	15	17.2	1	1.1	48	55.2	39	44.8	0	0
United Kingdom, Scotland *	270	100	40	14.8	0	0	43	15.9	83	30.7	183	67.8	4	1.5
United Kingdom, Wales *	116	100	16	13.8	18	15.5	0	0	34	29.3	82	70.7	0	0

Categories may not add up because of rounding off; Percentages are row percentages; When cells are left empty, (complete) data are unavailable

§ Data based on residents and non-residents

* Patients younger than 20 years of age are not reported

|| The transplantation activity reflects 70% of the total transplantation activity in the country, because there is an underreporting of preemptive transplantations

Table A.5.2
Renal transplants performed in 2013, per million population
by donor type

	Total	Living				Deceased	Donor type Unkn
	Pmp	Related	Unrelated	Type Unkn	All	Pmp	Pmp
		Pmp	Pmp	Pmp	Pmp		
Austria §	45.9	4.5	3.2	0	7.7	38.2	0
Belgium, Dutch-speaking *	41.0	3.4	0.5	0	3.9	35.8	1.3
Belgium, French-speaking *	38.7	2.1	0.4	0	2.5	36.2	0
Bosnia and Herzegovina	6.8	4.6	0.9	0	5.4	1.4	0
Denmark	37.7	10.1	8.6	0	18.7	19.0	0
Estonia	35.7	0.8	0	0	0.8	34.9	0
Finland	34.4	2.2	0	0	2.2	32.2	0
France	46.8	6.1	0	0	6.1	40.7	0
Greece	14.7	4.2	0.4	0	4.6	10.1	0
Iceland	24.7	15.4	0	9.3	24.7	0	0
Norway	53.0	8.5	4.7	0	13.2	39.8	0
Romania	8.9	1.7	0.3	0.2	2.2	5.4	1.4
Serbia	16.6	3.0	0.4	1.3	4.8	11.9	0
Slovenia	29.6	0	0	0	0	29.6	0
Spain, Andalusia	49.5	4.4	2.7	0	7.2	42.3	0
Spain, Aragon	67.4	8.2	0	0.7	9.0	58.4	0
Spain, Asturias	49.6	4.7	0	0	4.7	45.0	0
Spain, Basque country	74.6	0	0	17.5	17.5	57.1	0
Spain, Cantabria *	103.6	8.5	1.7	0	10.2	93.4	0
Spain, Castile and León *	48.3	0	0	0	0	48.3	0
Spain, Castile-La Mancha *	55.2						55.2
Spain, Catalonia	71.4	21.7	0	0	21.7	49.6	0
Spain, Extremadura	37.1	0.9	0.9	0	1.8	33.5	1.8
Spain, Galicia	47.9			10.2	10.2	37.8	0
Spain, Community of Madrid	54.8	3.5	0.3	0	3.8	51.0	0
Spain, Region of Murcia	42.8	0	0.7	2.7	3.4	39.4	0
Spain, Valencian region	46.1	1.6	0.2	0.6	2.3	43.8	0
Sweden	43.2	9.4	6.4	0	15.7	27.5	0
The Netherlands	56.4			30.6	30.6	25.5	0.2
United Kingdom, All countries *	48.2	6.9	3.6	5.2	15.7	32.2	0.2
United Kingdom, England *	48.7	6.7	3.6	5.4	15.7	32.8	0.2
United Kingdom, Northern Ireland *	47.5	17.5	8.2	0.5	26.2	21.3	0
United Kingdom, Scotland *	50.7	7.5	0	8.1	15.6	34.3	0.8
United Kingdom, Wales *	37.6	5.2	5.8	0	11.0	26.6	0

Categories may not add up because of rounding off; When cells are left empty, (complete) data are unavailable

§ The number of transplants differs from table A.5.1 as non-residents are excluded for this analysis

* Patients younger than 20 years of age are not reported

|| The transplantation activity reflects 70% of the total transplantation activity in the country, because there is an underreporting of preemptive transplantations

Table A.6.1

90-day, one-, two- and five-year survival probabilities (cohort 2004-2008): Incident RRT patients, unadjusted
from day 1 to 90 days, one, two, and five years, by age, gender, and primary diagnosis

	90 day Survival in % (95% CI)	1 year Survival in % (95% CI)	2 year Survival in % (95% CI)	5 year Survival in % (95% CI)
ALL COUNTRIES *				
0-19	98.8 (97.9-99.3)	96.5 (95.2-97.4)	95.7 (94.3-96.8)	93.6 (92.0-94.9)
20-44	99.0 (98.9-99.2)	96.4 (96.1-96.7)	93.5 (93.1-93.9)	87.2 (86.7-87.7)
45-64	96.6 (96.4-96.8)	89.2 (88.9-89.5)	81.7 (81.3-82.0)	63.9 (63.6-64.3)
65-74	92.8 (92.6-93.1)	79.3 (78.9-79.7)	66.5 (66.1-66.9)	38.3 (38.1-38.6)
75+	88.5 (88.2-88.8)	69.7 (69.3-70.0)	52.7 (52.4-53.0)	20.9 (20.8-21.0)
Men	93.9 (93.8-94.1)	82.3 (82.1-82.6)	71.2 (70.9-71.5)	48.0 (47.8-48.2)
Women	93.2 (92.9-93.4)	81.7 (81.4-82.0)	71.1 (70.8-71.4)	48.8 (48.6-49.1)
Diabetes	94.6 (94.3-94.9)	82.3 (81.8-82.7)	68.8 (68.4-69.2)	40.2 (39.9-40.4)
Hypertension / renal vascular disease	93.8 (93.4-94.1)	80.8 (80.3-81.3)	67.5 (67.0-68.0)	39.3 (39.0-39.6)
Glomerulonephritis	97.3 (97.0-97.6)	91.5 (91.0-91.9)	85.4 (84.8-85.9)	70.2 (69.6-70.8)
Other cause	92.8 (92.6-93.0)	80.9 (80.6-81.2)	70.9 (70.6-71.2)	50.6 (50.4-50.8)
All	93.6 (93.5-93.8)	82.1 (81.9-82.3)	71.2 (71.0-71.4)	48.3 (48.2-48.5)

* Based on data from Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and León), Spain (Castile-La Mancha), Spain (Catalonia), Spain (Extremadura), Spain (Valencian region), Sweden, the Netherlands, United Kingdom (All countries)

Table A.6.2

90-day, one-, two- and five-year survival probabilities (cohort 2004-2008): Incident RRT patients, adjusted
from day 1 to 90 days, one, two, and five years, adjusted for age, gender, and primary diagnosis

	90 day Survival in % (95% CI)	1 year Survival in % (95% CI)	2 year Survival in % (95% CI)	5 year Survival in % (95% CI)
ALL COUNTRIES *				
0-19	98.6 (97.8-99.3)	96.3 (95.0-97.5)	95.5 (94.1-96.8)	93.2 (91.6-94.9)
20-44	99.1 (98.9-99.2)	96.5 (96.1-96.8)	93.5 (93.0-93.9)	87.1 (86.5-87.7)
45-64	96.8 (96.6-97.0)	89.9 (89.6-90.2)	82.7 (82.2-83.1)	65.1 (64.6-65.7)
65-74	93.5 (93.2-93.8)	80.8 (80.4-81.3)	68.6 (68.0-69.1)	40.6 (40.0-41.2)
75+	89.3 (88.9-89.6)	71.1 (70.6-71.7)	54.5 (53.9-55.1)	22.2 (21.7-22.8)
Men	96.5 (96.4-96.6)	89.1 (88.9-89.4)	81.1 (80.8-81.4)	60.0 (59.6-60.5)
Women	96.2 (96.1-96.4)	89.1 (88.9-89.4)	81.8 (81.4-82.1)	62.1 (61.6-62.7)
Diabetes	96.4 (96.2-96.6)	87.8 (87.4-88.1)	77.3 (76.8-77.8)	50.6 (49.9-51.2)
Hypertension / renal vascular disease	97.1 (96.9-97.2)	90.4 (90.1-90.8)	82.7 (82.2-83.2)	61.1 (60.4-61.8)
Glomerulonephritis	97.7 (97.5-98.0)	92.7 (92.2-93.1)	87.0 (86.4-87.6)	71.1 (70.2-71.9)
Other cause	95.5 (95.4-95.7)	87.6 (87.3-87.8)	80.1 (79.7-80.4)	61.2 (60.8-61.7)
All	96.4 (96.3-96.5)	89.2 (89.0-89.3)	81.4 (81.1-81.7)	60.9 (60.5-61.3)

* Based on data from Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and León), Spain (Castile-La Mancha), Spain (Catalonia), Spain (Extremadura), Spain (Valencian region), Sweden, the Netherlands, United Kingdom (All countries)

Table A.6.3

One-, two- and five-year survival probabilities (cohort 2004-2008): Incident RRT patients, unadjusted
from day 91 to one, two, and five years + 90 days, by age, gender, and primary diagnosis

	1 year Survival in % (95% CI)	2 year Survival in % (95% CI)	5 year Survival in % (95% CI)
ALL COUNTRIES *			
0-19	97.6 (96.4-98.4)	96.8 (95.5-97.7)	94.5 (92.9-95.7)
20-44	96.7 (96.4-97.0)	93.8 (93.4-94.2)	87.6 (87.1-88.1)
45-64	90.3 (90.0-90.6)	82.8 (82.5-83.2)	64.7 (64.3-65.0)
65-74	81.8 (81.4-82.2)	68.9 (68.5-69.3)	39.1 (38.9-39.4)
75+	73.7 (73.3-74.1)	55.6 (55.2-55.9)	21.4 (21.3-21.5)
Men	84.6 (84.3-84.8)	73.4 (73.1-73.6)	49.3 (49.1-49.5)
Women	84.7 (84.4-85.1)	73.9 (73.6-74.3)	50.7 (50.4-51.0)
Diabetes	83.3 (82.8-83.7)	69.6 (69.2-70.1)	40.3 (40.0-40.6)
Hypertension / renal vascular disease	82.4 (81.9-82.9)	68.8 (68.3-69.3)	39.8 (39.5-40.1)
Glomerulonephritis	92.5 (92.0-92.9)	86.3 (85.7-86.8)	71.0 (70.4-71.6)
Other cause	84.4 (84.1-84.7)	74.3 (74.0-74.6)	53.0 (52.7-53.2)
All	84.6 (84.4-84.8)	73.6 (73.4-73.8)	49.8 (49.7-50.0)

* Based on data from Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and León), Spain (Castile-La Mancha), Spain (Catalonia), Spain (Extremadura), Spain (Valencian region), Sweden, the Netherlands, United Kingdom (All countries)

Table A.6.4

One-, two- and five-year survival probabilities (cohort 2004-2008): Incident RRT patients, adjusted from day 91 to one, two, and five years + 90 days, adjusted for age, gender, and primary diagnosis

	1 year Survival in % (95% CI)	2 year Survival in % (95% CI)	5 year Survival in % (95% CI)
ALL COUNTRIES *			
0-19	97.4 (96.3-98.4)	96.5 (95.3-97.8)	94.1 (92.5-95.7)
20-44	96.7 (96.4-97.0)	93.7 (93.3-94.2)	87.6 (87.0-88.2)
45-64	90.9 (90.6-91.2)	83.7 (83.3-84.2)	66.2 (65.6-66.7)
65-74	83.1 (82.6-83.6)	70.8 (70.2-71.4)	41.8 (41.2-42.5)
75+	74.9 (74.3-75.4)	57.2 (56.5-57.8)	23.0 (22.5-23.6)
Men	90.3 (90.1-90.5)	82.3 (82.0-82.6)	60.9 (60.5-61.3)
Women	90.8 (90.5-91.0)	83.3 (82.9-83.6)	63.3 (62.7-63.8)
Diabetes	88.3 (87.9-88.7)	77.8 (77.3-78.3)	50.7 (50.0-51.4)
Hypertension / renal vascular disease	91.2 (90.8-91.5)	83.3 (82.9-83.8)	61.5 (60.7-62.2)
Glomerulonephritis	93.4 (93.0-93.8)	87.6 (87.0-88.2)	71.7 (70.9-72.6)
Other cause	89.7 (89.5-90.0)	82.2 (81.8-82.5)	62.8 (62.3-63.3)
All	90.5 (90.3-90.7)	82.7 (82.4-82.9)	61.9 (61.5-62.2)

* Based on data from Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and León), Spain (Castile-La Mancha), Spain (Catalonia), Spain (Extremadura), Spain (Valencian region), Sweden, the Netherlands, United Kingdom (All countries)

Table A.6.5

90-day, one- and two-year survival probabilities (cohort 2007-2011): Incident RRT patients, unadjusted
from day 1 to 90 days, one, and two years, by age, gender, and primary diagnosis

	90 day Survival in % (95% CI)	1 year Survival in % (95% CI)	2 year Survival in % (95% CI)
ALL COUNTRIES *			
0-19	98.8 (97.9-99.3)	97.2 (95.9-98.1)	95.7 (94.2-96.8)
20-44	99.1 (98.9-99.2)	96.8 (96.5-97.1)	94.0 (93.6-94.4)
45-64	97.0 (96.9-97.2)	90.4 (90.1-90.7)	83.4 (83.0-83.7)
65-74	93.7 (93.5-94.0)	81.4 (81.0-81.8)	69.4 (69.0-69.8)
75+	89.7 (89.4-90.0)	71.8 (71.4-72.2)	55.7 (55.4-56.0)
Men	94.5 (94.3-94.6)	83.7 (83.4-83.9)	73.1 (72.9-73.4)
Women	94.1 (93.9-94.3)	83.2 (82.9-83.5)	73.1 (72.7-73.4)
Diabetes	95.3 (95.0-95.6)	83.9 (83.5-84.3)	71.1 (70.7-71.5)
Hypertension / renal vascular disease	94.4 (94.1-94.8)	82.0 (81.5-82.5)	69.2 (68.7-69.6)
Glomerulonephritis	97.5 (97.2-97.7)	92.2 (91.8-92.6)	86.8 (86.2-87.3)
Other cause	93.5 (93.3-93.7)	82.4 (82.1-82.7)	73.0 (72.7-73.3)
All	94.3 (94.2-94.5)	83.5 (83.3-83.7)	73.1 (72.9-73.3)

* Based on data from Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and León), Spain (Castile-La Mancha), Spain (Catalonia), Spain (Extremadura), Spain (Valencian region), Sweden, the Netherlands, United Kingdom (All countries)

Table A.6.6

90-day, one- and two-year survival probabilities (cohort 2007-2011): Incident RRT patients, adjusted from day 1 to 90 days, one, and two years, adjusted for age, gender, and primary diagnosis

	90 day Survival in % (95% CI)	1 year Survival in % (95% CI)	2 year Survival in % (95% CI)
ALL COUNTRIES *			
0-19	98.7 (97.9-99.4)	97.1 (96.0-98.2)	95.6 (94.2-97.0)
20-44	99.1 (99.0-99.3)	96.9 (96.6-97.2)	94.1 (93.7-94.5)
45-64	97.3 (97.1-97.5)	91.0 (90.7-91.3)	84.3 (83.9-84.7)
65-74	94.3 (94.0-94.6)	82.7 (82.3-83.2)	71.2 (70.7-71.7)
75+	90.4 (90.1-90.7)	73.2 (72.7-73.7)	57.5 (56.9-58.1)
Men	96.8 (96.7-96.9)	90.0 (89.8-90.2)	82.6 (82.3-82.9)
Women	96.7 (96.5-96.8)	90.0 (89.7-90.2)	82.9 (82.5-83.3)
Diabetes	96.9 (96.8-97.1)	89.0 (88.7-89.4)	79.4 (78.9-79.9)
Hypertension / renal vascular disease	97.3 (97.2-97.5)	91.0 (90.6-91.3)	83.5 (83.0-84.0)
Glomerulonephritis	97.8 (97.6-98.0)	93.2 (92.8-93.6)	88.1 (87.5-88.7)
Other cause	96.0 (95.8-96.1)	88.6 (88.3-88.8)	81.5 (81.2-81.9)
All	96.8 (96.7-96.9)	90.0 (89.8-90.2)	82.7 (82.5-83.0)

* Based on data from Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and León), Spain (Castile-La Mancha), Spain (Catalonia), Spain (Extremadura), Spain (Valencian region), Sweden, the Netherlands, United Kingdom (All countries)

Table A.6.7

One- and two-year survival probabilities (cohort 2007-2011): Incident RRT patients, unadjusted
from day 91 to one and two years + 90 days, by age, gender, and primary diagnosis

	1 year Survival in % (95% CI)	2 year Survival in % (95% CI)
ALL COUNTRIES *		
0-19	97.9 (96.8-98.6)	96.6 (95.3-97.6)
20-44	97.1 (96.8-97.3)	94.3 (93.9-94.6)
45-64	91.3 (91.0-91.5)	84.2 (83.9-84.6)
65-74	83.6 (83.3-84.0)	71.1 (70.7-71.5)
75+	75.3 (74.9-75.7)	57.9 (57.6-58.3)
Men	85.7 (85.4-85.9)	74.8 (74.6-75.1)
Women	85.7 (85.4-86.0)	75.2 (74.8-75.5)
Diabetes	84.5 (84.1-84.9)	71.4 (71.0-71.9)
Hypertension / renal vascular disease	83.5 (83.0-84.0)	69.9 (69.4-70.4)
Glomerulonephritis	93.2 (92.8-93.7)	87.6 (87.1-88.2)
Other cause	85.5 (85.2-85.8)	75.8 (75.5-76.1)
All	85.7 (85.5-85.9)	75.0 (74.8-75.2)

* Based on data from Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and León), Spain (Castile-La Mancha), Spain (Catalonia), Spain (Extremadura), Spain (Valencian region), Sweden, the Netherlands, United Kingdom (All countries)

Table A.6.8

One- and two-year survival probabilities (cohort 2007-2011): Incident RRT patients, adjusted from day 91 to one and two years + 90 days, adjusted for age, gender, and primary diagnosis

	1 year Survival in % (95% CI)	2 year Survival in % (95% CI)
ALL COUNTRIES *		
0-19	97.9 (96.9-98.8)	96.6 (95.3-97.8)
20-44	97.1 (96.8-97.4)	94.3 (93.9-94.7)
45-64	91.8 (91.5-92.1)	85.2 (84.8-85.6)
65-74	84.7 (84.3-85.2)	73.0 (72.4-73.5)
75+	76.4 (75.9-76.9)	59.8 (59.2-60.4)
Men	91.1 (90.9-91.3)	83.5 (83.2-83.8)
Women	91.3 (91.0-91.5)	84.0 (83.7-84.4)
Diabetes	89.3 (89.0-89.7)	79.6 (79.1-80.1)
Hypertension / renal vascular disease	91.6 (91.3-92.0)	83.8 (83.4-84.3)
Glomerulonephritis	94.0 (93.6-94.4)	88.8 (88.2-89.3)
Other cause	90.4 (90.2-90.7)	83.3 (83.0-83.6)
All	91.2 (91.0-91.3)	83.8 (83.5-84.0)

* Based on data from Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and León), Spain (Castile-La Mancha), Spain (Catalonia), Spain (Extremadura), Spain (Valencian region), Sweden, the Netherlands, United Kingdom (All countries)

Table A.6.9.a

90-day, one-, two- and five-year survival probabilities (cohort 2004-2008): Incident dialysis patients, unadjusted
from day 1 to 90 days, one, two, and five years, by age, gender, and primary diagnosis, with transplantation as censored observation

	90 day Survival in % (95% CI)	1 year Survival in % (95% CI)	2 year Survival in % (95% CI)	5 year Survival in % (95% CI)
ALL COUNTRIES *				
0-19	98.4 (97.2-99.1)	95.4 (93.5-96.8)	93.8 (91.4-95.6)	88.4 (84.2-91.6)
20-44	99.0 (98.8-99.2)	95.9 (95.5-96.2)	91.7 (91.2-92.2)	79.8 (79.0-80.6)
45-64	96.5 (96.3-96.7)	88.7 (88.3-89.0)	80.0 (79.7-80.4)	56.5 (56.1-56.9)
65-74	92.8 (92.5-93.1)	79.1 (78.7-79.5)	66.0 (65.6-66.4)	36.3 (36.1-36.5)
75+	88.5 (88.2-88.8)	69.6 (69.3-70.0)	52.7 (52.3-53.0)	20.8 (20.7-20.9)
Men	93.8 (93.6-94.0)	81.5 (81.3-81.8)	69.1 (68.8-69.4)	40.2 (40.1-40.4)
Women	92.9 (92.7-93.2)	80.8 (80.5-81.1)	69.0 (68.6-69.3)	41.3 (41.1-41.5)
Diabetes	94.5 (94.2-94.8)	81.8 (81.4-82.2)	67.6 (67.1-68.0)	35.0 (34.7-35.2)
Hypertension / renal vascular disease	93.7 (93.4-94.1)	80.6 (80.1-81.1)	66.6 (66.1-67.1)	35.2 (34.9-35.5)
Glomerulonephritis	97.2 (96.9-97.5)	90.7 (90.2-91.2)	83.3 (82.6-83.9)	60.2 (59.6-60.9)
Other cause	92.5 (92.3-92.8)	79.8 (79.5-80.1)	68.5 (68.2-68.8)	42.5 (42.2-42.7)
All	93.5 (93.3-93.6)	81.3 (81.1-81.5)	69.1 (68.9-69.3)	40.6 (40.5-40.8)

Survival was examined using the Kaplan Meier method, with transplantation as censored observation (see methods)

** Based on data from Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and León), Spain (Castile-La Mancha), Spain (Catalonia), Spain (Extremadura), Spain (Valencian region), Sweden, the Netherlands, United Kingdom (All countries)*

Table A.6.9.b (competing risks survival data)

90-day, one-, two- and five-year survival probabilities (cohort 2004-2008): Incident dialysis patients, unadjusted
from day 1 to 90 days, one, two, and five years, by age, gender, and primary diagnosis, with transplantation as competing event

	90 day Survival in % (95% CI)	1 year Survival in % (95% CI)	2 year Survival in % (95% CI)	5 year Survival in % (95% CI)
ALL COUNTRIES *				
0-19	98.4 (97.7-99.1)	96.3 (95.2-97.4)	95.6 (94.4-96.8)	94.4 (93.2-95.7)
20-44	99.0 (98.8-99.1)	96.2 (96.0-96.5)	93.2 (92.9-93.5)	87.5 (87.1-88.0)
45-64	96.5 (96.3-96.6)	89.0 (88.7-89.2)	81.4 (81.1-81.7)	64.9 (64.5-65.3)
65-74	92.7 (92.5-92.9)	79.1 (78.8-79.5)	66.5 (66.1-66.9)	39.3 (38.8-39.8)
75+	88.4 (88.1-88.7)	69.6 (69.1-70.0)	52.6 (52.2-53.1)	20.9 (20.5-21.3)
Men	93.7 (93.6-93.9)	81.9 (81.7-82.1)	70.7 (70.4-70.9)	48.0 (47.7-48.3)
Women	92.9 (92.7-93.1)	81.1 (80.8-81.4)	70.4 (70.0-70.7)	48.3 (47.9-48.7)
Diabetes	94.5 (94.3-94.7)	82.0 (81.6-82.4)	68.6 (68.2-69.0)	40.6 (40.1-41.1)
Hypertension / renal vascular disease	93.7 (93.4-94.0)	80.7 (80.3-81.2)	67.4 (66.9-68.0)	40.1 (39.5-40.7)
Glomerulonephritis	97.1 (96.9-97.4)	91.2 (90.8-91.6)	85.0 (84.6-85.6)	70.6 (69.9-71.3)
Other cause	92.4 (92.3-92.6)	80.2 (80.0-80.5)	70.1 (69.7-70.4)	50.0 (49.7-50.4)
All	93.4 (93.3-93.5)	81.6 (81.4-81.8)	70.5 (70.3-70.8)	48.1 (47.9-48.4)

Survival was examined using the cumulative incidence competing risk method, with transplantation as competing event (see methods)

** Based on data from Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and León), Spain (Castile-La Mancha), Spain (Catalonia), Spain (Extremadura), Spain (Valencian region), Sweden, the Netherlands, United Kingdom (All countries)*

Table A.6.10.a

90-day, one-, two- and five-year survival probabilities (cohort 2004-2008): Incident dialysis patients, adjusted

from day 1 to 90 days, one, two, and five years, adjusted for age, gender, and primary diagnosis, with transplantation as censored observation

	90 day Survival in % (95% CI)	1 year Survival in % (95% CI)	2 year Survival in % (95% CI)	5 year Survival in % (95% CI)
ALL COUNTRIES *				
0-19	98.2 (97.1-99.2)	95.2 (93.5-97.0)	93.4 (91.0-95.8)	86.5 (81.2-92.0)
20-44	99.0 (98.8-99.2)	96.0 (95.6-96.3)	91.7 (91.2-92.3)	79.0 (77.9-80.1)
45-64	96.7 (96.5-96.9)	89.3 (89.0-89.7)	81.1 (80.6-81.6)	57.2 (56.5-57.9)
65-74	93.4 (93.1-93.7)	80.5 (80.0-80.9)	67.8 (67.2-68.4)	37.9 (37.3-38.5)
75+	89.2 (88.8-89.5)	70.9 (70.4-71.5)	54.2 (53.6-54.8)	21.8 (21.3-22.3)
Men	95.9 (95.8-96.1)	87.3 (87.1-87.6)	78.0 (77.6-78.3)	52.6 (52.1-53.2)
Women	95.5 (95.3-95.7)	87.2 (86.9-87.5)	78.6 (78.1-79.0)	55.0 (54.4-55.6)
Diabetes	96.0 (95.7-96.2)	86.3 (85.8-86.7)	74.7 (74.1-75.2)	44.6 (43.9-45.3)
Hypertension / renal vascular disease	96.5 (96.2-96.7)	88.6 (88.2-89.0)	79.4 (78.9-80.0)	54.0 (53.2-54.9)
Glomerulonephritis	97.4 (97.2-97.7)	91.7 (91.2-92.2)	85.0 (84.4-85.7)	63.6 (62.5-64.7)
Other cause	94.7 (94.6-94.9)	85.5 (85.2-85.8)	76.7 (76.3-77.1)	53.8 (53.3-54.4)
All	95.8 (95.7-95.9)	87.3 (87.1-87.5)	78.2 (77.9-78.5)	53.6 (53.1-54.0)

Survival was examined using the Cox regression method, with transplantation as censored observation (see methods)

** Based on data from Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and León), Spain (Castile-La Mancha), Spain (Catalonia), Spain (Extremadura), Spain (Valencian region), Sweden, the Netherlands, United Kingdom (All countries)*

Table A.6.10.b (competing risks survival data)

90-day, one-, two- and five-year survival probabilities (cohort 2004-2008): Incident dialysis patients, adjusted

from day 1 to 90 days, one, two, and five years, adjusted for age, gender, and primary diagnosis, with transplantation as competing event

	90 day Survival in % (95% CI)	1 year Survival in % (95% CI)	2 year Survival in % (95% CI)	5 year Survival in % (95% CI)
ALL COUNTRIES *				
0-19	99.3 (99.3-99.3)	97.9 (97.8-97.9)	96.3 (96.2-96.3)	91.5 (91.3-91.7)
20-44	98.6 (98.6-98.6)	95.7 (95.6-95.8)	92.4 (92.3-92.6)	83.2 (83.0-83.5)
45-64	97.1 (97.1-97.2)	91.3 (91.2-91.4)	85.0 (84.9-85.2)	68.5 (68.2-68.8)
65-74	94.2 (94.1-94.3)	82.9 (82.7-83.1)	71.6 (71.4-71.9)	45.9 (45.6-46.2)
75+	88.4 (88.2-88.6)	68.0 (67.7-68.3)	50.3 (50.0-50.7)	20.1 (19.8-20.4)
Men	96.4 (96.4-96.5)	89.2 (89.1-89.4)	81.6 (81.3-81.8)	61.8 (61.5-62.1)
Women	96.6 (96.5-96.7)	89.7 (89.6-89.9)	82.4 (82.2-82.7)	63.4 (63.0-63.7)
Diabetes	95.8 (95.7-95.9)	87.3 (87.1-87.5)	78.5 (78.2-78.8)	56.6 (56.2-57.0)
Hypertension / renal vascular disease	96.1 (96.0-96.2)	88.3 (88.1-88.4)	80.1 (79.9-80.3)	59.3 (59.0-59.6)
Glomerulonephritis	96.4 (96.3-96.5)	89.2 (89.0-89.3)	81.5 (81.3-81.7)	61.9 (61.6-62.2)
Other cause	96.7 (96.6-96.8)	90.0 (89.9-90.2)	82.9 (82.7-83.1)	64.4 (64.1-64.7)
All	96.5 (96.4-96.6)	89.4 (89.3-89.6)	81.9 (81.7-82.1)	62.4 (62.2-62.8)

Survival was examined using the Fine and Gray competing risk method, with transplantation as competing event (see methods)

** Based on data from Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and León), Spain (Castile-La Mancha), Spain (Catalonia), Spain (Extremadura), Spain (Valencian region), Sweden, the Netherlands, United Kingdom (All countries)*

Table A.6.11.a

One-, two- and five-year survival probabilities (cohort 2004-2008): Incident dialysis patients, unadjusted

from day 91 to one, two, and five years + 90 days, by age, gender, and primary diagnosis, with transplantation as censored observation

	1 year Survival in % (95% CI)	2 year Survival in % (95% CI)	5 year Survival in % (95% CI)
ALL COUNTRIES *			
0-19	96.6 (94.6-97.8)	94.7 (92.1-96.5)	89.3 (84.6-92.7)
20-44	96.0 (95.6-96.4)	91.7 (91.1-92.2)	79.6 (78.7-80.4)
45-64	89.5 (89.2-89.9)	80.8 (80.4-81.2)	56.5 (56.1-56.9)
65-74	81.6 (81.2-82.0)	68.3 (67.9-68.7)	36.8 (36.6-37.1)
75+	73.7 (73.3-74.1)	55.5 (55.2-55.9)	21.3 (21.1-21.4)
Men	83.6 (83.3-83.8)	70.8 (70.6-71.1)	40.6 (40.4-40.8)
Women	83.7 (83.4-84.0)	71.4 (71.0-71.7)	42.2 (41.9-42.4)
Diabetes	82.7 (82.3-83.1)	68.1 (67.7-68.5)	34.5 (34.2-34.7)
Hypertension / renal vascular disease	82.0 (81.4-82.5)	67.6 (67.1-68.1)	35.2 (34.9-35.4)
Glomerulonephritis	91.5 (91.0-92.0)	83.7 (83.0-84.3)	60.0 (59.3-60.7)
Other cause	83.2 (82.9-83.5)	71.5 (71.1-71.8)	43.7 (43.5-43.9)
All	83.6 (83.4-83.8)	71.0 (70.8-71.3)	41.2 (41.0-41.3)

Survival was examined using the Kaplan Meier method, with transplantation as censored observation (see methods)

** Based on data from Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and León), Spain (Castile-La Mancha), Spain (Catalonia), Spain (Extremadura), Spain (Valencian region), Sweden, the Netherlands, United Kingdom (All countries)*

Table A.6.11.b (competing risks survival data)

One-, two- and five-year survival probabilities (cohort 2004-2008): Incident dialysis patients, unadjusted

from day 91 to one, two, and five years + 90 days, by age, gender, and primary diagnosis, with transplantation as competing event

	1 year Survival in % (95% CI)	2 year Survival in % (95% CI)	5 year Survival in % (95% CI)
ALL COUNTRIES *			
0-19	97.3 (96.4-98.2)	96.5 (95.4-97.6)	95.4 (94.1-96.5)
20-44	96.4 (96.2-96.7)	93.4 (93.1-93.8)	87.9 (87.4-88.4)
45-64	90.0 (89.7-90.3)	82.5 (82.2-82.9)	66.0 (65.5-66.4)
65-74	81.7 (81.3-82.0)	68.9 (68.5-69.4)	40.6 (40.1-41.1)
75+	73.6 (73.2-74.1)	55.5 (55.0-56.0)	21.7 (21.3-22.1)
Men	84.0 (83.8-84.3)	72.7 (72.4-73.0)	49.5 (49.2-49.8)
Women	84.1 (83.8-84.4)	73.0 (72.7-73.4)	50.3 (49.9-50.7)
Diabetes	83.0 (82.6-83.3)	69.4 (68.9-69.8)	41.0 (40.5-41.6)
Hypertension / renal vascular disease	82.2 (81.7-82.7)	68.7 (68.1-69.3)	41.0 (40.4-41.7)
Glomerulonephritis	92.1 (91.7-92.5)	85.8 (85.3-86.4)	71.3 (70.8-72.0)
Other cause	83.7 (83.5-84.0)	73.3 (73.0-73.6)	52.5 (52.1-52.8)
All	84.1 (83.9-84.2)	72.8 (72.6-73.0)	49.8 (49.5-50.1)

Survival was examined using the cumulative incidence competing risk method, with transplantation as competing event (see methods)

** Based on data from Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and León), Spain (Castile-La Mancha), Spain (Catalonia), Spain (Extremadura), Spain (Valencian region), Sweden, the Netherlands, United Kingdom (All countries)*

Table A.6.12.a

One-, two- and five-year survival probabilities (cohort 2004-2008): Incident dialysis patients, adjusted

from day 91 to one, two, and five years + 90 days, adjusted for age, gender, and primary diagnosis, with transplantation as censored observation

	1 year Survival in % (95% CI)	2 year Survival in % (95% CI)	5 year Survival in % (95% CI)
ALL COUNTRIES *			
0-19	96.4 (94.7-98.1)	94.0 (91.3-96.7)	86.3 (80.4-92.7)
20-44	96.0 (95.6-96.4)	91.7 (91.1-92.3)	78.9 (77.8-80.0)
45-64	90.2 (89.8-90.5)	81.8 (81.3-82.3)	57.5 (56.8-58.2)
65-74	82.7 (82.2-83.2)	69.9 (69.3-70.5)	38.8 (38.1-39.4)
75+	74.6 (74.0-75.2)	56.8 (56.1-57.4)	22.5 (22.0-23.1)
Men	88.5 (88.2-88.7)	78.9 (78.6-79.3)	52.7 (52.2-53.3)
Women	88.9 (88.6-89.2)	79.9 (79.5-80.3)	55.4 (54.8-56.1)
Diabetes	86.7 (86.3-87.1)	74.8 (74.3-75.4)	44.1 (43.3-44.8)
Hypertension / renal vascular disease	89.2 (88.8-89.6)	79.8 (79.2-80.4)	53.7 (52.9-54.6)
Glomerulonephritis	92.4 (91.9-92.9)	85.4 (84.7-86.1)	63.5 (62.4-64.7)
Other cause	87.8 (87.5-88.1)	78.7 (78.3-79.1)	54.7 (54.1-55.3)
All	88.7 (88.5-88.9)	79.3 (79.0-79.6)	53.8 (53.4-54.3)

Survival was examined using the Cox regression method, with transplantation as censored observation (see methods)

** Based on data from Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and León), Spain (Castile-La Mancha), Spain (Catalonia), Spain (Extremadura), Spain (Valencian region), Sweden, the Netherlands, United Kingdom (All countries)*

Table A.6.12.b (competing risks survival data)

One-, two- and five-year survival probabilities (cohort 2004-2008): Incident dialysis patients, adjusted

from day 91 to one, two, and five years + 90 days, adjusted for age, gender, and primary diagnosis, with transplantation as competing event

	1 year Survival in % (95% CI)	2 year Survival in % (95% CI)	5 year Survival in % (95% CI)
ALL COUNTRIES *			
0-19	98.1 (98.1-98.2)	96.5 (96.4-96.6)	91.7 (91.5-91.9)
20-44	96.2 (96.1-96.3)	93.0 (92.9-93.1)	83.7 (83.4-84.0)
45-64	92.4 (92.3-92.5)	86.1 (85.9-86.3)	69.3 (69.0-69.6)
65-74	84.9 (84.8-85.1)	73.5 (73.2-73.7)	47.0 (46.7-47.3)
75+	71.4 (71.1-71.8)	53.0 (52.6-53.3)	21.1 (20.8-21.5)
Men	90.5 (90.3-90.6)	82.7 (82.5-82.9)	62.5 (62.1-62.9)
Women	91.1 (90.9-91.2)	83.7 (83.5-84.0)	64.5 (64.1-64.9)
Diabetes	88.4 (88.2-88.6)	79.2 (78.9-79.4)	56.3 (55.8-56.7)
Hypertension / renal vascular disease	89.5 (89.4-89.7)	81.1 (80.9-81.3)	59.7 (59.3-60.0)
Glomerulonephritis	90.5 (90.4-90.7)	82.8 (82.6-83.0)	62.9 (62.6-63.2)
Other cause	91.5 (91.3-91.6)	84.5 (84.2-84.7)	66.0 (65.6-66.4)
All	90.7 (90.6-90.8)	83.1 (82.9-83.3)	63.3 (63.0-63.6)

Survival was examined using the Fine and Gray competing risk method, with transplantation as competing event (see methods)

** Based on data from Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and León), Spain (Castile-La Mancha), Spain (Catalonia), Spain (Extremadura), Spain (Valencian region), Sweden, the Netherlands, United Kingdom (All countries)*

Table A.6.13.a

90-day, one- and two-year survival probabilities (cohort 2007-2011): Incident dialysis patients, unadjusted
from day 1 to 90 days, one, and two years, by age, gender, and primary diagnosis, with transplantation as censored observation

	90 day Survival in % (95% CI)	1 year Survival in % (95% CI)	2 year Survival in % (95% CI)
ALL COUNTRIES *			
0-19	98.5 (97.2-99.2)	96.2 (94.3-97.4)	92.8 (90.1-94.8)
20-44	99.0 (98.8-99.2)	96.2 (95.8-96.5)	92.1 (91.5-92.6)
45-64	96.9 (96.7-97.1)	89.6 (89.3-89.9)	81.3 (80.9-81.7)
65-74	93.7 (93.4-93.9)	81.0 (80.6-81.4)	68.6 (68.2-69.0)
75+	89.7 (89.4-90.0)	71.8 (71.4-72.1)	55.6 (55.3-55.9)
Men	94.2 (94.0-94.4)	82.7 (82.4-82.9)	70.7 (70.5-71.0)
Women	93.8 (93.6-94.1)	82.1 (81.8-82.4)	70.6 (70.2-70.9)
Diabetes	95.2 (95.0-95.5)	83.4 (83.0-83.8)	69.7 (69.3-70.1)
Hypertension / renal vascular disease	94.4 (94.0-94.7)	81.6 (81.1-82.1)	68.0 (67.5-68.5)
Glomerulonephritis	97.3 (97.0-97.6)	91.3 (90.8-91.8)	84.4 (83.7-85.0)
Other cause	93.2 (93.0-93.4)	81.1 (80.8-81.4)	70.2 (69.9-70.5)
All	94.1 (93.9-94.2)	82.5 (82.3-82.7)	70.7 (70.5-70.9)

Survival was examined using the Kaplan Meier method, with transplantation as censored observation (see methods)

** Based on data from Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and León), Spain (Castile-La Mancha), Spain (Catalonia), Spain (Extremadura), Spain (Valencian region), Sweden, the Netherlands, United Kingdom (All countries)*

Table A.6.13.b (competing risks survival data)

90-day, one- and two-year survival probabilities (cohort 2007-2011): Incident dialysis patients, unadjusted

from day 1 to 90 days, one, and two years, by age, gender, and primary diagnosis, with transplantation as competing event

	90 day Survival in % (95% CI)	1 year Survival in % (95% CI)	2 year Survival in % (95% CI)
ALL COUNTRIES *			
0-19	98.4 (97.7-99.1)	96.8 (95.8-97.8)	95.1 (93.8-96.2)
20-44	99.0 (98.8-99.1)	96.5 (96.2-96.7)	93.5 (93.1-93.9)
45-64	96.9 (96.7-97.0)	89.9 (89.7-90.2)	82.7 (82.4-83.0)
65-74	93.6 (93.4-93.8)	81.1 (80.7-81.5)	69.2 (68.7-69.6)
75+	89.6 (89.4-89.9)	71.7 (71.3-72.0)	55.6 (55.2-56.0)
Men	94.2 (94.0-94.3)	83.0 (82.8-83.2)	72.2 (72.0-72.5)
Women	93.8 (93.6-94.0)	82.4 (82.1-82.7)	72.0 (71.6-72.3)
Diabetes	95.2 (95.0-95.4)	83.5 (83.2-83.9)	70.6 (70.1-71.1)
Hypertension / renal vascular disease	94.3 (94.0-94.6)	81.8 (81.3-82.2)	68.9 (68.4-69.4)
Glomerulonephritis	97.3 (97.0-97.5)	91.7 (91.4-92.1)	86.1 (85.6-86.6)
Other cause	93.1 (93.0-93.3)	81.5 (81.3-81.8)	71.7 (71.4-72.1)
All	94.0 (93.9-94.2)	82.8 (82.6-83.0)	72.1 (71.9-72.3)

Survival was examined using the cumulative incidence competing risk method, with transplantation as competing event (see methods)

** Based on data from Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and León), Spain (Castile-La Mancha), Spain (Catalonia), Spain (Extremadura), Spain (Valencian region), Sweden, the Netherlands, United Kingdom (All countries)*

Table A.6.14.a

90-day, one- and two-year survival probabilities (cohort 2007-2011): Incident dialysis patients, adjusted

from day 1 to 90 days, one, and two years, adjusted for age, gender, and primary diagnosis, with transplantation as censored observation

	90 day Survival in % (95% CI)	1 year Survival in % (95% CI)	2 year Survival in % (95% CI)
ALL COUNTRIES *			
0-19	98.3 (97.3-99.3)	96.0 (94.4-97.7)	92.5 (89.9-95.2)
20-44	99.0 (98.9-99.2)	96.4 (96.0-96.7)	92.2 (91.7-92.8)
45-64	97.1 (97.0-97.3)	90.3 (90.0-90.6)	82.3 (81.9-82.8)
65-74	94.2 (93.9-94.5)	82.3 (81.8-82.7)	70.2 (69.6-70.8)
75+	90.3 (90.0-90.7)	73.0 (72.5-73.5)	57.2 (56.6-57.8)
Men	96.4 (96.2-96.5)	88.6 (88.3-88.8)	79.9 (79.6-80.3)
Women	96.2 (96.0-96.3)	88.4 (88.1-88.7)	80.2 (79.8-80.6)
Diabetes	96.6 (96.4-96.8)	87.9 (87.5-88.2)	77.2 (76.7-77.7)
Hypertension / renal vascular disease	96.9 (96.7-97.1)	89.5 (89.2-89.9)	80.9 (80.4-81.4)
Glomerulonephritis	97.6 (97.3-97.8)	92.4 (91.9-92.8)	86.3 (85.6-86.9)
Other cause	95.4 (95.2-95.5)	86.9 (86.6-87.2)	78.7 (78.3-79.1)
All	96.3 (96.2-96.4)	88.5 (88.3-88.7)	80.1 (79.8-80.4)

Survival was examined using the Cox regression method, with transplantation as censored observation (see methods)

** Based on data from Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and León), Spain (Castile-La Mancha), Spain (Catalonia), Spain (Extremadura), Spain (Valencian region), Sweden, the Netherlands, United Kingdom (All countries)*

Table A.6.14.b (competing risks survival data)

90-day, one- and two-year survival probabilities (cohort 2007-2011): Incident dialysis patients, adjusted

from day 1 to 90 days, one, and two years, adjusted for age, gender, and primary diagnosis, with transplantation as competing event

	90 day Survival in % (95% CI)	1 year Survival in % (95% CI)	2 year Survival in % (95% CI)
ALL COUNTRIES *			
0-19	99.3 (99.3-99.2)	97.7 (97.7-97.6)	95.9 (96.0-95.8)
20-44	98.6 (98.6-98.5)	95.5 (95.6-95.4)	92.2 (92.3-92.0)
45-64	97.3 (97.3-97.2)	91.5 (91.6-91.4)	85.3 (85.5-85.1)
65-74	94.8 (94.9-94.7)	84.2 (84.3-84.0)	73.5 (73.7-73.2)
75+	90.1 (90.3-89.9)	71.5 (71.9-71.2)	54.9 (55.3-54.5)
Men	96.7 (96.8-96.6)	89.7 (89.9-89.6)	82.3 (82.5-82.1)
Women	96.8 (96.9-96.7)	90.1 (90.3-90.0)	83.0 (83.2-82.7)
Diabetes	96.3 (96.3-96.2)	88.5 (88.6-88.3)	80.2 (80.5-80.0)
Hypertension / renal vascular disease	96.5 (96.5-96.4)	89.1 (89.2-88.9)	81.2 (81.5-81.0)
Glomerulonephritis	96.7 (96.7-96.6)	89.7 (89.8-89.5)	82.2 (82.4-82.0)
Other cause	96.8 (96.9-96.8)	90.2 (90.4-90.0)	83.1 (83.3-82.9)
All	96.7 (96.8-96.7)	89.9 (90.0-89.8)	82.6 (82.8-82.4)

Survival was examined using the Fine and Gray competing risk method, with transplantation as competing event (see methods)

** Based on data from Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and León), Spain (Castile-La Mancha), Spain (Catalonia), Spain (Extremadura), Spain (Valencian region), Sweden, the Netherlands, United Kingdom (All countries)*

Table A.6.15.a

One- and two-year survival probabilities (cohort 2007-2011): Incident dialysis patients, unadjusted

from day 91 to one and two years + 90 days, by age, gender, and primary diagnosis, with transplantation as censored observation

	1 year Survival in % (95% CI)	2 year Survival in % (95% CI)
ALL COUNTRIES *		
0-19	96.9 (95.0-98.1)	93.6 (90.7-95.6)
20-44	96.3 (95.9-96.6)	92.0 (91.4-92.5)
45-64	90.3 (90.0-90.6)	81.8 (81.4-82.2)
65-74	83.2 (82.8-83.6)	70.1 (69.7-70.5)
75+	75.2 (74.8-75.6)	57.8 (57.5-58.2)
Men	84.5 (84.3-84.8)	72.0 (71.8-72.3)
Women	84.4 (84.1-84.8)	72.3 (71.9-72.6)
Diabetes	83.9 (83.5-84.3)	69.7 (69.3-70.2)
Hypertension / renal vascular disease	83.0 (82.5-83.5)	68.4 (67.9-68.9)
Glomerulonephritis	92.2 (91.7-92.6)	84.8 (84.1-85.4)
Other cause	84.1 (83.8-84.4)	72.6 (72.2-72.9)
All	84.5 (84.3-84.7)	72.1 (71.9-72.3)

Survival was examined using the Kaplan Meier method, with transplantation as censored observation (see methods)

** Based on data from Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and León), Spain (Castile-La Mancha), Spain (Catalonia), Spain (Extremadura), Spain (Valencian region), Sweden, the Netherlands, United Kingdom (All countries)*

Table A.6.15.b (competing risks survival data)

One- and two-year survival probabilities (cohort 2007-2011): Incident dialysis patients, unadjusted

from day 91 to one and two years + 90 days, by age, gender, and primary diagnosis, with transplantation as competing event

	1 year Survival in % (95% CI)	2 year Survival in % (95% CI)
ALL COUNTRIES *		
0-19	97.5 (96.6-98.4)	96.0 (94.7-97.1)
20-44	96.6 (96.4-96.9)	93.6 (93.3-94.0)
45-64	90.7 (90.4-90.9)	83.6 (83.3-83.9)
65-74	83.4 (83.0-83.7)	71.1 (70.7-71.6)
75+	75.1 (74.8-75.5)	58.0 (57.6-58.5)
Men	85.0 (84.8-85.2)	74.0 (73.7-74.2)
Women	84.8 (84.6-85.1)	74.1 (73.7-74.4)
Diabetes	84.1 (83.7-84.5)	71.1 (70.6-71.5)
Hypertension / renal vascular disease	83.2 (82.8-83.7)	69.7 (69.2-70.3)
Glomerulonephritis	92.7 (92.3-93.1)	86.9 (86.4-87.5)
Other cause	84.5 (84.3-84.8)	74.5 (74.2-74.8)
All	84.9 (84.7-85.1)	74.0 (73.8-74.2)

Survival was examined using the cumulative incidence competing risk method, with transplantation as competing event (see methods)

** Based on data from Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and León), Spain (Castile-La Mancha), Spain (Catalonia), Spain (Extremadura), Spain (Valencian region), Sweden, the Netherlands, United Kingdom (All countries)*

Table A.6.16.a

One- and two-year survival probabilities (cohort 2007-2011): Incident dialysis patients, adjusted

from day 91 to one and two years + 90 days, adjusted for age, gender, and primary diagnosis, with transplantation as censored observation

	1 year Survival in % (95% CI)	2 year Survival in % (95% CI)
ALL COUNTRIES *		
0-19	96.8 (95.1-98.5)	93.1 (90.2-96.0)
20-44	96.4 (96.0-96.7)	92.1 (91.5-92.7)
45-64	91.0 (90.6-91.3)	82.9 (82.5-83.4)
65-74	84.2 (83.8-84.7)	71.8 (71.2-72.4)
75+	76.2 (75.7-76.7)	59.4 (58.8-60.0)
Men	89.6 (89.3-89.8)	80.7 (80.3-81.0)
Women	89.7 (89.4-90.0)	81.2 (80.8-81.6)
Diabetes	88.0 (87.7-88.4)	77.1 (76.6-77.6)
Hypertension / renal vascular disease	90.1 (89.7-90.5)	80.9 (80.3-81.5)
Glomerulonephritis	93.1 (92.6-93.6)	86.7 (86.0-87.4)
Other cause	88.8 (88.5-89.1)	80.3 (79.9-80.7)
All	89.7 (89.5-89.9)	80.9 (80.6-81.2)

Survival was examined using the Cox regression method, with transplantation as censored observation (see methods)

** Based on data from Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and León), Spain (Castile-La Mancha), Spain (Catalonia), Spain (Extremadura), Spain (Valencian region), Sweden, the Netherlands, United Kingdom (All countries)*

Table A.6.16.b (competing risks survival data)

One- and two-year survival probabilities (cohort 2007-2011): Incident dialysis patients, adjusted

from day 91 to one and two years + 90 days, adjusted for age, gender, and primary diagnosis, with transplantation as competing event

	1 year Survival in % (95% CI)	2 year Survival in % (95% CI)
ALL COUNTRIES *		
0-19	97.9 (97.9-98.0)	96.1 (96.0-96.2)
20-44	96.0 (95.9-96.1)	92.6 (92.4-92.7)
45-64	92.4 (92.3-92.6)	86.1 (86.0-86.3)
65-74	85.9 (85.7-86.1)	75.0 (74.7-75.2)
75+	74.6 (74.2-74.9)	57.3 (56.9-57.7)
Men	90.8 (90.7-91.0)	83.2 (83.0-83.5)
Women	91.3 (91.1-91.4)	84.0 (83.8-84.3)
Diabetes	89.2 (89.0-89.4)	80.5 (80.2-80.8)
Hypertension / renal vascular disease	90.0 (89.9-90.2)	81.9 (81.7-82.2)
Glomerulonephritis	90.8 (90.7-91.0)	83.2 (83.0-83.5)
Other cause	91.5 (91.4-91.7)	84.5 (84.3-84.7)
All	91.0 (90.9-91.2)	83.5 (83.4-83.8)

Survival was examined using the Fine and Gray competing risk method, with transplantation as competing event (see methods)

** Based on data from Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and León), Spain (Castile-La Mancha), Spain (Catalonia), Spain (Extremadura), Spain (Valencian region), Sweden, the Netherlands, United Kingdom (All countries)*

Table A.6.17

One-, two- and five-year survival probabilities (cohort 2004-2008): First transplant patients (deceased donor), unadjusted
from day of transplant to one, two, and five years, by age, gender, and primary diagnosis

	1 year Survival in % (95% CI)	2 year Survival in % (95% CI)	5 year Survival in % (95% CI)
ALL COUNTRIES *			
0-19	98.3 (96.9-99.1)	97.8 (96.2-98.7)	95.7 (93.8-97.1)
20-44	97.9 (97.5-98.3)	97.0 (96.6-97.4)	94.0 (93.4-94.5)
45-64	95.3 (94.9-95.7)	93.0 (92.5-93.4)	85.0 (84.4-85.6)
65+	89.1 (87.7-90.3)	84.7 (83.2-86.1)	70.8 (69.2-72.3)
Men	95.3 (94.9-95.7)	93.2 (92.7-93.6)	86.2 (85.7-86.8)
Women	96.5 (96.0-96.9)	94.6 (94.1-95.1)	88.6 (87.9-89.2)
Diabetes	93.9 (93.0-94.7)	91.3 (90.3-92.2)	81.6 (80.3-82.7)
Hypertension / renal vascular disease	93.0 (91.8-94.0)	89.8 (88.4-91.0)	80.4 (78.8-81.8)
Glomerulonephritis	96.8 (96.3-97.3)	95.3 (94.7-95.9)	90.4 (89.6-91.2)
Other cause	96.3 (95.9-96.7)	94.6 (94.1-95.0)	88.7 (88.1-89.3)
All	95.7 (95.4-96.0)	93.7 (93.4-94.1)	87.1 (86.7-87.5)

* Based on data from Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and León), Spain (Catalonia), Spain (Extremadura), Spain (Valencian region), Sweden, the Netherlands, United Kingdom (All countries)

Table A.6.18

One-, two- and five-year survival probabilities (cohort 2004-2008): First transplant patients (deceased donor), adjusted from day of transplant to one, two, and five years, adjusted for age, gender, and primary diagnosis

	1 year Survival in % (95% CI)	2 year Survival in % (95% CI)	5 year Survival in % (95% CI)
ALL COUNTRIES *			
0-19	98.2 (97.1-99.4)	97.7 (96.4-99.0)	95.5 (93.7-97.3)
20-44	98.1 (97.8-98.4)	97.2 (96.8-97.6)	94.5 (94.0-95.1)
45-64	95.7 (95.3-96.1)	93.5 (93.0-94.0)	86.1 (85.4-86.9)
65+	90.1 (88.7-91.4)	86.0 (84.4-87.6)	73.0 (70.9-75.1)
Men	97.2 (96.9-97.4)	95.9 (95.5-96.2)	91.3 (90.8-91.9)
Women	97.7 (97.4-98.0)	96.5 (96.1-96.9)	92.4 (91.8-93.0)
Diabetes	95.8 (95.1-96.4)	93.8 (93.1-94.6)	86.5 (85.4-87.7)
Hypertension / renal vascular disease	96.6 (96.0-97.2)	94.9 (94.1-95.7)	89.7 (88.6-90.9)
Glomerulonephritis	97.8 (97.4-98.2)	96.7 (96.2-97.2)	93.1 (92.4-93.8)
Other cause	97.5 (97.2-97.8)	96.3 (95.9-96.6)	92.1 (91.6-92.7)
All	97.4 (97.2-97.6)	96.1 (95.9-96.4)	91.8 (91.4-92.2)

* Based on data from Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and León), Spain (Catalonia), Spain (Extremadura), Spain (Valencian region), Sweden, the Netherlands, United Kingdom (All countries)

Table A.6.19

One- and two-year survival probabilities (cohort 2007-2011): First transplant patients (deceased donor), unadjusted
from day of transplant to one and two years, by age, gender, and primary diagnosis

	1 year Survival in % (95% CI)	2 year Survival in % (95% CI)
ALL COUNTRIES *		
0-19	97.9 (96.2-98.9)	97.7 (96.0-98.7)
20-44	98.1 (97.8-98.4)	97.2 (96.8-97.6)
45-64	95.7 (95.3-96.1)	93.4 (92.9-93.8)
65+	90.9 (89.8-91.9)	86.9 (85.7-88.1)
Men	95.7 (95.3-96.0)	93.3 (92.9-93.7)
Women	96.6 (96.1-96.9)	95.0 (94.5-95.5)
Diabetes	94.8 (94.0-95.4)	92.2 (91.3-93.0)
Hypertension / renal vascular disease	93.8 (92.7-94.7)	91.0 (89.8-92.1)
Glomerulonephritis	97.5 (96.9-97.9)	95.9 (95.3-96.5)
Other cause	96.3 (95.9-96.6)	94.4 (93.9-94.8)
All	96.0 (95.7-96.2)	94.0 (93.6-94.3)

** Based on data from Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and León), Spain (Catalonia), Spain (Extremadura), Spain (Valencian region), Sweden, the Netherlands, United Kingdom (All countries)*

Table A.6.20

One- and two-year survival probabilities (cohort 2007-2011): First transplant patients (deceased donor), adjusted from day of transplant to one and two years, adjusted for age, gender, and primary diagnosis

	1 year Survival in % (95% CI)	2 year Survival in % (95% CI)
ALL COUNTRIES *		
0-19		
20-44	98.3 (98.0-98.6)	97.4 (97.0-97.8)
45-64	96.1 (95.7-96.4)	93.9 (93.4-94.4)
65+	91.9 (90.9-93.0)	88.2 (87.0-89.5)
Men	97.5 (97.2-97.7)	96.0 (95.7-96.4)
Women	97.8 (97.5-98.1)	96.8 (96.5-97.2)
Diabetes	96.5 (95.9-97.0)	94.7 (94.0-95.4)
Hypertension / renal vascular disease	96.9 (96.3-97.5)	95.4 (94.7-96.1)
Glomerulonephritis	98.3 (98.0-98.6)	97.3 (96.9-97.7)
Other cause	97.5 (97.2-97.8)	96.3 (95.9-96.6)
All	97.6 (97.4-97.8)	96.4 (96.1-96.6)

* Based on data from Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and León), Spain (Catalonia), Spain (Extremadura), Spain (Valencian region), Sweden, the Netherlands, United Kingdom (All countries)

Table A.6.21

One-, two- and five-year survival probabilities (cohort 2004-2008): First transplant patients (living donor), unadjusted
from day of transplant to one, two, and five years, by age, gender, and primary diagnosis

	1 year Survival in % (95% CI)	2 year Survival in % (95% CI)	5 year Survival in % (95% CI)
ALL COUNTRIES *			
0-19	98.3 (96.5-99.2)	98.3 (96.5-99.2)	97.3 (95.2-98.5)
20-44	99.3 (98.9-99.5)	98.9 (98.4-99.2)	97.7 (97.0-98.1)
45-64	97.8 (97.1-98.3)	96.4 (95.5-97.0)	91.6 (90.5-92.6)
65+	93.6 (90.5-95.7)	90.7 (87.3-93.2)	78.5 (74.7-81.8)
Men	98.1 (97.6-98.5)	97.2 (96.6-97.6)	93.5 (92.8-94.3)
Women	98.6 (98.1-99.0)	97.9 (97.2-98.4)	95.4 (94.5-96.2)
Diabetes	96.3 (94.2-97.6)	93.4 (90.9-95.2)	85.3 (82.3-87.8)
Hypertension / renal vascular disease	95.9 (93.7-97.4)	94.8 (92.4-96.4)	90.2 (87.4-92.4)
Glomerulonephritis	99.2 (98.6-99.5)	98.5 (97.8-99.0)	96.7 (95.7-97.4)
Other cause	98.6 (98.1-98.9)	97.9 (97.4-98.4)	95.1 (94.4-95.8)
All	98.3 (98.0-98.6)	97.4 (97.0-97.8)	94.3 (93.7-94.8)

* Based on data from Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and León), Spain (Catalonia), Spain (Extremadura), Spain (Valencian region), Sweden, the Netherlands, United Kingdom (All countries)

Table A.6.22

One-, two- and five-year survival probabilities (cohort 2004-2008): First transplant patients (living donor), adjusted from day of transplant to one, two, and five years, adjusted for age, gender, and primary diagnosis

	1 year Survival in % (95% CI)	2 year Survival in % (95% CI)	5 year Survival in % (95% CI)
ALL COUNTRIES *			
0-19			
20-44	99.3 (99.0-99.6)	98.9 (98.5-99.3)	97.7 (97.2-98.3)
45-64	98.0 (97.4-98.6)	96.7 (96.0-97.4)	92.5 (91.4-93.6)
65+	94.8 (92.4-97.2)	93.0 (90.3-95.8)	82.1 (78.0-86.5)
Men	98.6 (98.3-99.0)	97.9 (97.5-98.3)	95.1 (94.3-95.8)
Women	98.8 (98.4-99.2)	98.2 (97.7-98.7)	96.3 (95.5-97.0)
Diabetes	97.5 (96.4-98.7)	95.6 (94.0-97.2)	89.8 (87.5-92.3)
Hypertension / renal vascular disease	97.8 (96.7-98.8)	97.1 (95.9-98.3)	94.4 (92.7-96.2)
Glomerulonephritis	99.2 (98.8-99.6)	98.6 (98.1-99.2)	96.9 (96.1-97.8)
Other cause	98.7 (98.4-99.1)	98.2 (97.7-98.6)	95.6 (94.9-96.3)
All	98.7 (98.4-99.0)	98.1 (97.7-98.4)	95.6 (95.0-96.1)

** Based on data from Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and León), Spain (Catalonia), Spain (Extremadura), Spain (Valencian region), Sweden, the Netherlands, United Kingdom (All countries)*

Table A.6.23

One- and two-year survival probabilities (cohort 2007-2011): First transplant patients (living donor), unadjusted
from day of transplant to one and two years, by age, gender, and primary diagnosis

	1 year Survival in % (95% CI)	2 year Survival in % (95% CI)
ALL COUNTRIES *		
0-19	99.3 (97.8-99.8)	99.3 (97.8-99.8)
20-44	99.5 (99.2-99.7)	99.2 (98.8-99.4)
45-64	98.1 (97.6-98.5)	96.8 (96.2-97.3)
65+	95.7 (93.9-97.1)	92.1 (89.9-93.9)
Men	98.6 (98.2-98.9)	97.7 (97.2-98.0)
Women	98.6 (98.2-99.0)	97.5 (96.9-98.0)
Diabetes	96.8 (95.3-97.9)	94.9 (93.0-96.2)
Hypertension / renal vascular disease	97.0 (95.3-98.0)	95.2 (93.3-96.6)
Glomerulonephritis	99.2 (98.7-99.5)	98.5 (97.9-99.0)
Other cause	98.9 (98.5-99.1)	98.0 (97.6-98.4)
All	98.6 (98.3-98.8)	97.6 (97.3-97.9)

** Based on data from Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and León), Spain (Catalonia), Spain (Extremadura), Spain (Valencian region), Sweden, the Netherlands, United Kingdom (All countries)*

Table A.6.24

One- and two-year survival probabilities (cohort 2007-2011): First transplant patients (living donor), adjusted from day of transplant to one and two years, adjusted for age, gender, and primary diagnosis

	1 year Survival in % (95% CI)	2 year Survival in % (95% CI)
ALL COUNTRIES *		
0-19		
20-44	99.5 (99.3-99.7)	99.2 (98.9-99.5)
45-64	98.3 (97.9-98.7)	97.1 (96.5-97.6)
65+	96.0 (94.5-97.6)	92.9 (90.8-95.0)
Men	99.1 (98.9-99.3)	98.6 (98.3-98.9)
Women	99.0 (98.7-99.3)	98.2 (97.7-98.6)
Diabetes	98.1 (97.3-98.9)	96.9 (95.8-98.0)
Hypertension / renal vascular disease	98.5 (97.8-99.2)	97.6 (96.7-98.5)
Glomerulonephritis	99.3 (99.0-99.6)	98.8 (98.3-99.2)
Other cause	99.2 (98.9-99.4)	98.5 (98.2-98.9)
All	99.1 (98.9-99.3)	98.4 (98.2-98.7)

* Based on data from Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and León), Spain (Catalonia), Spain (Extremadura), Spain (Valencian region), Sweden, the Netherlands, United Kingdom (All countries)

Table A.6.25

One-, two- and five-year survival probabilities (cohort 2004-2008): First graft (deceased donor), unadjusted
from day of transplant to one, two, and five years, by age, gender, and primary diagnosis

	1 year Survival in % (95% CI)	2 year Survival in % (95% CI)	5 year Survival in % (95% CI)
ALL COUNTRIES *			
0-19	90.4 (87.9-92.4)	88.2 (85.5-90.4)	77.2 (74.4-79.8)
20-44	92.8 (92.2-93.4)	90.5 (89.8-91.1)	83.6 (82.8-84.4)
45-64	89.5 (88.9-90.1)	86.4 (85.8-87.0)	76.7 (76.0-77.3)
65+	82.3 (80.8-83.8)	78.0 (76.4-79.5)	63.6 (62.1-65.0)
Men	90.0 (89.5-90.5)	87.0 (86.4-87.5)	77.5 (76.9-78.1)
Women	90.0 (89.3-90.6)	87.3 (86.5-88.0)	78.4 (77.6-79.1)
Diabetes	89.4 (88.4-90.4)	86.0 (84.9-87.1)	74.4 (73.2-75.6)
Hypertension / renal vascular disease	86.6 (85.1-87.9)	83.1 (81.6-84.5)	71.0 (69.5-72.5)
Glomerulonephritis	90.8 (89.9-91.6)	87.8 (86.9-88.7)	79.7 (78.7-80.7)
Other cause	90.5 (89.9-91.0)	87.9 (87.3-88.5)	79.5 (78.8-80.1)
All	90.0 (89.6-90.4)	87.1 (86.6-87.5)	77.8 (77.4-78.3)

* Based on data from Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and León), Spain (Catalonia), Spain (Extremadura), Spain (Valencian region), Sweden, the Netherlands, United Kingdom (All countries)

Table A.6.26

One-, two- and five-year survival probabilities (cohort 2004-2008): First graft (deceased donor), adjusted from day of transplant to one, two, and five years, adjusted for age, gender, and primary diagnosis

	1 year Survival in % (95% CI)	2 year Survival in % (95% CI)	5 year Survival in % (95% CI)
ALL COUNTRIES *			
0-19	90.0 (87.5-92.6)	87.7 (84.9-90.6)	76.3 (72.7-80.1)
20-44	93.0 (92.4-93.7)	90.8 (90.1-91.5)	84.2 (83.3-85.2)
45-64	89.8 (89.2-90.5)	86.9 (86.2-87.6)	77.3 (76.5-78.2)
65+	83.1 (81.4-84.9)	78.9 (77.0-80.9)	64.8 (62.6-67.1)
Men	91.4 (90.9-91.9)	88.8 (88.2-89.4)	80.4 (79.6-81.2)
Women	91.1 (90.4-91.8)	88.7 (87.9-89.4)	80.6 (79.6-81.5)
Diabetes	90.4 (89.3-91.4)	87.2 (86.0-88.5)	76.3 (74.8-77.9)
Hypertension / renal vascular disease	89.3 (88.0-90.6)	86.6 (85.1-88.0)	76.4 (74.5-78.3)
Glomerulonephritis	91.5 (90.6-92.3)	88.8 (87.8-89.7)	81.1 (80.0-82.4)
Other cause	91.4 (90.9-92.0)	89.0 (88.4-89.7)	81.3 (80.4-82.1)
All	91.3 (90.9-91.7)	88.7 (88.3-89.2)	80.5 (79.8-81.1)

* Based on data from Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and León), Spain (Catalonia), Spain (Extremadura), Spain (Valencian region), Sweden, the Netherlands, United Kingdom (All countries)

Table A.6.27

One- and two-year survival probabilities (cohort 2007-2011): First graft (deceased donor), unadjusted
from day of transplant to one and two years, by age, gender, and primary diagnosis

	1 year Survival in % (95% CI)	2 year Survival in % (95% CI)
ALL COUNTRIES *		
0-19	91.3 (88.7-93.4)	88.2 (85.4-90.5)
20-44	93.3 (92.8-93.9)	91.2 (90.6-91.8)
45-64	90.4 (89.8-90.9)	87.2 (86.6-87.8)
65+	85.1 (83.9-86.3)	81.4 (80.0-82.6)
Men	90.6 (90.2-91.1)	87.6 (87.1-88.1)
Women	90.9 (90.3-91.5)	88.3 (87.6-88.9)
Diabetes	90.4 (89.5-91.3)	87.2 (86.2-88.2)
Hypertension / renal vascular disease	87.8 (86.5-89.0)	84.9 (83.5-86.1)
Glomerulonephritis	92.0 (91.2-92.8)	89.2 (88.3-90.0)
Other cause	90.9 (90.3-91.4)	88.1 (87.5-88.6)
All	90.7 (90.4-91.1)	87.9 (87.4-88.2)

** Based on data from Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and León), Spain (Catalonia), Spain (Extremadura), Spain (Valencian region), Sweden, the Netherlands, United Kingdom (All countries)*

Table A.6.28

One- and two-year survival probabilities (cohort 2007-2011): First graft (deceased donor), adjusted from day of transplant to one and two years, adjusted for age, gender, and primary diagnosis

	1 year Survival in % (95% CI)	2 year Survival in % (95% CI)
ALL COUNTRIES *		
0-19	91.1 (88.6-93.7)	88.0 (85.1-91.0)
20-44	93.5 (92.9-94.1)	91.4 (90.7-92.1)
45-64	90.6 (90.0-91.2)	87.5 (86.9-88.2)
65+	85.9 (84.5-87.3)	82.2 (80.7-83.8)
Men	92.0 (91.5-92.5)	89.4 (88.8-89.9)
Women	91.9 (91.3-92.5)	89.5 (88.8-90.2)
Diabetes	91.4 (90.5-92.3)	88.5 (87.4-89.5)
Hypertension / renal vascular disease	90.2 (89.0-91.4)	87.7 (86.3-89.0)
Glomerulonephritis	92.8 (92.0-93.6)	90.2 (89.3-91.1)
Other cause	91.8 (91.3-92.3)	89.3 (88.7-89.9)
All	92.0 (91.6-92.4)	89.4 (89.0-89.9)

** Based on data from Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and León), Spain (Catalonia), Spain (Extremadura), Spain (Valencian region), Sweden, the Netherlands, United Kingdom (All countries)*

Table A.6.29

One-, two- and five-year survival probabilities (cohort 2004-2008): First graft (living donor), unadjusted
from day of transplant to one, two, and five years, by age, gender, and primary diagnosis

	1 year Survival in % (95% CI)	2 year Survival in % (95% CI)	5 year Survival in % (95% CI)
ALL COUNTRIES *			
0-19	94.9 (92.4-96.5)	92.9 (90.2-94.9)	84.0 (80.8-86.8)
20-44	95.5 (94.8-96.2)	93.9 (93.0-94.7)	88.8 (87.7-89.8)
45-64	95.6 (94.7-96.3)	93.5 (92.4-94.3)	86.6 (85.4-87.8)
65+	91.7 (88.4-94.1)	88.1 (84.6-90.9)	75.9 (72.1-79.3)
Men	95.1 (94.4-95.8)	93.4 (92.6-94.1)	86.4 (85.5-87.4)
Women	95.6 (94.7-96.4)	93.3 (92.3-94.2)	87.7 (86.5-88.9)
Diabetes	93.4 (90.9-95.3)	89.9 (87.1-92.1)	80.0 (76.9-82.8)
Hypertension / renal vascular disease	92.5 (89.9-94.5)	89.8 (86.9-92.0)	81.1 (77.9-83.9)
Glomerulonephritis	95.8 (94.7-96.6)	93.4 (92.2-94.5)	87.1 (85.6-88.5)
Other cause	95.7 (94.9-96.3)	94.2 (93.4-94.9)	88.6 (87.6-89.5)
All	95.3 (94.8-95.8)	93.3 (92.7-93.9)	86.9 (86.2-87.7)

* Based on data from Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and León), Spain (Catalonia), Spain (Extremadura), Spain (Valencian region), Sweden, the Netherlands, United Kingdom (All countries)

Table A.6.30

One-, two- and five-year survival probabilities (cohort 2004-2008): First graft (living donor), adjusted from day of transplant to one, two, and five years, adjusted for age, gender, and primary diagnosis

	1 year Survival in % (95% CI)	2 year Survival in % (95% CI)	5 year Survival in % (95% CI)
ALL COUNTRIES *			
0-19	94.2 (91.8-96.6)	92.2 (89.5-95.0)	82.5 (78.6-86.5)
20-44	95.5 (94.7-96.3)	93.8 (92.9-94.7)	88.7 (87.5-89.9)
45-64	95.6 (94.8-96.5)	93.5 (92.5-94.6)	86.9 (85.5-88.3)
65+	92.7 (89.8-95.6)	90.1 (86.8-93.5)	78.3 (73.8-83.1)
Men	95.2 (94.4-95.9)	93.4 (92.6-94.2)	86.4 (85.3-87.6)
Women	95.4 (94.5-96.3)	93.1 (92.0-94.2)	87.4 (86.0-88.9)
Diabetes	93.7 (91.5-95.9)	90.2 (87.6-93.0)	80.6 (77.1-84.3)
Hypertension / renal vascular disease	92.9 (90.6-95.3)	90.4 (87.7-93.1)	82.1 (78.6-85.7)
Glomerulonephritis	95.7 (94.7-96.7)	93.3 (92.0-94.6)	86.9 (85.2-88.6)
Other cause	95.5 (94.8-96.2)	94.1 (93.2-94.9)	88.3 (87.1-89.4)
All	95.2 (94.7-95.8)	93.3 (92.6-94.0)	86.8 (85.9-87.7)

* Based on data from Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and León), Spain (Catalonia), Spain (Extremadura), Spain (Valencian region), Sweden, the Netherlands, United Kingdom (All countries)

Table A.6.31

One- and two-year survival probabilities (cohort 2007-2011): First graft (living donor), unadjusted
from day of transplant to one and two years, by age, gender, and primary diagnosis

	1 year Survival in % (95% CI)	2 year Survival in % (95% CI)
ALL COUNTRIES *		
0-19	95.6 (93.3-97.2)	94.4 (91.9-96.1)
20-44	96.2 (95.5-96.7)	94.4 (93.6-95.1)
45-64	95.7 (95.0-96.3)	93.7 (92.9-94.4)
65+	94.2 (92.1-95.7)	90.6 (88.2-92.5)
Men	95.7 (95.2-96.2)	94.1 (93.5-94.7)
Women	95.9 (95.1-96.5)	93.3 (92.4-94.1)
Diabetes	94.9 (93.0-96.3)	92.2 (90.0-93.8)
Hypertension / renal vascular disease	93.8 (91.7-95.3)	90.9 (88.6-92.7)
Glomerulonephritis	95.4 (94.4-96.2)	93.7 (92.6-94.6)
Other cause	96.4 (95.9-96.9)	94.6 (93.9-95.2)
All	95.8 (95.3-96.2)	93.8 (93.3-94.3)

** Based on data from Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and León), Spain (Catalonia), Spain (Extremadura), Spain (Valencian region), Sweden, the Netherlands, United Kingdom (All countries)*

Table A.6.32

One- and two-year survival probabilities (cohort 2007-2011): First graft (living donor), adjusted from day of transplant to one and two years, adjusted for age, gender, and primary diagnosis

	1 year Survival in % (95% CI)	2 year Survival in % (95% CI)
ALL COUNTRIES *		
0-19	95.0 (92.8-97.3)	93.9 (91.5-96.4)
20-44	96.2 (95.5-96.8)	94.5 (93.7-95.2)
45-64	95.7 (95.1-96.4)	93.8 (93.0-94.6)
65+	94.3 (92.4-96.3)	90.9 (88.6-93.4)
Men	95.9 (95.3-96.5)	94.4 (93.8-95.1)
Women	95.8 (95.0-96.5)	93.1 (92.2-94.0)
Diabetes	95.1 (93.6-96.8)	92.5 (90.6-94.5)
Hypertension / renal vascular disease	94.2 (92.4-96.0)	91.5 (89.4-93.7)
Glomerulonephritis	95.2 (94.3-96.2)	93.5 (92.4-94.6)
Other cause	96.4 (95.8-96.9)	94.6 (93.9-95.3)
All	95.8 (95.4-96.3)	93.9 (93.4-94.5)

* Based on data from Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and León), Spain (Catalonia), Spain (Extremadura), Spain (Valencian region), Sweden, the Netherlands, United Kingdom (All countries)

Figure A.6.1
**Adjusted survival (cohort 2004-2008):
 Incident dialysis patients and patients receiving
 a first transplant (between 2004 and 2008)**
*from day 91, by modality,
 adjusted for age, gender, and primary diagnosis*




Figure A.6.2
**Adjusted survival (cohort 2004-2008):
 Incident haemodialysis patients**
*from day 91, by primary diagnosis,
 adjusted for age and gender*





Figure A.6.3
**Adjusted survival (cohort 2004-2008):
 Incident peritoneal dialysis patients**
*from day 91, by primary diagnosis,
 adjusted for age and gender*



Survival on dialysis was examined using the Cox regression method, with transplantation as censored observation (see methods)

Figure A.6.4
**Adjusted survival (cohort 2004-2008):
 Incident dialysis patients and patients receiving
 a first transplant (between 2004 and 2008)**
*from day 91, by modality,
 adjusted for age, gender, and primary diagnosis*




Figure A.6.5
**Adjusted survival (cohort 2004-2008):
 Incident haemodialysis patients**
*from day 91, by primary diagnosis,
 adjusted for age and gender*





Figure A.6.6
**Adjusted survival (cohort 2004-2008):
 Incident peritoneal dialysis patients**
*from day 91, by primary diagnosis,
 adjusted for age and gender*



Survival on dialysis was examined using the Fine and Gray competing risk method, with transplantation as competing event (see methods)

Table A.7.1

Expected remaining lifetimes (years) of the general population in 2010, and of prevalent dialysis and transplant patients in 2012 and 2013 (includes mortality in the first 90 days)*by age and gender*

General population				ESRD: Dialysis				ESRD: Transplant			
Age	All	Men	Women	Age	All	Men	Women	Age	All	Men	Women
0	80.7	78.5	82.9	0-19	37.9	37.7	38.3	0-19	60.4	59.7	61.4
5	76.1	73.8	78.2								
10	71.1	68.9	73.3								
15	66.1	63.9	68.3								
20	61.2	59.0	63.3	20-24	21.2	21.2	21.3	20-24	42.3	41.6	43.5
25	56.3	54.2	58.4	25-29	19.0	19.0	18.9	25-29	38.0	37.5	38.8
30	51.4	49.3	53.5	30-34	15.9	15.8	16.0	30-34	33.6	33.2	34.4
35	46.6	44.5	48.6	35-39	13.6	13.5	13.8	35-39	29.5	29.1	30.1
40	41.7	39.7	43.7	40-44	11.6	11.4	11.9	40-44	25.6	25.2	26.3
45	37.0	35.0	38.9	45-49	9.8	9.5	10.2	45-49	21.9	21.5	22.6
50	32.3	30.4	34.2	50-54	8.1	8.0	8.4	50-54	18.3	17.9	18.9
55	27.8	26.0	29.5	55-59	6.9	6.6	7.2	55-59	15.1	14.8	15.6
60	23.5	21.8	25.1	60-64	5.9	5.8	6.1	60-64	12.2	12.0	12.5
65	19.3	17.8	20.7	65-69	5.1	5.0	5.3	65-69	9.7	9.6	9.8
70	15.4	14.1	16.6	70-74	4.4	4.3	4.5	70-74	7.2	7.2	7.3
75	11.8	10.7	12.7	75-79	3.6	3.6	3.7	75-79	5.0	5.0	5.0
80	8.6	7.7	9.2	80-84	2.5	2.5	2.5				
85	6.0	5.4	6.3								

Based on data from Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque Country), Spain (Cantabria), Spain (Castile and León), Spain (Catalonia), Spain (Valencian region), Sweden, the Netherlands, United Kingdom (England and Wales), United Kingdom (Scotland)

III Reference Tables - Section B

Table B.1.1
General population of the country/region and percent coverage of general population

	General population of whole country/region in thousands	% Coverage of general population by the registry
Albania	2890	100
Bulgaria	7364	97.0
Croatia	4284	80.0
Cyprus	855	100
Czech Republic	10512	98.0
Georgia	4484	95.6
Israel	8059	100
Latvia	2001	80.0
Lithuania	2972	100
Montenegro	620	100
Poland	38564	95.0
Portugal	10487	100
Russia	143667	100
Slovakia	5414	100
Spain (18 of 19 regions)	47130	95.3
Switzerland	8091	94.0
Turkey	76666	100
Ukraine	45373	100

Table B.1.2

Renal centres: total number of centres and number of collaborating centres

	Total number of renal centres of whole country/region	Number of renal centres collaborating with the registry
Albania	8	8
Bulgaria	68	66
Croatia	48	34
Cyprus	6	6
Czech Republic	103	100
Georgia	15	14
Israel	76	76
Latvia	24	22
Lithuania	62	62
Montenegro	10	10
Poland	280	276
Portugal	120	120
Russia *	426	410
Slovakia	69	69
Spain (18 of 19 regions)	340	325
Switzerland	85	79
Turkey	1054	1054
Ukraine	64	64

* Some renal centres are non-operational

Table B.2.1
Incident counts and incident rates per million population, unadjusted
at day 1

	All		Men		Women	
	N	Pmp	N	Pmp	N	Pmp
Albania	214	74.0	137	94.1	77	53.7
Bulgaria †	1184	165.8	591	171.3	593	160.5
Croatia	537	156.7	321	194.3	216	121.7
Cyprus	160	187.1	116	278.2	44	100.5
Czech Republic †	2045	198.5				
Georgia	775	180.8	484	236.7	291	129.8
Israel	1462	181.4	944	236.5	518	127.3
Latvia	129	80.6	77	105.0	52	60.0
Lithuania †	332	111.7	212	154.9	120	74.9
Montenegro	17	27.4	12	39.2	5	15.9
Poland	4876	133.1				
Portugal	2417	230.5				
Russia	7196	50.1	3888	58.4	3308	42.9
Slovakia †	855	157.9	488	185.0	367	132.2
Spain (18 of 19 regions)	5705	127.0	3746	169.5	1959	85.9
Switzerland †	713	93.7	457	121.7	256	66.5
Turkey	10601	138.3				
Ukraine	1350	29.8				

Categories may not add up to total or to 100% because of missing values

When cells are left empty, the data are unavailable

† Data include dialysis patients only

Table B.2.2
Gender, mean age, and median age of incident patients
at day 1

	All				Men				Women			
	%	Mean (years)	SD	Median (years)	%	Mean (years)	SD	Median (years)	%	Mean (years)	SD	Median (years)
Albania	100	52.6	14.4	55.0	64.0	52.1	14.6	53.0	36.0	53.6	14.3	57.0
Bulgaria †	100				49.9				50.1			
Croatia	100	64.3	13.5	67.0	59.8	63.2	13.6	65.0	40.2	66.0	13.0	70.0
Cyprus	100	65.4	14.5	67.0	72.5	66.2	13.6	69.0	27.5	63.0	16.7	64.0
Czech Republic												
Georgia	100	58.9	15.8	60.5	62.5	58.2	15.0	59.3	37.5	60.1	16.6	62.3
Israel	100	64.0	17.4	66.5	64.6	63.6	17.3	66.0	35.4	64.8	17.6	67.7
Latvia	100	60.6	15.7	64.0	59.7	58.5	16.8	59.0	40.3	63.6	13.6	66.0
Lithuania †	100				63.9				36.1			
Montenegro	100	62.3	11.4	62.0	70.6	64.5	10.6	57.0	29.4	57.0	12.8	62.0
Poland												
Portugal												
Russia	100	53.8	15.5	56.0	54.0	52.5	15.7	55.0	46.0	55.4	15.2	57.0
Slovakia †	100	62.9	13.7	64.0	57.1	61.3	13.5	62.0	42.9	65.0	13.9	67.0
Spain (18 of 19 regions)	100	62.7	0.9	67.4	65.7	62.7	1.1	67.3	34.3	62.6	1.5	67.7
Switzerland †	100	65.5	15.1	68.3	64.1	66.2	14.0	67.9	35.9	64.5	16.9	68.5
Turkey												
Ukraine												

Categories may not add up to total or to 100% because of missing values or rounding off

When cells are left empty, the data are unavailable

† Data include dialysis patients only

Table B.2.3
Incident rates per million population, adjusted
at day 1, adjusted for age and gender

	All	Men	Women
	Pmp	Pmp	Pmp
Albania	90.1	114.4	65.8
Bulgaria			
Croatia	149.9	194.0	112.7
Cyprus	226.0	322.9	118.7
Czech Republic			
Georgia	199.9	274.7	139.3
Israel	269.2	345.0	191.9
Latvia			
Lithuania †	112.5	166.9	71.5
Montenegro	41.2	66.5	18.5
Poland			
Portugal			
Russia			
Slovakia †	176.0	215.0	144.1
Spain (18 of 19 regions)	121.4	158.6	83.1
Switzerland †	93.9	119.1	67.7
Turkey			
Ukraine			

When cells are left empty, the data are unavailable

† Data include dialysis patients only

Table B.2.4
Incident rates per million population and percentages, unadjusted
at day 1, by cause of renal failure

	Total		GN		PN		PKD		DM						HT		RVD		Misc		Unkn		Missing	
	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Type I		Type II		Both		Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%
									Pmp	%	Pmp	%	Pmp	%										
Albania	74.0	100	9.3	12.6	18.3	24.8	2.8	3.7	1.7	2.3	8.0	10.7	9.7	13.1	5.5	7.5	1.7	2.3	6.2	8.4	20.4	27.6	0	0
Bulgaria †	165.8	100	25.6	15.5	16.5	10.0	16.0	9.6					36.0	21.7	16.5	10.0	18.2	11.0	18.8	11.3	14.6	8.8	3.6	2.2
Croatia	156.7	100	15.2	9.7	13.7	8.8	8.2	5.2	7.9	5.0	36.8	23.5	44.6	28.5	23.1	14.7	5.5	3.5	30.9	19.7	15.5	9.9	0	0
Cyprus	187.1	100	15.2	8.1	9.4	5.0	8.2	4.4	4.7	2.5	53.8	28.8	58.5	31.3	30.4	16.3	1.2	0.6	31.6	16.9	15.2	8.1	17.5	9.4
Czech Republic																								
Georgia	180.8	100	21.2	11.7	13.3	7.4	10.5	5.8	5.4	3.0	32.0	17.7	37.3	20.6	16.1	8.9	8.4	4.6	19.1	10.6	49.5	27.4	5.4	3.0
Israel	181.4	100	11.2	6.2	4.6	2.5	5.6	3.1	52.7	29.1	30.5	16.8	83.3	45.9	16.3	9.0	6.8	3.8	22.0	12.1	23.0	12.7	8.8	4.9
Latvia	80.6	100	11.9	14.7	7.5	9.3	5.6	7.0	1.2	1.6	12.5	15.5	13.7	17.1	11.9	14.7	0	0	15.6	19.4	14.4	17.8	0	0
Lithuania † +	111.7	100	15.1	13.6	6.1	5.4	1.7	1.5					13.8	12.3	20.2	18.1			21.5	19.3	0	0	33.3	29.8
Montenegro	27.4	100	6.5	23.5	0	0	0	0	6.5	23.5	1.6	5.9	8.1	29.4	4.8	17.6	0	0	6.5	23.5	1.6	5.9	0	0
Poland	133.1	100	22.4	16.8	3.5	2.6	5.1	3.8					28.1	21.1	21.5	16.2	1.0	0.8	10.1	7.6	23.3	17.5	18.1	13.6
Portugal & +	230.5	100	22.9	9.9			11.1	4.8					69.9	30.3	26.5	11.5			44.4	19.3	39.7	17.2	6.5	2.8
Russia	50.1	100	11.4	22.7	7.4	14.7	3.9	7.8	2.7	5.4	5.9	11.8	8.6	17.1	5.1	10.1	0.3	0.5	6.2	12.5	7.3	14.5	0	0
Slovakia †	157.9	100	17.7	11.2	15.9	10.1	5.4	3.4					61.1	38.7	12.4	7.8	7.2	4.6	34.4	21.8	3.9	2.5	0	0
Spain (18 of 19 regions) ¶	127.0	100	15.7	12.4	11.2	8.8	9.1	7.2					31.3	24.6	20.6	16.2			13.0	10.2	26.1	20.5	0	0
Switzerland †	93.7	100	12.1	12.9	1.3	1.4	6.2	6.6	2.6	2.8	20.1	21.5	22.7	24.3	17.2	18.4	3.8	4.1	21.7	23.1	8.7	9.3	0	0
Turkey ‡	85.1	100	6.3	7.4	1.0	1.2	2.4	2.9	3.8	4.4	24.3	28.6	28.1	33.0	23.5	27.6	0.8	0.9	11.1	13.0	11.3	13.3	0.6	0.7
Ukraine +	29.8	100	11.2	37.6	4.9	16.4	2.9	9.8					5.2	17.5	1.6	5.5			3.5	11.8	0.1	0.4	0.3	1.0

Abbreviations used: GN: glomerulonephritis/sclerosis; PN: pyelonephritis; PKD: polycystic kidneys, adult type; DM: diabetes mellitus; HT: hypertension; RVD: renal vascular disease; Misc: miscellaneous; Unkn: unknown

When cells are left empty, the data are unavailable

† Data include dialysis patients only

‡ Data available for 6524 of 10601 patients (62%)

& Pyelonephritis is not reported separately, but is included into miscellaneous

+ Renal vascular disease is not reported separately, but is included into miscellaneous

¶ Renal vascular disease is not reported separately, but is included into hypertension

Table B.3.1
Incident counts and incident rates per million population, unadjusted
at day 91

	All		Men		Women	
	N	Pmp	N	Pmp	N	Pmp
Albania	171	59.2	115	79.0	56	39.1
Bulgaria †	945	132.3	478	138.6	467	126.4
Croatia	457	133.3	265	160.4	192	108.2
Cyprus	150	175.4	110	263.8	40	91.3
Czech Republic †	1435	139.3				
Georgia	637	148.6	398	194.7	239	106.6
Israel	1384	171.7	900	225.5	484	119.0
Latvia	113	70.6	67	91.3	46	53.0
Lithuania †	316	106.3	203	148.3	113	70.5
Montenegro	14	22.6	11	35.9	3	9.6
Poland						
Portugal	2296	218.9				
Russia						
Slovakia †	717	132.4	426	161.5	291	104.8
Spain (18 of 19 regions)						
Switzerland						
Turkey						
Ukraine						

Categories may not add up to total or to 100% because of missing values

When cells are left empty, the data are unavailable

† Data include dialysis patients only

Table B.3.2
Gender, mean age, and median age of incident patients
at day 91

	All				Men				Women			
	%	Mean (years)	SD	Median (years)	%	Mean (years)	SD	Median (years)	%	Mean (years)	SD	Median (years)
Albania	100	51.4	14.2	54.0	67.3	51.2	14.3	52.0	32.7	51.8	14.1	56.0
Bulgaria †	100				50.6				49.4			
Croatia	100	63.0	13.8	66.0	58.0	61.5	13.7	63.0	42.0	65.1	13.2	68.0
Cyprus	100	64.8	14.6	66.5	73.3	65.6	13.6	67.0	26.7	62.8	17.1	64.0
Czech Republic												
Georgia	100	57.4	16.1	58.8	62.5	56.8	15.7	58.0	37.5	58.4	16.6	60.9
Israel	100	63.5	17.3	66.1	65.0	63.0	17.3	65.6	35.0	64.3	17.4	67.1
Latvia	100	60.8	15.7	64.0	59.3	59.3	16.6	60.0	40.7	62.9	14.1	65.0
Lithuania †	100	60.7	16.3	61.0	64.2	59.5	17.8	60.0	35.8	62.9	12.9	65.0
Montenegro	100	61.3	11.7	62.0	78.6	63.4	10.3	62.0	21.4	53.7	16.1	47.0
Poland												
Portugal												
Russia												
Slovakia †	100	61.8	13.4	36.0	59.4	60.6	13.0	61.0	40.6	63.6	13.8	66.0
Spain (18 of 19 regions)												
Switzerland												
Turkey												
Ukraine												

Categories may not add up to total or to 100% because of missing values or rounding off

When cells are left empty, the data are unavailable

† Data include dialysis patients only

Table B.3.3
Incident rates per million population, adjusted
at day 91, adjusted for age and gender

	All	Men	Women
	Pmp	Pmp	Pmp
Albania	65.1	87.1	43.2
Bulgaria			
Croatia	127.2	158.8	100.1
Cyprus	212.9	304.2	113.2
Czech Republic			
Georgia	163.1	224.9	112.8
Israel	254.0	328.6	178.6
Latvia			
Lithuania †	107.0	159.8	67.3
Montenegro	33.9	58.9	11.3
Poland			
Portugal			
Russia			
Slovakia †	144.9	184.4	112.0
Spain (18 of 19 regions)			
Switzerland			
Turkey			
Ukraine			

When cells are left empty, the data are unavailable

† Data include dialysis patients only

Table B.3.4
Incident rates per million population and percentages, unadjusted
at day 91, by cause of renal failure

	Total		GN		PN		PKD		DM						HT		RVD		Misc		Unkn		Missing	
									Type I		Type II		Both											
	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%
Albania	59.2	100	7.6	12.9	15.6	26.3	2.4	4.1	1.0	1.8	6.9	11.7	8.0	13.5	4.5	7.6	1.4	2.3	4.2	7.0	15.6	26.3	0	0
Bulgaria †	132.3	100	20.0	15.1	12.5	9.4	13.3	10.1					26.3	19.9	13.4	10.2	14.3	10.8	19.6	14.8	10.2	7.7	2.7	2.0
Croatia	133.3	100	13.1	9.8	10.8	8.1	7.9	5.9	7.6	5.7	31.8	23.9	39.4	29.5	21.0	15.8	5.3	3.9	20.4	15.3	15.5	11.6	0	0
Cyprus	175.4	100	15.2	8.7	8.2	4.7	8.2	4.7	4.7	2.7	49.1	28.0	53.8	30.7	29.2	16.7	1.2	0.7	30.4	17.3	14.0	8.0	15.2	8.7
Czech Republic																								
Georgia	148.6	100	19.4	13.0	12.6	8.5	10.5	7.1	4.9	3.3	25.2	17.0	30.1	20.3	15.2	10.2	5.8	3.9	13.5	9.1	36.2	24.3	5.4	3.6
Israel	171.7	100	11.0	6.4	4.2	2.5	5.6	3.3	50.3	29.3	29.3	17.1	79.5	46.3	15.5	9.0	6.6	3.8	20.5	11.9	21.2	12.4	7.6	4.4
Latvia	70.6	100	11.2	15.9	5.0	7.1	5.0	7.1	1.2	1.8	11.9	16.8	13.1	18.6	11.9	16.8	0	0	12.5	17.7	11.9	16.8	0	0
Lithuania † +	106.3	100	12.8	12.0	6.1	5.7	1.7	1.6					13.5	12.7	20.2	19.0			18.8	17.7	0	0	33.3	31.3
Montenegro	22.6	100	3.2	14.3	0	0	0	0	6.5	28.6	1.6	7.1	8.1	35.7	4.8	21.4	0	0	6.5	28.6	0	0	0	0
Poland																								
Portugal																								
Russia																								
Slovakia †	132.4	100	16.8	12.7	12.6	9.5	4.8	3.6					52.6	39.7	10.5	7.9	5.4	4.0	27.2	20.5	2.6	2.0	0	0
Spain (18 of 19 regions)																								
Switzerland																								
Turkey																								
Ukraine																								

Abbreviations used: GN: glomerulonephritis/sclerosis; PN: pyelonephritis; PKD: polycystic kidneys, adult type; DM: diabetes mellitus; HT: hypertension; RVD: renal vascular disease; Misc: miscellaneous; Unkn: unknown

When cells are left empty, the data are unavailable

† Data include dialysis patients only

+ Renal vascular disease is not reported separately, but is included into miscellaneous

Table B.3.5
Incident counts
at day 91, by established therapy

	Total	Haemodialysis						Peritoneal dialysis				Transplant			Missing	
		HD hospital/ centre	HD home	HD type Unkn	HF	HDF	Total HD/ HF/HDF	APD	CAPD	PD type Unkn	Total PD	Living	Deceased	Tx type Unkn		Total Tx
		N	N	N	N	N	N	N	N	N	N	N	N	N		N
Albania	171	155	0	0	0	0	155	0	14	0	14	2	0	0	2	0
Bulgaria †	945	903	0	0	0	18	921	9	15	0	24					0
Croatia	457	387	0	0	0	35	422	19	12	0	31	1	3	0	4	0
Cyprus	150		0	124	0		124	9	12	0	21	4	1	0	5	0
Czech Republic †	1435			1344			1344			91	91					0
Georgia	637	597	0	0	0	0	597	23	2	0	25	1	0	0	1	14
Israel	1384	1184	0	0	0	0	1184	69	60	2	131	57	2	10	69	0
Latvia	113	98	0	0	0	0	98			14	14	0	1	0	1	0
Lithuania †	316	296	0	0	0	0	296			20	20					
Montenegro	14	9	0	0	0	0	9	0	0	0	0	4	1	0	5	0
Poland																
Portugal #	2296			2085			2085			202	202	9	0	0	9	0
Russia																
Slovakia †	717	301	0	0	4	391	696	7	14	0	21					
Spain (18 of 19 regions)																
Switzerland																
Turkey																
Ukraine																

Abbreviations used: HD: haemodialysis; Unkn: unknown; HF: haemofiltration; HDF: haemodiafiltration; APD: automated peritoneal dialysis; CAPD: continuous ambulatory peritoneal dialysis; PD: peritoneal dialysis; Tx: transplant

When cells are left empty, the data are unavailable

† Data include dialysis patients only

Only pre-emptive transplantations (at day 1) are included

Table B.3.6
Incident rates per million population, unadjusted
at day 91, by established therapy

	Total	Haemodialysis						Peritoneal dialysis				Transplant			Missing	
		HD hospital/ centre	HD home	HD type Unkn	HF	HDF	Total HD/ HF/HDF	APD	CAPD	PD type Unkn	Total PD	Living	Deceased	Tx type Unkn	Total Tx	
	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp
Albania	59.2	53.6	0	0	0	0	53.6	0	4.8	0	4.8	0.7	0	0	0.7	0
Bulgaria †	132.3	126.4	0	0	0	2.5	128.9	1.3	2.1	0	3.4					0
Croatia	133.3	112.9	0	0	0	10.2	123.1	5.5	3.5	0	9.0	0.3	0.9	0	1.2	0
Cyprus	175.4		0	145.0	0		145.0	10.5	14.0	0	24.6	4.7	1.2	0	5.8	0
Czech Republic †	139.3			130.5			130.5			8.8	8.8					0
Georgia	148.6	139.3	0	0	0	0	139.3	5.4	0.5	0	5.8	0.2	0	0	0.2	3.3
Israel	171.7	146.9	0	0	0	0	146.9	8.6	7.4	0.2	16.3	7.1	0.2	1.2	8.6	0
Latvia	70.6	61.2	0	0	0	0	61.2			8.7	8.7	0	0.6	0	0.6	0
Lithuania †	106.3	99.6	0	0	0	0	99.6			6.7	6.7					
Montenegro	22.6	14.5	0	0	0	0	14.5	0	0	0	0	6.5	1.6	0	8.1	0
Poland																
Portugal #	218.9			198.8			198.8			19.3	19.3	0.9	0	0	0.9	0
Russia																
Slovakia †	132.4	55.6	0	0	0.7	72.2	128.6	1.3	2.6	0	3.9					
Spain (18 of 19 regions)																
Switzerland																
Turkey																
Ukraine																

Abbreviations used: HD: haemodialysis; Unkn: unknown; HF: haemofiltration; HDF: haemodiafiltration; APD: automated peritoneal dialysis; CAPD: continuous ambulatory peritoneal dialysis; PD: peritoneal dialysis; Tx: transplant

When cells are left empty, the data are unavailable

† Data include dialysis patients only

Only pre-emptive transplantations (at day 1) are included

Table B.3.7
Percentages of established therapy, unadjusted
at day 91

	Total	Haemodialysis					Peritoneal dialysis				Transplant			Missing		
		HD hospital/centre	HD home	HD type Unkn	HF	HDF	Total HD/HF/HDF	APD	CAPD	PD type Unkn	Total PD	Living	Deceased		Tx type Unkn	Total Tx
	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%
Albania	100	90.6	0	0	0	0	90.6	0	8.2	0	8.2	1.2	0	0	1.2	0
Bulgaria †	100	95.6	0	0	0	1.9	97.5	1.0	1.6	0	2.5					0
Croatia	100	84.7	0	0	0	7.7	92.3	4.2	2.6	0	6.8	0.2	0.7	0	0.9	0
Cyprus	100		0	82.7	0		82.7	6.0	8.0	0	14.0	2.7	0.7	0	3.3	0
Czech Republic †	100			93.7			93.7			6.3	6.3					0
Georgia	100	93.7	0	0	0	0	93.7	3.6	0.3	0	3.9	0.2	0	0	0.2	2.2
Israel	100	85.5	0	0	0	0	85.5	5.0	4.3	0.1	9.5	4.1	0.1	0.7	5.0	0
Latvia	100	86.7	0	0	0	0	86.7			12.4	12.4	0	0.9	0	0.9	0
Lithuania †	100	93.7	0	0	0	0	93.7			6.3	6.3					
Montenegro	100	64.3	0	0	0	0	64.3	0	0	0	0	28.6	7.1	0	35.7	0
Poland																
Portugal #	100			90.8			90.8			8.8	8.8	0.4	0	0	0.4	0
Russia																
Slovakia †	100	42.0	0	0	0.6	54.5	97.1	1.0	2.0	0	2.9					
Spain (18 of 19 regions)																
Switzerland																
Turkey																
Ukraine																

Abbreviations used: HD: haemodialysis; Unkn: unknown; HF: haemofiltration; HDF: haemodiafiltration; APD: automated peritoneal dialysis; CAPD: continuous ambulatory peritoneal dialysis; PD: peritoneal dialysis; Tx: transplant

When cells are left empty, the data are unavailable

† Data include dialysis patients only

Only pre-emptive transplantations (at day 1) are included

Table B.4.1
Prevalent counts and prevalence per million population, unadjusted
prevalent patients on December 31

	All		Men		Women	
	N	Pmp	N	Pmp	N	Pmp
Albania	984	340.5	639	438.9	345	240.6
Bulgaria	3864	540.9	1944	563.6	1920	519.8
Croatia	2740	799.5	1572	951.6	1168	658.0
Cyprus						
Czech Republic	10647	1033.5				
Georgia	1651	385.2	1057	517.0	594	265.0
Israel †	5921	734.7	3590	899.5	2331	573.0
Latvia	961	600.3	504	687.0	457	527.0
Lithuania	2137	719.0				
Montenegro	189	304.8	115	375.8	74	235.7
Poland	30131	822.4				
Portugal	18345	1749.3	10690	1946.8	7241	1449.4
Russia	34680	241.4	18706	281.1	15974	207.1
Slovakia †	3297	609.0	1914	725.5	1383	498.2
Spain (18 of 19 regions)	50565	1125.8	31594	1429.3	18971	831.7
Switzerland †	2902	381.6	1795	477.9	1106	287.3
Turkey	66711	870.2				
Ukraine	7214	159.0				

Categories may not add up to total or to 100% because of missing values

When cells are left empty, the data are unavailable

† Data include dialysis patients only

Table B.4.2
Gender, mean age, and median age
prevalent patients on December 31

	All				Men				Women			
	%	Mean (years)	SD	Median (years)	%	Mean (years)	SD	Median (years)	%	Mean (years)	SD	Median (years)
Albania	100	49.1	13.5	51.0	64.9	49.6	13.5	51.0	35.1	48.2	13.5	51.0
Bulgaria	100				50.3				49.7			
Croatia	100	63.3	13.8	66.0	57.4	62.4	13.7	63.0	42.6	64.5	13.9	66.0
Cyprus												
Czech Republic												
Georgia	100	55.0	14.0	56.0	64.0	55.4	13.8	56.4	36.0	54.3	14.5	55.3
Israel †	100	61.3	16.9	64.2	60.6	61.2	16.7	63.7	39.4	61.4	17.1	65.0
Latvia	100	54.9	15.8	56.0	52.4	53.6	16.4	54.0	47.6	56.3	15.0	58.0
Lithuania												
Montenegro	100	57.0	12.7	57.0	60.8	57.5	11.8	59.5	39.2	56.2	14.4	57.0
Poland												
Portugal	100	66.1			58.3				39.5			
Russia	100	50.1	15.0	52.0	53.9	49.4	14.9	51.0	46.1	51.0	15.0	53.0
Slovakia †	100	62.5	13.6	64.0	58.1	61.4	13.2	62.0	41.9	64.0	13.9	66.0
Spain (18 of 19 regions)	100	59.6	0.3	62.7	62.5	59.4	0.4	62.3	37.5	59.8	0.5	63.2
Switzerland †	100	68.8	14.2	71.6	61.9	68.8	13.8	71.4	38.1	68.7	14.7	72.1
Turkey												
Ukraine												

Categories may not add up to total or to 100% because of missing values or rounding off

When cells are left empty, the data are unavailable

† Data include dialysis patients only

Table B.4.3

Prevalence per million population, adjusted*prevalent patients on December 31, adjusted for age and gender*

	All	Men	Women
	Pmp	Pmp	Pmp
Albania	394.4	519.7	271.2
Bulgaria			
Croatia	765.8	940.8	618.1
Cyprus			
Czech Republic			
Georgia	426.2	602.2	282.8
Israel †	1070.0	1305.7	832.9
Latvia			
Lithuania			
Montenegro	393.6	519.4	284.8
Poland			
Portugal			
Russia			
Slovakia †	672.4	838.6	536.8
Spain (18 of 19 regions)	1087.4	1360.6	809.8
Switzerland †	382.1	466.2	293.0
Turkey			
Ukraine			

*When cells are left empty, the data are unavailable**† Data include dialysis patients only*

Table B.4.4
Prevalence per million population and percentages, unadjusted
prevalent patients on December 31, by cause of renal failure

	Total		GN		PN		PKD		DM						HT		RVD		Misc		Unkn		Missing	
									Type I		Type II		Both											
	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%	Pmp	%
Albania	340.5	100	63.7	18.7	92.0	27.0	20.4	6.0	4.8	1.4	21.5	6.3	26.3	7.7	19.7	5.8	12.5	3.7	28.4	8.3	77.5	22.8	0	0
Bulgaria																								
Croatia	799.5	100	138.6	17.3	86.1	10.8	57.2	7.2	40.0	5.0	138.9	17.4	178.9	22.4	113.2	14.2	21.0	2.6	121.1	15.1	83.5	10.4	0	0
Cyprus																								
Czech Republic																								
Georgia	385.2	100	66.3	17.2	9.6	2.5	29.9	7.8	15.4	4.0	71.4	18.5	86.8	22.5	2.8	0.7	3.3	0.8	39.2	10.2	144.9	37.6	2.6	0.7
Israel †	734.7	100	72.3	9.8	30.6	4.2	28.2	3.8	207.6	28.3	127.9	17.4	335.5	45.7	76.8	10.5	19.7	2.7	91.3	12.4	76.1	10.4	4.1	0.6
Latvia	600.3	100	200.5	33.4	75.0	12.5	68.1	11.3					68.7	11.4	62.5	10.4	1.9	0.3	86.2	14.4	37.5	6.2	0	0
Lithuania																								
Montenegro	304.8	100	80.6	26.5	11.3	3.7	24.2	7.9	27.4	9.0	30.6	10.1	58.1	19.0	88.7	29.1	1.6	0.5	33.9	11.1	6.5	2.1	0	0
Poland □	822.4	100	102.5	12.5	57.7	7.0	42.6	5.2					126.5	15.4	78.9	9.6	1.8	0.2	66.0	8.0	31.4	3.8	315.0	38.3
Portugal □ & +	1749.3	100	128.1	7.3			71.4	4.1					304.9	17.4	169.7	9.7			212.8	12.2	212.7	12.2	649.7	37.1
Russia	241.4	100	90.2	37.4	26.1	10.8	23.9	9.9	13.8	5.7	15.1	6.3	28.9	12.0	15.3	6.3	1.6	0.7	34.0	14.1	21.5	8.9	0	0
Slovakia †	609.0	100	83.9	13.8	78.7	12.9	31.2	5.1					201.5	33.1	44.1	7.2	26.2	4.3	130.4	21.4	12.9	2.1	0	0
Spain (18 of 19 regions) ¶	1125.8	100	216.3	19.2	131.5	11.7	109.5	9.7					168.3	15.0	141.2	12.5			121.1	10.8	229.2	20.4	8.5	0.8
Switzerland †	381.6	100	50.5	13.2	13.7	3.6	27.9	7.3	9.3	2.4	71.7	18.8	81.0	21.2	72.1	18.9	13.5	3.5	80.6	21.1	42.1	11.0	0.3	0.1
Turkey ‡	278.3	100	21.3	7.6	4.6	1.6	12.8	4.6	12.4	4.4	76.0	27.3	88.3	31.7	78.1	28.1	2.5	0.9	29.2	10.5	39.6	14.2	1.9	0.7
Ukraine +	159.0	100	74.5	46.9	22.8	14.3	16.0	10.0					20.5	12.9	6.0	3.8			15.9	10.0	0.3	0.2	3.0	1.9

Abbreviations used: GN: glomerulonephritis/sclerosis; PN: pyelonephritis; PKD: polycystic kidneys, adult type; DM: diabetes mellitus; HT: hypertension; RVD: renal vascular disease; Misc: miscellaneous; Unkn: unknown

When cells are left empty, the data are unavailable

† Data include dialysis patients only

‡ Data available for 21337 of 66711 patients (32%)

□ Data on cause of renal failure are available for dialysis patients only (transplant patients are included into missing)

& Pyelonephritis is not reported separately, but is included into miscellaneous

+ Renal vascular disease is not reported separately, but is included into miscellaneous

¶ Renal vascular disease is not reported separately, but is included into hypertension

Table B.4.5

Prevalent counts*prevalent patients on December 31, by established therapy*

	Total	Haemodialysis						Peritoneal dialysis				Transplant			Missing	
		HD hospital/ centre	HD home	HD type Unkn	HF	HDF	Total HD/ HF/HDF	APD	CAPD	PD type Unkn	Total PD	Living	Deceased	Tx type Unkn		Total Tx
Albania	984	743	0	0	0	0	743	0	52	0	52	141	40	8	189	0
Bulgaria	3864	3192	0	0	0	18	3210	47	112	0	159			495	495	0
Croatia	2740	1768	0	0	0	231	1999	55	72	0	127	30	512	6	548	66
Cyprus																
Czech Republic	10647	2148	0	0	187	3458	5793			518	518			4336	4336	0
Georgia	1651	1389	0	0	0	0	1389	83	6	0	89	165	0	0	165	8
Israel †	5921	5578	0	0	0	0	5578	188	146	8	342					1
Latvia	961	355	0	0	0	0	355			86	86	20	500	0	520	0
Lithuania	2137	1413	0	0	0	0	1413			47	47			677	677	0
Montenegro	189	79	0	0	0	4	83	0	3	0	3	78	21	4	103	0
Poland	30131	18809	0	0			18809			1022	1022			10300	10300	0
Portugal	18345	5426	0	0	0	5551	10977	428	304	0	732			6636	6636	0
Russia	34680	21019	0	0	0	4814	25833	184	1798	0	1982	1002	5863	0	6865	0
Slovakia †	3297	1073	0	0	9	2128	3210	36	51	0	87					
Spain (18 of 19 regions)	50565	19509		2144			21653		1667	1120	2787			26046	26046	79
Switzerland †	2902	2635	15	8	0	0	2658	57	179	7	243					1
Turkey	66711	51146	181	68	5	1275	52675			4537	4537			9499	9499	0
Ukraine	7214	5236	0	0	0	99	5335	35	931	0	966	528			913	0

Abbreviations used: HD: haemodialysis; Unkn: unknown; HF: haemofiltration; HDF: haemodiafiltration; APD: automated peritoneal dialysis; CAPD: continuous ambulatory peritoneal dialysis; PD: peritoneal dialysis; Tx: transplant
When cells are left empty, the data are unavailable

† Data include dialysis patients only

Table B.4.6

Prevalence per million population, unadjusted*prevalent patients on December 31, by established therapy*

	Total	Haemodialysis						Peritoneal dialysis				Transplant			Missing	
		HD hospital/ centre	HD home	HD type Unkn	HF	HDF	Total HD/ HF/HDF	APD	CAPD	PD type Unkn	Total PD	Living	Deceased	Tx type Unkn	Total Tx	
	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp
Albania	340.5	257.1	0	0	0	0	257.1	0	18.0	0	18.0	48.8	13.8	2.8	65.4	0
Bulgaria	540.9	446.9	0	0	0	2.5	449.4	6.6	15.7	0	22.3			69.3	69.3	0
Croatia	799.5	515.9	0	0	0	67.4	583.3	16.0	21.0	0	37.1	8.8	149.4	1.8	159.9	19.3
Cyprus																
Czech Republic	1033.5	208.5	0	0	18.2	335.7	562.3			50.3	50.3			420.9	420.9	0
Georgia	385.2	324.1	0	0	0	0	324.1	19.4	1.4	0	20.8	38.5	0	0	38.5	1.9
Israel †	734.7	692.1	0	0	0	0	692.1	23.3	18.1	1.0	42.4					0.1
Latvia	600.3	221.8	0	0	0	0	221.8			53.7	53.7	12.5	312.3	0	324.8	0
Lithuania	719.0	475.4	0	0	0	0	475.4			15.8	15.8			227.8	227.8	0
Montenegro	304.8	127.4	0	0	0	6.5	133.9	0	4.8	0	4.8	125.8	33.9	6.5	166.1	0
Poland	822.4	513.4	0	0			513.4			27.9	27.9			281.1	281.1	0
Portugal	1749.3	517.4	0	0	0	529.3	1046.7	40.8	29.0	0	69.8			632.8	632.8	0
Russia	241.4	146.3	0	0	0	33.5	179.8	1.3	12.5	0	13.8	7.0	40.8	0	47.8	0
Slovakia †	609.0	198.2	0	0	1.7	393.1	592.9	6.6	9.4	0	16.1					
Spain (18 of 19 regions)	1125.8	434.4		47.7			482.1		37.1	24.9	62.1			579.9	579.9	1.8
Switzerland †	381.6	346.5	2.0	1.1	0	0	349.5	7.5	23.5	0.9	32.0					0.1
Turkey	870.2	667.1	2.4	0.9	0.1	16.6	687.1			59.2	59.2			123.9	123.9	0
Ukraine	159.0	115.4	0	0	0	2.2	117.6	0.8	20.5	0	21.3	11.6			20.1	0

Abbreviations used: HD: haemodialysis; Unkn: unknown; HF: haemofiltration; HDF: haemodiafiltration; APD: automated peritoneal dialysis; CAPD: continuous ambulatory peritoneal dialysis; PD: peritoneal dialysis; Tx: transplant
When cells are left empty, the data are unavailable

† Data include dialysis patients only

Table B.4.7
Percentages of established therapy, unadjusted
prevalent patients on December 31

	Total	Haemodialysis					Peritoneal dialysis				Transplant			Missing		
		HD hospital/centre	HD home	HD type Unkn	HF	HDF	Total HD/HF/HDF	APD	CAPD	PD type Unkn	Total PD	Living	Deceased		Tx type Unkn	Total Tx
	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%
Albania	100	75.5	0	0	0	0	75.5	0	5.3	0	5.3	14.3	4.1	0.8	19.2	0
Bulgaria	100	82.6	0	0	0	0.5	83.1	1.2	2.9	0	4.1			12.8	12.8	0
Croatia	100	64.5	0	0	0	8.4	73.0	2.0	2.6	0	4.6	1.1	18.7	0.2	20.0	2.4
Cyprus	100															
Czech Republic	100	20.2	0	0	1.8	32.5	54.4			4.9	4.9			40.7	40.7	0
Georgia	100	84.1	0	0	0	0	84.1	5.0	0.4	0	5.4	10.0	0	0	10.0	0.5
Israel †	100	94.2	0	0	0	0	94.2	3.2	2.5	0.1	5.8					0
Latvia	100	36.9	0	0	0	0	36.9			8.9	8.9	2.1	52.0	0	54.1	0
Lithuania	100	66.1	0	0	0	0	66.1			2.2	2.2			31.7	31.7	0
Montenegro	100	41.8	0	0	0	2.1	43.9	0	1.6	0	1.6	41.3	11.1	2.1	54.5	0
Poland	100	62.4	0	0			62.4			3.4	3.4			34.2	34.2	0
Portugal	100	29.6	0	0	0	30.3	59.8	2.3	1.7	0	4.0			36.2	36.2	0
Russia	100	60.6	0	0	0	13.9	74.5	0.5	5.2	0	5.7	2.9	16.9	0	19.8	0
Slovakia †	100	32.5	0	0	0.3	64.5	97.4	1.1	1.5	0	2.6					
Spain (18 of 19 regions)	100	38.6		4.2			42.8		3.3	2.2	5.5			51.5	51.5	0.2
Switzerland †	100	90.8	0.5	0.3	0	0	91.6	2.0	6.2	0.2	8.4					0
Turkey	100	76.7	0.3	0.1	0	1.9	79.0			6.8	6.8			14.2	14.2	0
Ukraine	100	72.6	0	0	0	1.4	74.0	0.5	12.9	0	13.4	7.3			12.7	0

Abbreviations used: HD: haemodialysis; Unkn: unknown; HF: haemofiltration; HDF: haemodiafiltration; APD: automated peritoneal dialysis; CAPD: continuous ambulatory peritoneal dialysis; PD: peritoneal dialysis; Tx: transplant
 When cells are left empty, the data are unavailable

† Data include dialysis patients only

Table B.5.1
Renal transplants performed in 2013, counts and percentages
by donor type

	Total		Living						Deceased		Donor type Unkn			
	N	%	Related		Unrelated		Type Unkn		All		N	%	N	%
			N	%	N	%	N	%	N	%				
Albania	8	100	6	75.0	2	25.0	0	0	8	100	0	0	0	0
Bulgaria	54	100	12	22.2	0	0	0	0	12	22.2	42	77.8	0	0
Croatia	206	100	2	1.0	3	1.5	0	0	5	2.4	196	95.1	5	2.4
Cyprus	32	100	16	50.0	7	21.9	0	0	23	71.9	9	28.1	0	0
Czech Republic	460	100					83	18.0	83	18.0	377	82.0	0	0
Georgia	31	100	31	100	0	0	0	0	31	100	0	0	0	0
Israel	307	100					136	44.3	136	44.3	128	41.7	43	14.0
Latvia	58	100	2	3.4	3	5.2	0	0	5	8.6	53	91.4	0	0
Lithuania	84	100	7	8.3	0	0	0	0	7	8.3	77	91.7	0	0
Montenegro	15	100	12	80.0	0	0	2	13.3	14	93.3	1	6.7	0	0
Poland	1133	100	57	5.0	0	0	0	0	57	5.0	1076	95.0	0	0
Portugal	448	100					51	11.4	51	11.4	397	88.6	0	0
Russia	935	100	188	20.1	0	0	0	0	188	20.1	747	79.9	0	0
Slovakia +	118	100	9	7.6	1	0.8	0	0	10	8.5	108	91.5	0	0
Spain (18 of 19 regions) □	2552	100	341	13.4	41	1.6	0	0	382	15.0	2170	85.0	0	0
Switzerland	276	100	52	18.8	57	20.7	0	0	109	39.5	167	60.5	0	0
Turkey	2944	100	1711	58.1	648	22.0	0	0	2359	80.1	585	19.9	0	0
Ukraine	115	100											115	100

Categories may not add up to total or to 100% because of missing values or rounding off

When cells are left empty, the data are unavailable

+ Data from: Slovak Centre of Organ Transplantation

□ Data from: Organización Nacional de Trasplantes (ONT), 2013 from total Spanish population

Table B.5.2
Renal transplants performed in 2013, per million population
by donor type

	Total	Living				Deceased	Donor type Unkn
		Related	Unrelated	Type Unkn	All		
	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp	Pmp
Albania	2.8	2.1	0.7	0	2.8	0	0
Bulgaria	7.6	1.7	0	0	1.7	5.9	0
Croatia	60.1	0.6	0.9	0	1.5	57.2	1.5
Cyprus	37.4	18.7	8.2	0	26.9	10.5	0
Czech Republic	44.7			8.1	8.1	36.6	0
Georgia	7.2	7.2	0	0	7.2	0	0
Israel	38.1			16.9	16.9	15.9	5.3
Latvia	36.2	1.2	1.9	0	3.1	33.1	0
Lithuania	28.3	2.4	0	0	2.4	25.9	0
Montenegro	24.2	19.4	0	3.2	22.6	1.6	0
Poland	30.9	1.6	0	0	1.6	29.4	0
Portugal	42.7			4.9	4.9	37.9	0
Russia	6.5	1.3	0	0	1.3	5.2	0
Slovakia +	21.8	1.7	0.2	0	1.8	19.9	0
Spain (18 of 19 regions) □	54.2	7.2	0.9	0	8.1	46.0	0
Switzerland	36.3	6.8	7.5	0	14.3	22.0	0
Turkey	38.4	22.3	8.5	0	30.8	7.6	0
Ukraine	2.5						2.5

Categories may not add up to total or to 100% because of missing values or rounding off

When cells are left empty, the data are unavailable

+ Data from: Slovak Centre of Organ Transplantation

□ Data from: Organización Nacional de Trasplantes (ONT), 2013 from total Spanish population

IV Summary Data

IV Summary Data

The summary data on the incidence and prevalence of renal replacement therapy in 2013 are based on data of national or regional registries that provided individual patient data for Section A or aggregated patient data for Section B of this annual report.

Table S.1.1

Section A - Summary data from registries providing individual patient data

	General population covered by the registry in thousands	Incidence in 2013, at day 1				Prevalence on December 31, 2013			
		Total N	Total Pmp	DM N	DM Pmp	Total N	Total Pmp	DM N	DM Pmp
Austria	8452	1198	142	310	37	8906	1054	1794	212
Belgium, Dutch-speaking *	6396	1193	187	234	37	7823	1223	1388	217
Belgium, French-speaking *	4729	864	183	177	37	6005	1270	1022	216
Bosnia and Herzegovina	3508	407	116	111	32	2620	747	466	133
Denmark	5671	663	117	152	27	4973	877	833	147
Estonia	1318	84	64	17	13	754	572	143	109
Finland	5439	485	89	154	28	4492	826	1160	213
France	65698	10470	159	2341	36	77199	1175	11962	182
Greece	10948	2362	216	635	58	12832	1172	2402	219
Iceland	324	25	77	4	12	222	686	24	74
Norway	5080	513	101	97	19	4574	901	585	115
Romania //	19784	2862	145	434	22	16162	817	1712	87
Serbia	6734	992	147	229	34	5651	839	838	124
Slovenia	2060	260	126	67	33	2077	1008	329	160
Spain, Andalusia	8391	1061	126	266	32	9295	1108	1342	160
Spain, Aragon	1335	176	132	56	42	1510	1131	263	197
Spain, Asturias	1068	170	159	41	38	1208	1131	195	183
Spain, Basque country	2172	264	122	45	21	2553	1175	271	125
Spain, Cantabria *	589	52	88	13	22	588	999	86	146
Spain, Castile and León *	2507	270	108	83	33	2817	1124	468	187
Spain, Castile-La Mancha *	2085	215	103	58	28	2138	1026	324	155
Spain, Catalonia	7554	1095	145	247	33	9534	1262	1343	178
Spain, Extremadura	1104	136	123	46	42	1194	1082	190	172
Spain, Galicia	2755	392	142	95	35	3363	1221	559	203
Spain, Community of Madrid	6496	793	122	222	34	6491	999	1126	173
Spain, Region of Murcia	1472	160	109	37	25	1767	1200	229	156
Spain, Valencian region	5114	686	134	137	27	6303	1233	792	155
Sweden	9600	1111	116	275	29	9020	940	1618	169
The Netherlands	16804	1939	115	319	19	15887	945	1903	113
United Kingdom, England *	53866	5904	110	1314	24	47961	890	7663	142
United Kingdom, Northern Ireland *	1830	178	97	37	20	1548	846	236	129
United Kingdom, Scotland	5328	510	96	121	23	4614	866	675	127
United Kingdom, Wales *	3082	345	112	98	32	2731	886	486	158
All countries	279293	37835	135	8472	30	284812	1020	44427	159

DM = diabetes mellitus as cause of renal failure

* Patients younger than 20 years of age are not reported. The true incidence and prevalence counts are therefore slightly higher than the counts reported here

// The overall prevalence of RRT is underestimated by approximately 3% due to an estimated 30% underreporting of patients living on a functioning graft

Table S.1.2

Section B - Summary data from registries providing aggregated data

	General population covered by the registry in thousands	Incident patients accepted for RRT in 2013, at day 1				Prevalent patients on RRT in 2013			
		Total N	Total Pmp	DM N	DM Pmp	Total N	Total Pmp	DM N	DM Pmp
Albania	2890	214	74	28	10	984	341	76	26
Bulgaria †	7143	1184	166	257	36	3864	541		
Croatia	3427	537	157	153	45	2740	800	613	179
Cyprus	855	160	187	50	59				
Czech Republic †	10302	2045	199			10647	1034		
Georgia	4287	775	181	160	37	1651	385	372	87
Israel *	8059	1462	181	671	83	5921	735	2704	336
Latvia	1601	129	81	22	14	961	600	110	69
Lithuania †	2972	332	112	41	14	2137	719		
Montenegro	620	17	27	5	8	189	305	36	58
Poland +	36636	4876	133	1031	28	30131	822	4635	127
Portugal	10487	2417	231	733	70	18345	1749	3197	305
Russia	143667	7196	50	1234	9	34680	241	4155	29
Slovakia † *	5414	855	158	331	61	3297	609	1091	202
Spain (18 of 19 regions)	44915	5705	127	1406	31	50565	1126	7561	168
Switzerland † *	7606	713	94	173	23	2902	382	616	81
Turkey ‡ &	76666	10601	138	2155	28	66711	870	6772	88
Ukraine	45373	1350	30	236	5	7214	159	932	21
All countries	412920	40568	98	8686	23	242939	590	32870	97

When cells are left empty, the data are unavailable and could therefore not be used for the calculations of the summary data

DM = diabetes mellitus as cause of renal failure

† Data on incidence include dialysis patients only

* Data on prevalence include dialysis patients only

+ Data on prevalence of cause of renal failure (DM) include dialysis patients only

‡ Incidence data by cause of renal failure (DM) is based on 6524 out of 10601 incident patients (62%)

& Prevalence data by cause of renal failure (DM) is based on 21337 out of 66711 prevalent patients (32%)

V Reference Tables - Section Paediatric RRT

V Reference Tables - Section Paediatric RRT

The incidence and prevalence of RRT in paediatric patients are based on data from 25 registries from 16 countries that provided individual patient data on children via the ERA-EDTA Registry, including Austria, Bosnia and Herzegovina, Denmark, Estonia, Finland, France, Greece, Iceland, Norway, Romania, Serbia, Slovenia, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Catalonia), Spain (Extremadura), Spain (Galicia), Spain (Community of Madrid), Spain (Region of Murcia), Spain (Valencian region), Sweden, The Netherlands, and United Kingdom (Scotland). In the analyses the data collected between 2004 and 2013 were used. As not all countries provided data over the complete period and to allow for comparison over the years, data regarding 2006 through 2013 are shown both including and excluding the data from Bosnia and Herzegovina, Estonia, France, Romania, Serbia, Slovenia, Spain (Aragon), Spain (Extremadura), and Spain (Galicia). The methods that were applied to the data on paediatric patients were similar to those applied to the data on adult patients and are described in Chapter VI Methods. However, in Spain as not all regions did have specialized paediatric centres, also non-residents were included in the incidence and prevalence.

P1 GENERAL CHARACTERISTICS

Table P.1.1
Population covered (in thousands)
by age and year

Cohort	Total	0-4	5-9	10-14	15-19
	N	N	N	N	N
2004	19952	4780	4796	5184	5193
2005	19971	4815	4775	5157	5224
2006	19777	4791	4746	5043	5196
2007	19843	4832	4758	4996	5256
2008	20047	4907	4851	4973	5316
2009	20008	4973	4841	4895	5300
2010	20016	5012	4877	4861	5266
2011	19986	5021	4912	4853	5199
2012	19952	4993	4954	4878	5127
2013	19864	4926	4993	4889	5056
2007 *	38734	9378	9326	9560	10471
2008 *	41058	10086	9986	10033	10954
2009 *	41816	10439	10209	10185	10983
2010 *	42647	10725	10538	10409	10975
2011 *	45247	11261	11292	11145	11549
2012 *	45763	11400	11429	11330	11605
2013 *	45711	11273	11550	11400	11488
2004-2013 *	378940	93279	93032	93864	98765

* Including data from France (coverage from 76.6% in 2006 to 100% in 2012), Romania and Spain (Aragon, Extremadura) since 2006, Spain (Galicia) since 2007, Slovenia and Spain (Community of Madrid) since 2008, Bosnia and Herzegovina and Serbia since 2011, Spain (Region of Murcia) since 2012, and Estonia since 2013

Table P.1.2
Grouping of primary renal diseases for paediatric patients
groups and codes included

Primary renal disease group	Primary renal disease code (see appendix 1)
Congenital anomalies of the kidney and urinary tract (CAKUT)	20, 21, 22, 23, 24, 25, 29, 60, 61, 63, and 66
Glomerulonephritis	10, 11, 12, 13, 14, 15, 16, 17, 19, and 86
Cystic kidney disease	40, 41, 42, 43, and 49
Hereditary nephropathy	50, 51, and 59
Ischaemic renal failure	90
Haemolytic uraemic syndrome (HUS)	88
Metabolic disorders	52, 53, 54, 92, and 93
Vasculitis	73, 74, 84, 85, and 87
Miscellaneous	30, 31, 32, 33, 34, 39, 70, 71, 72, 75, 76, 78, 79, 80, 81, 82, 83, 89, 91, 94, 95, 96, and 99
Missing, unknown	missing and 00

P2 INCIDENT PATIENTS ACCEPTED FOR RRT, AT DAY 1

Table P.2.1
Incident counts
at day 1, by age and cohort

Cohort	Total	0-4	5-9	10-14	15-19
	N	N	N	N	N
2004-2005	403	72	48	115	168
2006-2007	405	92	49	96	168
2008-2009	418	94	65	107	152
2010-2011	347	97	39	84	127
2012-2013	337	67	61	79	130
2008-2009 *	790	152	125	194	319
2010-2011 *	722	165	86	163	308
2012-2013 *	686	135	96	175	280
2004-2013 *	3156	636	422	774	1324

* Including data from France (coverage from 76.6% in 2006 to 100% in 2012), Romania and Spain (Aragon, Extremadura) since 2006, Spain (Galicia) since 2007, Slovenia and Spain (Community of Madrid) since 2008, Bosnia and Herzegovina and Serbia since 2011, Spain (Region of Murcia) since 2012, and Estonia since 2013

Table P.2.2
Incident counts
at day 1, by age, treatment modality, and cohort

Cohort	Total			0-4			5-9			10-14			15-19		
	HD	PD	Tx	HD	PD	Tx	HD	PD	Tx	HD	PD	Tx	HD	PD	Tx
	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N
2004-2005	176	127	100	13	45	14	14	19	15	44	37	34	105	26	37
2006-2007	166	138	98	17	62	13	10	15	24	43	26	25	96	35	36
2008-2009	154	142	119	19	61	14	20	19	25	32	31	43	83	31	37
2010-2011	147	116	84	23	59	15	11	13	15	34	19	31	79	25	23
2012-2013	145	90	102	17	42	8	20	12	29	29	16	34	79	20	31
2008-2009 *	359	214	188	35	89	22	51	31	36	84	41	61	189	53	69
2010-2011 *	371	189	153	48	93	23	34	20	27	80	30	52	209	46	51
2012-2013 *	362	157	163	41	76	16	42	19	35	86	29	58	193	33	54
2004-2013 *†	1535	850	721	161	375	90	163	106	141	359	166	234	852	203	256

* Including data from France (coverage from 76.6% in 2006 to 100% in 2012), Romania and Spain (Aragon, Extremadura) since 2006, Spain (Galicia) since 2007, Slovenia and Spain (Community of Madrid) since 2008, Bosnia and Herzegovina and Serbia since 2011, Spain (Region of Murcia) since 2012, and Estonia since 2013

† For 50 patients information on treatment modality at start was unavailable

Table P.2.3
Incident counts
between 2004 and 2013, at day 1, by age and cause of renal failure

	Total	0-4	5-9	10-14	15-19
	N	N	N	N	N
CAKUT	987	232	136	281	338
Glomerulonephritis	599	67	70	130	332
Cystic kidney disease	277	47	57	88	85
Hereditary Nephropathy	247	95	29	48	75
Ischaemic Renal Failure	54	19	8	17	10
HUS	96	30	12	17	37
Metabolic disorders	69	21	19	18	11
Vasculitis	80	2	2	19	57
Miscellaneous	359	81	52	66	160
Missing, unknown	388	42	37	90	219

Including data from France (coverage from 76.6% in 2006 to 100% in 2012), Romania and Spain (Aragon, Extremadura) since 2006, Spain (Galicia) since 2007, Slovenia and Spain (Community of Madrid) since 2008, Bosnia and Herzegovina and Serbia since 2011, Spain (Region of Murcia) since 2012, and Estonia since 2013

P2 INCIDENT PATIENTS ACCEPTED FOR RRT, AT DAY 1

Table P.2.4

Incident rates per million age-related population (per year)

at day 1, by age and cohort

Cohort	Total	0-4	5-9	10-14	15-19
	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp
2004-2005	10.1	7.5	5.0	11.1	16.1
2006-2007	10.2	9.6	5.2	9.6	16.1
2008-2009	10.4	9.5	6.7	10.8	14.3
2010-2011	8.7	9.7	4.0	8.6	12.1
2012-2013	8.5	6.8	6.1	8.1	12.8
2008-2009 *	9.5	7.4	6.2	9.6	14.5
2010-2011 *	8.2	7.5	3.9	7.6	13.7
2012-2013 *	7.5	6.0	4.2	7.7	12.1
2004-2013 *	8.3	6.8	4.5	8.2	13.4

* Including data from France (coverage from 76.6% in 2006 to 100% in 2012), Romania and Spain (Aragon, Extremadura) since 2006, Spain (Galicia) since 2007, Slovenia and Spain (Community of Madrid) since 2008, Bosnia and Herzegovina and Serbia since 2011, Spain (Region of Murcia) since 2012, and Estonia since 2013

Table P.2.5

Incident rates per million age-related population (per year)

at day 1, by age, treatment modality, and cohort

Cohort	Total			0-4			5-9			10-14			15-19		
	HD	PD	Tx	HD	PD	Tx	HD	PD	Tx	HD	PD	Tx	HD	PD	Tx
	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp
2004-2005	4.4	3.2	2.5	1.4	4.7	1.5	1.5	2.0	1.6	4.3	3.6	3.3	10.1	2.5	3.6
2006-2007	4.2	3.5	2.5	1.8	6.4	1.4	1.1	1.6	2.5	4.3	2.6	2.5	9.2	3.3	3.4
2008-2009	3.8	3.5	3.0	1.9	6.2	1.4	2.1	2.0	2.6	3.2	3.1	4.4	7.8	2.9	3.5
2010-2011	3.7	2.9	2.1	2.3	5.9	1.5	1.1	1.3	1.5	3.5	2.0	3.2	7.5	2.4	2.2
2012-2013	3.6	2.3	2.6	1.7	4.2	0.8	2.0	1.2	2.9	3.0	1.6	3.5	7.8	2.0	3.0
2008-2009 *	4.3	2.6	2.3	1.7	4.3	1.1	2.5	1.5	1.8	4.2	2.0	3.0	8.6	2.4	3.1
2010-2011 *	4.2	2.2	1.7	2.2	4.2	1.0	1.6	0.9	1.2	3.7	1.4	2.4	9.3	2.0	2.3
2012-2013 *	4.0	1.7	1.8	1.8	3.4	0.7	1.8	0.8	1.5	3.8	1.3	2.6	8.4	1.4	2.3
2004-2013 *†	4.1	2.2	1.9	1.7	4.0	1.0	1.8	1.1	1.5	3.8	1.8	2.5	8.6	2.1	2.6

* Including data from France (coverage from 76.6% in 2006 to 100% in 2012), Romania and Spain (Aragon, Extremadura) since 2006, Spain (Galicia) since 2007, Slovenia and Spain (Community of Madrid) since 2008, Bosnia and Herzegovina and Serbia since 2011, Spain (Region of Murcia) since 2012, and Estonia since 2013

† For 50 patients information on treatment modality at start was unavailable

Table P.2.6

Incident rates per million age-related population

between 2004 and 2013, at day 1, by age and cause of renal failure

	Total	0-4	5-9	10-14	15-19
	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp
CAKUT	2.6	2.5	1.5	3.0	3.4
Glomerulonephritis	1.6	0.7	0.8	1.4	3.4
Cystic kidney disease	0.7	0.5	0.6	0.9	0.9
Hereditary Nephropathy	0.7	1.0	0.3	0.5	0.8
Ischaemic Renal Failure	0.1	0.2	0.1	0.2	0.1
HUS	0.3	0.3	0.1	0.2	0.4
Metabolic disorders	0.2	0.2	0.2	0.2	0.1
Vasculitis	0.2	0.0	0.0	0.2	0.6
Miscellaneous	0.9	0.9	0.6	0.7	1.6
Missing, unknown	1.0	0.5	0.4	1.0	2.2

Including data from France (coverage from 76.6% in 2006 to 100% in 2012), Romania and Spain (Aragon, Extremadura) since 2006, Spain (Galicia) since 2007, Slovenia and Spain (Community of Madrid) since 2008, Bosnia and Herzegovina and Serbia since 2011, Spain (Region of Murcia) since 2012, and Estonia since 2013

P3 PREVALENT PATIENTS ON RRT

Table P.3.1

Prevalent counts

prevalent patients on December 31, by age and year

Cohort	Total	0-4	5-9	10-14	15-19
	N	N	N	N	N
2007	1378	116	219	340	703
2008	1381	108	222	346	705
2009	1402	132	233	358	679
2010	1372	134	224	350	664
2011	1367	144	220	371	632
2012	1349	131	236	379	603
2013	1332	113	245	361	613
2007 *	2241	168	332	566	1175
2008 *	2371	170	361	613	1227
2009 *	2488	208	401	630	1249
2010 *	2485	208	395	628	1254
2011 *	2540	236	394	667	1243
2012 *	2518	219	412	676	1211
2013 *	2529	203	423	686	1217

* Including data from France (coverage from 76.6% in 2006 to 100% in 2012), Romania and Spain (Aragon, Extremadura) since 2006, Spain (Galicia) since 2007, Slovenia and Spain (Community of Madrid) since 2008, Bosnia and Herzegovina and Serbia since 2011, Spain (Region of Murcia) since 2012, and Estonia since 2013

Table P.3.2

Prevalent counts

prevalent patients on December 31, by age and year

Cohort	Total			0-4			5-9			10-14			15-19		
	HD	PD	Tx	HD	PD	Tx	HD	PD	Tx	HD	PD	Tx	HD	PD	Tx
	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N
2007	154	120	1095	14	44	58	17	15	186	28	22	289	95	39	562
2008	147	86	1136	13	33	62	15	15	191	29	17	297	90	21	586
2009	154	115	1122	18	48	66	17	22	194	30	20	305	89	25	557
2010	149	113	1101	18	52	64	15	18	191	30	15	303	86	28	543
2011	158	114	1086	22	54	68	14	22	184	31	15	323	91	23	511
2012	142	113	1087	19	55	57	12	15	209	32	17	329	79	26	492
2013	141	97	1085	13	34	65	18	18	209	28	16	316	82	29	495
2007 *	344	175	1680	27	59	81	32	23	272	71	32	457	214	61	870
2008 *	339	159	1813	23	55	86	34	27	293	76	32	489	206	45	945
2009 *	370	193	1872	32	70	96	44	32	323	77	36	504	217	55	949
2010 *	374	194	1878	32	77	92	36	30	326	77	33	508	229	54	952
2011 *	404	209	1888	46	79	107	36	37	314	81	35	543	241	58	924
2012 *	388	207	1898	45	80	91	41	32	337	74	39	559	228	56	911
2013 *	413	192	1912	44	65	92	43	34	345	79	36	570	247	57	905

* Including data from France (coverage from 76.6% in 2006 to 100% in 2012), Romania and Spain (Aragon, Extremadura) since 2006, Spain (Galicia) since 2007, Slovenia and Spain (Community of Madrid) since 2008, Bosnia and Herzegovina and Serbia since 2011, Spain (Region of Murcia) since 2012, and Estonia since 2013

Table P.3.3

Prevalent counts

prevalent patients on December 31, 2013, by age and cause of renal failure

	Total	0-4	5-9	10-14	15-19
	N	N	N	N	N
CAKUT	874	75	154	239	406
Glomerulonephritis	406	16	51	113	226
Cystic kidney disease	250	12	49	62	127
Hereditary Nephropathy	239	38	54	66	81
Ischaemic Renal Failure	59	8	14	17	20
HUS	97	5	16	33	43
Metabolic disorders	72	7	17	22	26
Vasculitis	35	0	1	6	28
Miscellaneous	267	25	46	74	122
Missing, unknown	230	17	21	54	138

Including data from France (coverage from 76.6% in 2006 to 100% in 2012), Romania and Spain (Aragon, Extremadura) since 2006, Spain (Galicia) since 2007, Slovenia and Spain (Community of Madrid) since 2008, Bosnia and Herzegovina and Serbia since 2011, Spain (Region of Murcia) since 2012, and Estonia since 2013

P3 PREVALENT PATIENTS ON RRT

Table P.3.4

Prevalence per million age-related population (per year)

prevalent patients on December 31, by age and year

Cohort	Total	0-4	5-9	10-14	15-19
	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp
2007	69.4	24.0	46.0	68.0	133.7
2008	68.9	22.0	45.8	69.6	132.6
2009	70.1	26.5	48.1	73.1	128.1
2010	68.5	26.7	45.9	72.0	126.1
2011	68.4	28.7	44.8	76.4	121.6
2012	67.6	26.2	47.6	77.7	117.6
2013	67.1	22.9	49.1	73.8	121.2
2007 *	57.9	17.9	35.6	59.2	112.2
2008 *	57.7	16.9	36.2	61.1	112.0
2009 *	59.5	19.9	39.3	61.9	113.7
2010 *	58.3	19.4	37.5	60.3	114.3
2011 *	56.1	21.0	34.9	59.8	107.6
2012 *	55.0	19.2	36.0	59.7	104.4
2013 *	55.3	18.0	36.6	60.2	105.9

* Including data from France (coverage from 76.6% in 2006 to 100% in 2012), Romania and Spain (Aragon, Extremadura) since 2006, Spain (Galicia) since 2007, Slovenia and Spain (Community of Madrid) since 2008, Bosnia and Herzegovina and Serbia since 2011, Spain (Region of Murcia) since 2012, and Estonia since 2013

Table P.3.5

Prevalence per million age-related population (per year)

prevalent patients on December 31, by age and year

Cohort	Total			0-4			5-9			10-14			15-19		
	HD	PD	Tx	HD	PD	Tx	HD	PD	Tx	HD	PD	Tx	HD	PD	Tx
	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp
2007	7.8	6.0	55.2	2.9	9.1	12.0	3.6	3.2	39.1	5.6	4.4	57.8	18.1	7.4	106.9
2008	7.3	4.3	56.7	2.6	6.7	12.6	3.1	3.1	39.4	5.8	3.4	59.7	16.9	4.0	110.2
2009	7.7	5.7	56.1	3.6	9.7	13.3	3.5	4.5	40.1	6.1	4.1	62.3	16.8	4.7	105.1
2010	7.4	5.6	55.0	3.6	10.4	12.8	3.1	3.7	39.2	6.2	3.1	62.3	16.3	5.3	103.1
2011	7.9	5.7	54.3	4.4	10.8	13.5	2.8	4.5	37.5	6.4	3.1	66.6	17.5	4.4	98.3
2012	7.1	5.7	54.5	3.8	11.0	11.4	2.4	3.0	42.2	6.6	3.5	67.4	15.4	5.1	96.0
2013	7.1	4.9	54.6	2.6	6.9	13.2	3.6	3.6	41.9	5.7	3.3	64.6	16.2	5.7	97.9
2007 *	8.9	4.5	43.4	2.9	6.3	8.6	3.4	2.5	29.2	7.4	3.3	47.8	20.4	5.8	83.1
2008 *	8.3	3.9	44.2	2.3	5.5	8.5	3.4	2.7	29.3	7.6	3.2	48.7	18.8	4.1	86.3
2009 *	8.8	4.6	44.8	3.1	6.7	9.2	4.3	3.1	31.6	7.6	3.5	49.5	19.8	5.0	86.4
2010 *	8.8	4.5	44.0	3.0	7.2	8.6	3.4	2.8	30.9	7.4	3.2	48.8	20.9	4.9	86.7
2011 *	8.9	4.6	41.7	4.1	7.0	9.5	3.2	3.3	27.8	7.3	3.1	48.7	20.9	5.0	80.0
2012 *	8.5	4.5	41.5	3.9	7.0	8.0	3.6	2.8	29.5	6.5	3.4	49.3	19.6	4.8	78.5
2013 *	9.0	4.2	41.8	3.9	5.8	8.2	3.7	2.9	29.9	6.9	3.2	50.0	21.5	5.0	78.8

* Including data from France (coverage from 76.6% in 2006 to 100% in 2012), Romania and Spain (Aragon, Extremadura) since 2006, Spain (Galicia) since 2007, Slovenia and Spain (Community of Madrid) since 2008, Bosnia and Herzegovina and Serbia since 2011, Spain (Region of Murcia) since 2012, and Estonia since 2013

Table P.3.6

Prevalence per million age-related population

prevalent patients on December 31, 2013, by age and cause of renal failure

	Total	0-4	5-9	10-14	15-19
	Pmarp	Pmarp	Pmarp	Pmarp	Pmarp
CAKUT	19.1	6.7	13.3	21.0	35.3
Glomerulonephritis	8.9	1.4	4.4	9.9	19.7
Cystic kidney disease	5.5	1.1	4.2	5.4	11.1
Hereditary Nephropathy	5.2	3.4	4.7	5.8	7.1
Ischaemic Renal Failure	1.3	0.7	1.2	1.5	1.7
HUS	2.1	0.4	1.4	2.9	3.7
Metabolic disorders	1.6	0.6	1.5	1.9	2.3
Vasculitis	0.8	0.0	0.1	0.5	2.4
Miscellaneous	5.8	2.2	4.0	6.5	10.6
Missing, unknown	5.0	1.5	1.8	4.7	12.0

Including data from France (coverage from 76.6% in 2006 to 100% in 2012), Romania and Spain (Aragon, Extremadura) since 2006, Spain (Galicia) since 2007, Slovenia and Spain (Community of Madrid) since 2008, Bosnia and Herzegovina and Serbia since 2011, Spain (Region of Murcia) since 2012, and Estonia since 2013

VI Methods

VI Methods

The ERA-EDTA Registry is located at the Department of Medical Informatics of the Academic Medical Center in Amsterdam, The Netherlands. This department hosts several clinical registries which share a quality management system with Standard Operating Procedures (SOPs) for data collection, data storage, data analysis, and the production of the annual report. The quality management system has been certified according to the ISO 9001:2000 norm since 2004 and according to the ISO 9001:2008 norm since September 2010.

Data collection and preparation

Section A

Data collection

Once a year data sets containing individual patient data are sent to the office of the ERA-EDTA Registry in Amsterdam. Data delivery takes place in one of the Open Data Base Connectivity (ODBC) compatible file formats, like Microsoft Access and Microsoft Excel, or in other formats like text, SPSS or SAS. Collaborating registries send data by e-mail and most data sets are received in PGP encrypted format.

Variables

The ERA-EDTA Registry asks national and regional registries for the data in Table 1.

Table 1: Variables collected for Section A

Patient data	Transaction data
Patient identifier	Patient identifier
Country of registry	Date of event
Date of birth	Type of event / treatment
Gender	Cause of death
Primary Renal Disease	Treatment centre
Date of first RRT	Source registry
	Destination registry

Collaborating registries and participating countries

Individual patient data of 31 national and regional registries from 17 countries were used to create the tables in Section A of this annual report (see Figure 1).

Registry data are subject to continuous alteration and improvement. Small differences between ERA-EDTA Registry data and the data presented in the national and regional registry's own annual reports may result from different times of data extraction. Minor differences between the numbers reported by the UK Renal Registry and this annual report may occur because the prevalence as reported in the UK Renal Registry Report is based on quarterly data returns, whereas the prevalence as reported in this annual report is based on data derived from the modality timeline.

The data on Spain presented in Section A of this report are based on separate datasets from 13 of 19 regions, including Andalusia, Aragon, Asturias, Basque country, Cantabria, Castile and León, Castile-La Mancha, Catalonia, Extremadura, Galicia, Community of Madrid, Region of Murcia and Valencian region.

Differences between collaborating registries

Definitions and collection of data

In the comparison of data between registries it should be recognized that there may be small differences between registries in definitions and in the collection of their data. For example, the different registries do not collect data at the same level of detail, especially with regard to the various subtypes of the treatment modalities.

Patient population

The data from Belgium (Dutch-speaking), Belgium (French-speaking), Spain (Cantabria), Spain (Castile and León), Spain (Castile-La Mancha), and United Kingdom (England/Northern Ireland/Wales) only comprised patients older than 20 years of age. It has been estimated that inclusion of data on children would add about 2 per million population (Pmp) to the incidence rate and about 13 Pmp to the prevalence.

For the calculation of the incidence of those alive and on RRT on day 91, registries were asked to provide data with follow-up until 31 March 2014. For the following registries data were only available until 31 December 2013: Austria, Spain (Asturias), Spain (Catalonia), Spain (Extremadura), and UK (England, Wales and Northern Ireland). For these registries the incidence on day 91 was estimated as explained in the paragraph on statistical analyses.

For Romania, the kidney transplantation activity reported reflects 70% of the total kidney transplantation activity in the country because there is an underreporting of pre-emptive transplantations. As a consequence, the overall incidence and prevalence of RRT were underestimated by approximately 1% and 3%, respectively.

Data loading and cleaning

The registry data were imported using an in-house developed import utility. This program first unifies the data and then translates any non-standard codes. Consistency checks were performed, and thereafter the data were converted to the desired format in order to make storage in the relational and event-driven database possible. The new data, annually provided by national and regional registries, replaced all existing data in the ERA-EDTA Registry database. Changes in the data sets made by the national and regional registries were in this way adopted by the ERA-EDTA Registry. The import utility performed extensive logging and the logging-results were used to provide the national and regional registries with feedback concerning inconsistencies or other problems in the data.

After data analysis, the results were compared to the annual reports published by the national and regional registries as a first check for errors. In case of discrepancies the registry was contacted and potential problems regarding (the interpretation of) their data set were solved. Thereafter, more detailed reports were produced which needed the approval from the registries before publication in this ERA-EDTA Registry Annual Report.

ERA-EDTA Registry database

Microsoft SQL Server (a database management system) was used to manage the ERA-EDTA Registry database. This relational and event-driven database consists of a patient and a transaction table which can be extended according to future needs.

General population data

Midyear population data of the contributing countries were provided by Eurostat, the national bureau of statistics or the national or regional registry. The sources of the population data used for the analyses in Section A are shown in Table 2.

Reference population

In this year's Annual Report, the age and gender distribution of the EU27 of 2010 as provided by Eurostat is used for the adjustment of incidence rates and prevalence for age and gender [1]. The age and gender distribution of EU27 in 2010 is shown in Table 3.

Table 2: Sources of general population data for the national and regional registries participating in Section A

Registry	Sources of general population data of 2013
Austria	Registry
Belgium, Dutch-speaking	http://aps.vlaanderen.be/
Belgium, French-speaking	http://aps.vlaanderen.be/
Bosnia and Herzegovina	http://www.fzs.ba/
Denmark	http://ec.europa.eu/eurostat/
Greenland	http://www.stat.gl/
Estonia	http://ec.europa.eu/eurostat/
Finland	http://ec.europa.eu/eurostat/
France	http://ec.europa.eu/eurostat/
Greece	http://ec.europa.eu/eurostat/
Iceland	http://ec.europa.eu/eurostat/
Norway	http://ec.europa.eu/eurostat/
Romania	http://ec.europa.eu/eurostat/
Serbia	http://ec.europa.eu/eurostat/
Slovenia	http://ec.europa.eu/eurostat/
Spain, Andalusia	http://www.ine.es/
Spain, Aragon	http://www.ine.es/
Spain, Asturias	http://www.ine.es/
Spain, Basque country	http://www.ine.es/
Spain, Cantabria	http://www.ine.es/
Spain, Castile and León	http://www.ine.es/
Spain, Castile-La Mancha	http://www.ine.es/
Spain, Catalonia	http://www.ine.es/
Spain, Extremadura	http://www.ine.es/
Spain, Galicia	http://www.ine.es/
Spain, Community of Madrid	http://www.ine.es/
Spain, Region of Murcia	http://www.ine.es/
Spain, Valencian region	http://www.ine.es/
Sweden	http://ec.europa.eu/eurostat/
The Netherlands	http://ec.europa.eu/eurostat/
United Kingdom, England/Northern Ireland/Wales	http://www.ons.gov.uk/
United Kingdom, Scotland	http://www.ons.gov.uk/

Table 3: The age and gender distribution of the reference population EU27 (2010)

Age groups	All	Men	Women
	N	N	N
0-4	26.395.042	13.538.482	12.856.560
5-9	25.671.423	13.164.757	12.506.666
10-14	26.227.258	13.447.626	12.779.632
15-19	28.871.932	14.799.902	14.072.030
20-24	31.748.967	16.165.507	15.583.460
25-29	33.637.765	17.036.136	16.601.629
30-34	34.721.373	17.582.565	17.138.808
35-39	36.330.818	18.323.844	18.006.974
40-44	37.936.179	19.089.702	18.846.477
45-49	36.959.424	18.442.336	18.517.088
50-54	34.559.527	17.057.371	17.502.156
55-59	32.008.654	15.585.644	16.423.010
60-64	28.943.516	13.927.064	15.016.452
65-69	24.005.279	11.254.363	12.750.916
70-74	21.947.335	9.832.684	12.114.651
75-79	17.793.563	7.435.782	10.357.781
80-84	12.919.229	4.816.223	8.103.006
85+	10.407.098	3.110.189	7.296.909
Total	501.084.382	244.610.177	256.474.205

Section B

Data collection

Section B relates to national registries from countries providing the ERA-EDTA Registry with aggregated data. Data were provided via a Microsoft Excel template and imported for inclusion in this annual report.

Collaborating registries

Aggregated data from 18 national registries are used for the preparation of the tables in Section B (see Figure 1). The following countries participated in Section B of this year's annual report: Albania, Bulgaria, Croatia, Cyprus, Czech Republic, Georgia, Israel, Latvia, Lithuania, Montenegro, Poland, Portugal, Russia, Slovakia, Spain, Switzerland, Turkey, and Ukraine.

Data from Spain are based on 18 of the 19 regions, including Andalusia, Aragon, Asturias, Balearic Islands, Basque country, Cantabria, Castile and León, Castile-La Mancha, Catalonia, Extremadura, Galicia, La Rioja, Community of Madrid, Region of Murcia, Navarre, Valencian region, and the overseas cities Ceuta and Melilla.

Data loading and cleaning

The Microsoft Excel templates used for data collection included automated consistency checks. Additional checks were performed manually.

General population data

The population data needed for the calculation of incidence rates and prevalence Pmp were reported by the collaborating registries.

Reference population

As in Section A, we used the age and gender distribution of the EU27 of 2010 (see Table 3) as provided by Eurostat for the adjustment of incidence rates and prevalence [1].

Definitions and coding systems

The definitions given below apply to both Section A and B.

Incidence and prevalence

Incidence is the number of new cases of a condition during a specific period of time which, in this annual report, is a year (2013). Prevalence is the number of people in a given population with a particular disease at a given time, in this annual report at December 31, 2013.

Primary cause of renal failure

Renal diseases were defined according to both the old and new (2012) ERA-EDTA coding systems and subsequently classified into groups (Appendix 1 and 2). When 2012 PRD codes were provided, those were categorized into the old groups, which resulted in a somewhat different distribution of PRD groups.

Causes of death

Causes of death were defined according to the ERA-EDTA coding systems and subsequently classified into groups (Appendix 3).

Treatment modalities

Appendix 4 provides an overview of the coding currently used for treatment modalities in the ERA-EDTA database.

Statistical analyses

An overview of the renal registries contributing data for the different types of analyses is given in Appendix 5.

For the data analyses SAS 9.3 and SAS 9.4 (only for competing risks analyses) [2] were used. This statistical software package is able to maintain large datasets, is syntax driven which increases reproducibility of results, and has extensive capabilities regarding statistics and data management.

Section A

Incidence and prevalence

The incidence and prevalence tables were based on 31 data sets from national or regional registries from 17 countries that provided individual patient data for 2013, including Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Bosnia and Herzegovina, Denmark, Estonia, Finland, France, Greece, Iceland, Norway, Romania, Serbia, Slovenia, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and León), Spain (Castile-La Mancha), Spain (Catalonia), Spain (Extremadura), Spain (Galicia), Spain (Community of Madrid), Spain (Region of Murcia), Spain (Valencian region), Sweden, The Netherlands, United Kingdom (England/Northern Ireland/Wales) and United Kingdom (Scotland).

Methods for calculating incidence and prevalence

Incidence and prevalence of those alive and on RRT were calculated for the total population and for subgroups based on gender, age group, treatment modality, and cause of renal failure. The incidence or prevalence Pmp is the observed incident or prevalent count divided by the general population in that year and multiplied by one million. For the incidence or prevalence per million age-related population (Pmarp) the observed incident or prevalent count per age category was divided by the general population in that age category and multiplied by one million.

For those registries that had no data available with a follow-up until March 31, 2014, the incidence of RRT on day 91 was estimated. We assumed that the relative difference between the incidence on day 1 and the incidence on day 91 was similar for patients who started RRT in the first nine months of 2013, when compared to patients who started RRT in the last three months of 2013.

For the calculation of the mean and median age for incident patients on day 91, we used the actual age on day 91.

Adjustment of incidence and prevalence

Differences in unadjusted incidence and prevalence across countries might be due to the differences in the age and gender distribution of the general population. The EU27 age and gender distribution of the European population was therefore used to adjust incidence and prevalence for age and gender [1]. Adjusted rates were derived by applying the weights of the reference population to the observed variable-specific rates (e.g. incidence rate per age group) in a country. This weighed average provides for each country a single summary rate that would be expected if that country had the age and gender distribution of the reference population. The following example shows how to calculate the age adjusted incidence. In this example the incidence rate of country A is 269 Pmp, the age-specific rates of country A and the reference population distribution with respect to age are shown in Table 4.

Table 4: Calculation of the adjusted incidence rate

Age groups	Incidence rate country A	Reference population
	Pmp	%
0-19	332	31.7
20-44	261	39.3
45-64	64	29.0
Total	269	100

The adjusted incident rate of country A is: $(0.317 * 332) + (0.393 * 261) + (0.29 * 64) = 226$ Pmp

Performed renal transplants

For all participating countries and regions the number of renal transplants performed during the year was presented by donor type. In Iceland the number of transplants was somewhat lower, because several patients received transplants in other countries. Rates are expressed as numbers, percentages and Pmp.

Survival probability

In this annual report, patient survival on RRT, patient survival on dialysis, patient survival after the first transplant, and graft survival after the first transplant are presented in tables by age, gender and cause of renal failure. In the figures, the patient survival is presented by treatment modality and by cause of renal failure. Survival probabilities are presented as percentages from 0 to 100.

Survival was analysed from day 1 and from day 91 onwards for those patients alive and on RRT on those days. For the analysis of survival data two five-year cohorts were used:

- 2004-2008 - for the presentation of 90-day, one-, two- and five-year survival probabilities.
- 2007-2011 - for the presentation of 90-day, one- and two-year survival probabilities.

These analyses were based on data from Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and León), Spain (Castile-La Mancha), Spain (Catalonia), Spain (Extremadura), Spain (Valencian region), Sweden, The Netherlands, United Kingdom (England/Wales/Northern Ireland) and United Kingdom (Scotland).

December 31, 2013 was applied as censoring date for all survival analyses. For the different types of survival analysis the events, competing events and censoring were defined as shown in Table 5.

Table 5: Overview of the events, competing events, and censoring as defined for the survival analyses in Section A

Survival type	Event	Competing event	Censoring
Patients on renal replacement therapy	Death of patient		Recovery of renal function * Loss to follow-up End of follow-up time
Patients on dialysis			
1)	Death of patient		Transplantation * Recovery of renal function * Loss to follow-up End of follow-up time
2)	Death of patient	Transplantation	Recovery of renal function * Loss to follow-up End of follow-up time
First transplant recipients	Death of patient		Loss to follow-up End of follow-up time
First graft	Death of patient Graft failure		Loss to follow-up End of follow-up time

* Only when a patients' renal function recovered for more than 30 days this was considered as a censored observation.

In this annual report we present cumulative survival probabilities (also indicated as "survival probabilities"). The cumulative survival probability is calculated as 100% minus the cumulative death probability. The cumulative death probabilities of patients on dialysis (Tables A.6.9-A.6.16) were calculated in two different ways (see also Table 5). First, it was calculated as an estimate of the so-called "marginal probability" or "net risk" using the Kaplan Meier method. Within these analyses transplantation is a censored observation. Second, it was calculated as an estimate of the so called "cause-specific probability" or "crude risk". Within these analyses transplantation was treated as a competing event, because in dialysis patients kidney transplantation is an event that competes with death.

When treating transplantation as a censored observation, we examine the patients's cumulative death probability that would be observed given the patient stays on dialysis, i.e. the patient would not stop dialysis due to a kidney transplant (the net risk). The main assumption in such analyses is that at any time the patients who are censored have the same survival prospects as those who are still being followed in the study. In other words, it assumes that censored individuals can be represented by those who remain at risk. Nevertheless, patients who are censored due to kidney transplantation may have a lower death risk than those remaining on dialysis, for example because they are younger. In that case, when censoring for kidney transplantation, this assumption of non-informative censoring is violated. However, this may be less of a problem if we stratify by age group or adjust for age, gender and primary diagnosis, because the assumption of non-informative censoring then only applies to individuals with the same value of these characteristics.

On the other hand, when treating transplantation as a competing event, we quantify the cumulative probability to die without having had a kidney transplant (the crude risk). The resulting probability does not only reflect the occurrence of death, but also takes into account the frequency of transplantation. If the probability to receive a kidney transplant is increased, the crude risk of death goes down. In other words, when treating transplantation as a competing event, the number of transplants performed in the period of interest (i.e. 90 days, 1-, 2- and 5 year) influences the death probabilities of patients while on dialysis [3,4].

Unadjusted survival probabilities

Unadjusted survival probabilities were calculated using the Kaplan-Meier method. Unadjusted survival probabilities of patients on dialysis were also calculated using cumulative incidence competing risk (CICR) method with transplantation as competing event [3]. In unadjusted survival analysis the cells in the tables were left blank when there were less than 30 patients in that cell.

Adjusted survival probabilities

The Cox regression model was used to calculate survival probabilities while accounting for confounders [5]. Adjusted survival probabilities of patients on dialysis were also calculated using the Fine and Gray method with transplantation as competing event [3]. Survival probabilities were adjusted for age, gender and primary renal disease. As the ERA-EDTA Registry database is still growing with respect to the coverage of European countries, it was decided to adjust for fixed values for a number of variables in the survival analyses to make results more comparable across time periods. The fixed values of variables used for the survival tables are shown in Table 6.

In the adjusted survival analyses, cells with less than 30 events were left empty. Patients for whom age, gender, or primary renal disease was missing were excluded.

Confidence intervals

When survival probabilities were calculated using the Kaplan-Meier method or Cox regression method, the corresponding confidence intervals were calculated according to Bie et al. [6], using the standard error. When survival probabilities were calculated by the cumulative incidence competing risk (CICR) method or Fine and Gray method, the corresponding confidence intervals were calculated using bootstrapping. Bootstrapping is a nonparametric method which involves resampling (with replacement) a given data set a specified number of times. Within our analyses we used 500 resamples, with each resample of the same size as the original dataset. The 500 calculated survival probabilities from each resample provided us with a bootstrap distribution of survival probabilities. Then the 95% confidence interval of the bootstrap distribution of survival probabilities was calculated as the interval between the 2.5% and 97.5% percentiles.

Survival figures

In the Figures A.6.1 to A.6.6 survival was adjusted for age 60 years and gender 60% men. In addition, Figure A.6.1 and Figure A.6.4 were adjusted for primary renal disease distribution: 20% Diabetes; 17% Hypertension / renal vascular disease; 15% Glomerulonephritis and 48% Other cause.

The differences between the survival probabilities of this annual report and survival probabilities published in earlier annual reports of the ERA-EDTA Registry may be partly due to differences in participating countries.

Table 6: Overview of the variables used to adjust the survival probabilities in Section A

Survival type	Age	Gender	Renal disease
Patients on renal replacement therapy	60 years	60% men	20% Diabetes 17% Hypertension / renal vascular disease 15% Glomerulonephritis 48% Other cause
Patients on dialysis	60 years	60% men	20% Diabetes 17% Hypertension / renal vascular disease 15% Glomerulonephritis 48% Other cause
First transplant recipients (deceased donor)	45 years	60% men	10% Diabetes 8% Hypertension / renal vascular disease 28% Glomerulonephritis 54% Other cause
First transplant recipients (living donor)	45 years	60% men	10% Diabetes 8% Hypertension / renal vascular disease 28% Glomerulonephritis 54% Other cause
First graft (deceased donor)	45 years	60% men	10% Diabetes 8% Hypertension / renal vascular disease 28% Glomerulonephritis 54% Other cause
First graft (living donor)	45 years	60% men	10% Diabetes 8% Hypertension / renal vascular disease 28% Glomerulonephritis 54% Other cause

Expected remaining lifetimes

Expected remaining lifetimes represent the average number of years of life remaining for persons who have reached a given age. In this annual report, expected remaining lifetimes were calculated for RRT patients and for the general population. For the calculation of expected remaining lifetimes of both groups, the methodology of the United States Renal Data System (USRDS) was adopted [7].

To be able to calculate expected remaining lifetimes we used data from registries providing data from 2002 until 2013. Consequently, the data of the following national or regional registries from 11 countries were suitable for this analysis: Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castille and León), Spain (Catalonia), Spain (Valencian region), Sweden, The Netherlands, United Kingdom (England/Wales) and United Kingdom (Scotland). With regard to the inclusion of the data, it should be noted that the differences between the expected remaining lifetimes of this annual report and expected remaining lifetimes published in earlier annual reports of the ERA-EDTA Registry may be partly due to differences in participating countries.

RRT population

The expected remaining lifetimes for RRT patients are presented by age, gender and treatment modality. The expected remaining lifetime for a certain patient group is the average of the remaining life expectancies for the patients in that group. Although this can not be known until all the patients in the group have died, the expected remaining lifetime can be projected by assuming that patients in the patient group will die at the same rates as those observed among older groups of recent prevalent RRT patients.

General population

The death rates Pmp by gender and age of the general population of the contributing countries were provided by Eurostat (based on EU27 in 2010). The size of the contribution of each country to the general population that was used to calculate expected remaining lifetimes was in proportion to the size of the general population covered by its renal registry.

Section B

Incidence and prevalence counts were provided by the contributing registries themselves. To increase the consistency of the data, general explanations of how to complete the Microsoft Excel template and how to calculate adjusted incidence and prevalence counts were provided to support the participating registries.

Paediatric Section

The incidence and prevalence tables were based on data from 25 national or regional registries from 16 countries that provided complete individual patient data in their paediatric population for 2004 to 2013, including Austria, Bosnia and Herzegovina, Denmark, Estonia, Finland, France, Greece, Iceland, Norway, Romania, Serbia, Slovenia, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Catalonia), Spain (Extremadura), Spain (Galicia), Spain (community of Madrid), Spain (Region of Murcia), Spain (Valencian region), Sweden, The Netherlands, and United Kingdom (Scotland). France (coverage from 76.6% in 2006 to 100% in 2012), Romania and Spain (Aragon, Extremadura) provided data since 2006, Spain (Galicia) since 2007, Slovenia and Spain (Community of Madrid) since 2008, Bosnia and Herzegovina and Serbia since 2011, Spain (Region of Murcia) since 2012, and Estonia since 2013. Furthermore, as not every region in Spain had a specialised paediatric centre, paediatric patients could be treated in other regions than their resident region. This would result in an underestimation of the incidence and prevalence in these regions. To adjust for this, non-resident paediatric patients were not excluded in the paediatric section.

Incidence (on day 1) and prevalence on RRT were calculated for subgroups based on age, treatment modality, and cause of renal failure. Incidence on RRT by 2-year cohorts was presented for paediatric patients who started RRT between 2004 and 2013. The cohorts 2008-2009, 2010-2011 and 2012-2013 were presented twice, once including and once excluding the countries with a limited follow-up to allow for a comparison over time. The incidence on RRT Pmarp was the observed incident count in that particular time period divided by the age-related general population in that time period (for example the total population in 2012 + the total population in 2013) multiplied by one million. The grouping of primary renal disease codes for the paediatric population is described in Table P.1.2 as it differs from the grouping in the adult population.

The prevalence on RRT was presented at December 31 of each year from 2007 to 2013 and were presented twice, once including and once excluding the above mentioned countries and periods to allow for a comparison over time. The prevalence on RRT by cause of renal failure was calculated for patients prevalent on December 31, 2013.

Bibliography

- 1) Eurostat: <http://ec.europa.eu/eurostat/data/database>.
- 2) SAS Institute Inc., Cary, NC, USA.
- 3) Noordzij M, Leffondré K, van Stralen KJ, Zoccali C, Dekker FW, Jager KJ. When do we need competing risks methods for survival analysis in nephrology? *Nephrol Dial Transplant*. 2013 Nov; 28 :2670-2677.
- 4) Wolbers M, Koller MT, Stel VS, Schaer B, Jager KJ, Leffondré K, Heinze G. Competing risks analyses: objectives and approaches.
- 5) Altman, D. *Practical statistics for medical research*. second ed. 1999, London: Chapman & Hall.
- 6) Bie O, Borgan O and Liestol K. Confidence intervals and confidence bands for the cumulative hazard rate function and their small sample properties. *Scandinavian Journal of Statistics* 1987; 14: 221-233.
- 7) U.S. Renal Data System, *USRDS 2012 Annual Data Report: Atlas of End-Stage Renal Disease in the United States*, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2012.

VII Appendices

Appendix 1 - Grouping of primary renal diseases

1994 code	1995 code	PRD group	Primary renal disease
10	10	I	Glomerulonephritis; histologically NOT examined
11	11	I	Focal segmental glomerulosclerosis with nephrotic syndrome in children
12	12	I	IgA nephropathy (proven by immunofluorescence, not code 76 or 85)
13	13	I	Dense deposit disease; membrano-proliferative GN; type II (proven by immunofluorescence / electron microscopy)
14	14	I	Membranous nephropathy
15	15	I	Membrano-proliferative GN; type I (proven by immunofluorescence / electron microscopy, not code 84 or 89)
16	16	I	Crescentic (extracapillary) glomerulonephritis (type I, II, III)
17	17	I	Focal segmental glomerulosclerosis with nephrotic syndrome in adults
19	19	I	Glomerulonephritis; histologically examined, not given above
20	20	II	Pyelonephritis; cause not specified
21	21	II	Pyelonephritis associated with neurogenic bladder
22	22	II	Pyelonephritis due to congenital obstructive uropathy with/without vesico-ureteric reflux
23	23	II	Pyelonephritis due to acquired obstructive uropathy
24	24	II	Pyelonephritis due to vesico-ureteric reflux without obstruction
25	25	II	Pyelonephritis due to urolithiasis
29	29	II	Pyelonephritis due to other cause
30	30	VII	Interstitial nephritis (not pyelonephritis) due to other cause, or unspecified (not mentioned above)
31	31	VII	Nephropathy (interstitial) due to analgesic drugs
32	32	VII	Nephropathy (interstitial) due to cis-platinum
33	33	VII	Nephropathy (interstitial) due to cyclosporin A
	34	VII	Lead induced nephropathy (interstitial)
39	39	VII	Drug induced nephropathy (interstitial) not mentioned above
40	40	VII	Cystic kidney disease - type unspecified
41	41	III	Polycystic kidneys; adult type (dominant)
42	42	VII	Polycystic kidneys; infantile (recessive)
43	43	VII	Medullary cystic disease; including nephronophthisis
49	49	VII	Cystic kidney disease - other specified type
50	50	VII	Hereditary / Familial nephropathy - type unspecified
51	51	VII	Hereditary nephritis with nerve deafness (Alport's Syndrome)
52	52	VII	Cystinosis
53	53	VII	Primary oxalosis
54	54	VII	Fabry's disease
59	59	VII	Hereditary nephropathy - other specified type
60	60	VII	Renal hypoplasia (congenital) - type unspecified
61	61	VII	Oligomeganephronic hypoplasia
63	63	VII	Congenital renal dysplasia with or without urinary tract malformation
66	66	VII	Syndrome of agenesis of abdominal muscles (Prune Belly)
70	70	V	Renal vascular disease - type unspecified
71	71	IV	Renal vascular disease due to malignant hypertension
72	72	IV	Renal vascular disease due to hypertension
73	73	VII	Renal vascular disease due to polyarteritis
74	74	VII	Wegener's granulomatosis
	75	VII	Ischaemic renal disease/cholesterol embolism (1998 prd code)
76	76	VII	Glomerulonephritis related to liver cirrhosis
	78	VII	Cryoglobulinaemic glomerulonephritis
79	79	V	Renal vascular disease - due to other cause (not given above and not code 84-88)
80	80	VI	Diabetes glomerulosclerosis or diabetic nephropathy - Type I
81	80	VI	Diabetes glomerulosclerosis or diabetic nephropathy - Type II
82	82	VII	Myelomatosis / light chain deposit disease
83	83	VII	Amyloid
84	84	VII	Lupus erythematosus
85	85	VII	Henoch-Schoenlein purpura
86	86	VII	Goodpasture's Syndrome
87	87	VII	Systemic sclerosis (scleroderma)
88	88	VII	Haemolytic Uraemic Syndrome (including Moschowitz Syndrome)
89	89	VII	Multi-system disease - other (not mentioned above)
90	90	VII	Tubular necrosis (irreversible) or cortical necrosis (different from 88)
91	91	VII	Tuberculosis
92	92	VII	Gout
93	93	VII	Nephrocalcinosis and hypercalcaemic nephropathy
94	94	VII	Balkan nephropathy
95	95	VII	Kidney tumour
96	96	VII	Traumatic or surgical loss of kidney
99	99	VII	Other identified renal disorders
00	00	VIII	Chronic renal failure; aetiology uncertain

PRD group: I: glomerulonephritis / sclerosis; II: pyelonephritis; III: polycystic kidneys, adult type; IV: hypertension; V: renal vascular disease; VI: diabetes; VII: miscellaneous; VIII: unknown

Appendix 2 - Grouping of primary renal disease codes 2012

I: GLOMERULAR DISEASE

Code Primary renal disease

1003	Adult nephrotic syndrome - no histology
1472	Anti-Glomerular basement membrane (GBM) disease / Goodpasture's syndrome - histologically proven
1464	Anti-Glomerular basement membrane (GBM) disease / Goodpasture's syndrome - no histology
1440	Churg-Strauss syndrome - histologically proven
1438	Churg-Strauss syndrome - no histology
1088	Congenital nephrotic syndrome (CNS) - congenital infection
1057	Congenital nephrotic syndrome (CNS) - diffuse mesangial sclerosis
1042	Congenital nephrotic syndrome (CNS) - Finnish type - histologically proven
1035	Congenital nephrotic syndrome (CNS) - Finnish type - no histology
1061	Congenital nephrotic syndrome (CNS) - focal segmental glomerulosclerosis (FSGS)
1026	Congenital nephrotic syndrome (CNS) - no histology
1570	Cryoglobulinaemia secondary to hepatitis C - histologically proven
1562	Cryoglobulinaemia secondary to hepatitis C - no histology
1591	Cryoglobulinaemia secondary to systemic disease - histologically proven
1589	Cryoglobulinaemia secondary to systemic disease - no histology
1074	Denys-Drash syndrome
1331	Diffuse endocapillary glomerulonephritis
1558	Essential mixed cryoglobulinaemia - histologically proven
1543	Essential mixed cryoglobulinaemia - no histology
1308	Familial focal segmental glomerulosclerosis (FSGS) - autosomal dominant - histologically proven
1298	Familial focal segmental glomerulosclerosis (FSGS) - autosomal dominant - no histology
1280	Familial focal segmental glomerulosclerosis (FSGS) - autosomal recessive - histologically proven
1279	Familial focal segmental glomerulosclerosis (FSGS) - autosomal recessive - no histology
1144	Familial IgA nephropathy - histologically proven
1137	Familial IgA nephropathy - no histology
1354	Focal and segmental proliferative glomerulonephritis
1320	Focal segmental glomerulosclerosis (FSGS) secondary to obesity - histologically proven
1312	Focal segmental glomerulosclerosis (FSGS) secondary to obesity - no histology
1377	Glomerulonephritis - histologically indeterminate
3749	Glomerulonephritis - no histology
1365	Glomerulonephritis - secondary to other systemic disease
1417	Granulomatosis with polyangiitis - histologically proven
1401	Granulomatosis with polyangiitis - no histology
1515	Henoch-Schönlein purpura / nephritis - histologically proven
1504	Henoch-Schönlein purpura / nephritis - no histology
1251	Idiopathic rapidly progressive (crescentic) glomerulonephritis
1128	IgA nephropathy - histologically proven
1116	IgA nephropathy - no histology
1163	IgA nephropathy secondary to liver cirrhosis - histologically proven
1159	IgA nephropathy secondary to liver cirrhosis - no histology
1171	IgM - associated nephropathy
1205	Membranous nephropathy - drug induced
1185	Membranous nephropathy - idiopathic
1214	Membranous nephropathy - infection associated
1192	Membranous nephropathy - malignancy associated
1349	Mesangial proliferative glomerulonephritis
1222	Mesangiocapillary glomerulonephritis type 1
1233	Mesangiocapillary glomerulonephritis type 2 (dense deposit disease)
1246	Mesangiocapillary glomerulonephritis type 3
1429	Microscopic polyangiitis - histologically proven
1100	Minimal change nephropathy - histologically proven
1090	Minimal change nephropathy - no histology
3615	Nephrotic syndrome of childhood - no trial of steroids - no histology
3604	Nephrotic syndrome of childhood - steroid resistant - no histology
1019	Nephrotic syndrome of childhood - steroid sensitive - no histology
1455	Polyarteritis nodosa
1267	Primary focal segmental glomerulosclerosis (FSGS)
1536	Renal scleroderma / systemic sclerosis - histologically proven
1527	Renal scleroderma / systemic sclerosis - no histology
1493	Systemic lupus erythematosus / nephritis - histologically proven
1486	Systemic lupus erythematosus / nephritis - no histology
1383	Systemic vasculitis - ANCA negative - histologically proven
1396	Systemic vasculitis - ANCA positive - no histology

II: TUBULOINTERSTITIAL DISEASE**Code Primary renal disease**

1768	Acquired obstructive nephropathy due to neurogenic bladder
1752	Acquired obstructive uropathy / nephropathy
2196	Acute urate nephropathy - histologically proven
2183	Acute urate nephropathy - no histology
1995	Aristolochic acid nephropathy (Balkan / Chinese herb / endemic nephropathy) - histologically proven
1982	Aristolochic acid nephropathy (Balkan / Chinese herb / endemic nephropathy) - no histology
1710	Bladder exstrophy
1845	Calcium oxalate urolithiasis
1832	Calculus nephropathy / urolithiasis
2203	Chronic urate nephropathy - histologically proven
3636	Chronic urate nephropathy - no histology
1625	Congenital dysplasia / hypoplasia
1706	Congenital neurogenic bladder
1660	Congenital pelvi-ureteric junction obstruction
1673	Congenital vesico-ureteric junction obstruction
2014	Drug-induced tubulointerstitial nephritis - histologically proven
2005	Drug-induced tubulointerstitial nephritis - no histology
1641	Dysplasia due to fetal ACE-inhibitor exposure
1850	Enteric hyperoxaluria
1911	Familial interstitial nephropathy - histologically proven
1907	Familial interstitial nephropathy - no histology
1618	Familial reflux nephropathy
1656	Glomerulocystic disease
2257	Hantavirus nephropathy
3662	Hypercalcaemic nephropathy
1813	Idiopathic retroperitoneal fibrosis
2177	Lead induced nephropathy - histologically proven
2165	Lead induced nephropathy - no histology
2242	Leptospirosis
1866	Magnesium ammonium phosphate (struvite) urolithiasis
1723	Megacystis-megaureter
1639	Multicystic dysplastic kidneys
2098	Nephropathy due to aminoglycosides - histologically proven
2080	Nephropathy due to aminoglycosides - no histology
2112	Nephropathy due to amphotericin - histologically proven
2108	Nephropathy due to amphotericin - no histology
2033	Nephropathy due to analgesic drugs - histologically proven
2022	Nephropathy due to analgesic drugs - no histology
2051	Nephropathy due to ciclosporin - histologically proven
2046	Nephropathy due to ciclosporin - no histology
2131	Nephropathy due to cisplatin - histologically proven
2120	Nephropathy due to cisplatin - no histology
2154	Nephropathy due to lithium - histologically proven
2149	Nephropathy due to lithium - no histology
2079	Nephropathy due to tacrolimus - histologically proven
2067	Nephropathy due to tacrolimus - no histology
2288	Nephropathy related to HIV - histologically proven
2274	Nephropathy related to HIV - no histology
1799	Obstructive nephropathy due to bladder cancer
1809	Obstructive nephropathy due to other malignancies
1781	Obstructive nephropathy due to prostate cancer
1775	Obstructive nephropathy due to prostatic hypertrophy
1734	Oligomeganephronia
2300	Other specific infection
1687	Posterior urethral valves
1602	Primary reflux nephropathy - sporadic
2219	Radiation nephritis
2226	Renal / perinephric abscess
3627	Renal cysts and diabetes syndrome
1747	Renal papillary necrosis - cause unknown
1976	Renal sarcoidosis - histologically proven
1969	Renal sarcoidosis - no histology
2235	Renal tuberculosis
3689	Retroperitoneal fibrosis secondary to drugs
1821	Retroperitoneal fibrosis secondary to malignancies
3670	Retroperitoneal fibrosis secondary to peri-aortitis
2290	Schistosomiasis
1694	Syndrome of agenesis of abdominal muscles - prune belly syndrome
1897	Tubulointerstitial nephritis - histologically proven

II: TUBULOINTERSTITIAL DISEASE (continued)**Code Primary renal disease**

1884	Tubulointerstitial nephritis - no histology
1930	Tubulointerstitial nephritis associated with autoimmune disease - histologically proven
1924	Tubulointerstitial nephritis associated with autoimmune disease - no histology
1953	Tubulointerstitial nephritis with uveitis (TINU) - histologically proven
1948	Tubulointerstitial nephritis with uveitis (TINU) - no histology
1878	Uric acid urolithiasis
2261	Xanthogranulomatous pyelonephritis

III: SYSTEMIC DISEASE AFFECTING THE KIDNEY**Code Primary renal disease**

2513	AA amyloid secondary to chronic inflammation
2392	Ageing kidney - no histology
2521	AL amyloid secondary to plasma cell dyscrasia
2448	Atheroembolic renal disease - histologically proven
2430	Atheroembolic renal disease - no histology
2623	Atypical haemolytic uraemic syndrome (HUS) - diarrhoea negative
2482	Cardiorenal syndrome
2363	Chronic hypertensive nephropathy - histologically proven
2359	Chronic hypertensive nephropathy - no histology
2652	Congenital haemolytic uraemic syndrome (HUS)
2328	Diabetic nephropathy in type I diabetes - histologically proven
2316	Diabetic nephropathy in type I diabetes - no histology
2344	Diabetic nephropathy in type II diabetes - histologically proven
2337	Diabetic nephropathy in type II diabetes - no histology
2566	Familial AA amyloid secondary to familial Mediterranean fever / TRAPS (Hibernian fever) - histologically proven
2550	Familial AA amyloid secondary to familial Mediterranean fever / TRAPS (Hibernian fever) - no histology
2545	Familial amyloid secondary to protein mutations - histologically proven
2532	Familial amyloid secondary to protein mutations - no histology
2668	Familial haemolytic uraemic syndrome (HUS)
2675	Familial thrombotic thrombocytopenic purpura (TTP)
2453	Fibromuscular dysplasia of renal artery
2610	Haemolytic uraemic syndrome (HUS) - diarrhoea associated
2647	Haemolytic uraemic syndrome (HUS) secondary to systemic disease
2495	Hepatorenal syndrome
2606	Immunotactoid / fibrillary nephropathy
2407	Ischaemic nephropathy - no histology
2411	Ischaemic nephropathy / microvascular disease - histologically proven
2597	Light chain deposition disease
2385	Malignant hypertensive nephropathy / accelerated hypertension nephropathy - histologically proven
2371	Malignant hypertensive nephropathy / accelerated hypertension nephropathy - no histology
2584	Myeloma cast nephropathy - histologically proven
2578	Myeloma kidney - no histology
2681	Nephropathy due to pre-eclampsia / eclampsia
2509	Renal amyloidosis
2469	Renal arterial thrombosis / occlusion
2424	Renal artery stenosis
2476	Renal vein thrombosis
2702	Sickle cell nephropathy - histologically proven
2699	Sickle cell nephropathy - no histology
2634	Thrombotic thrombocytopenic purpura (TTP)

IV: FAMILIAL / HEREDITARY NEPHROPATHIES**Code Primary renal disease**

3071	Alagille syndrome
2760	Alport syndrome - histologically proven
2756	Alport syndrome - no histology
3118	Apparent mineralocorticoid excess
2718	Autosomal dominant (AD) polycystic kidney disease
2725	Autosomal dominant (AD) polycystic kidney disease type I
2739	Autosomal dominant (AD) polycystic kidney disease type II
2741	Autosomal recessive (AR) polycystic kidney disease
3085	Bartter syndrome
2773	Benign familial haematuria
3322	Branchio-oto-renal syndrome
2794	Cystic kidney disease
2964	Cystinosis

IV: FAMILIAL / HEREDITARY NEPHROPATHIES (continued)**Code Primary renal disease**

2955	Cystinuria
2929	Dent disease
3028	Distal renal tubular acidosis (RTA) - type I
3037	Distal renal tubular acidosis with sensorineural deafness - gene mutations
3230	Fabry disease - histologically proven
3224	Fabry disease - no histology
3173	Familial hypercalciuric hypocalcaemia
3160	Familial hypocalciuric hypercalcaemia
3187	Familial hypomagnesaemia
3379	Familial nephropathy
3314	Frasier syndrome
3092	Gitelman syndrome
3125	Glucocorticoid suppressible hyperaldosteronism
3305	Horse-shoe kidney
2993	Hypophosphataemic rickets autosomal recessive (AR)
2986	Hypophosphataemic rickets X-linked (XL)
3139	Inherited / genetic diabetes mellitus type II
2940	Inherited aminoaciduria
2972	Inherited renal glycosuria
3351	Lawrence-Moon-Biedl / Bardet-Biedl syndrome
3059	Lesch Nyhan syndrome - hypoxanthine guanine phosphoribosyl transferase deficiency
3102	Liddle syndrome
2938	Lowe syndrome (oculocerebrorenal syndrome)
2804	Medullary cystic kidney disease type I
2815	Medullary cystic kidney disease type II
3295	Medullary sponge kidneys
3367	Mitochondrial cytopathy
3253	Nail-patella syndrome
3044	Nephrogenic diabetes insipidus
2836	Nephronophthisis
2843	Nephronophthisis - type 1 (juvenile type)
2858	Nephronophthisis - type 2 (infantile type)
2862	Nephronophthisis - type 3 (adolescent type)
2870	Nephronophthisis - type 4 (juvenile type)
2889	Nephronophthisis - type 5
2891	Nephronophthisis - type 6
3063	Phosphoribosyl pyrophosphate synthetase (PRPPS) superactivity
2901	Primary Fanconi syndrome
3194	Primary hyperoxaluria
3207	Primary hyperoxaluria type I
3211	Primary hyperoxaluria type II
3731	Primary hyperoxaluria type III
3000	Primary renal tubular acidosis (RTA)
3016	Proximal renal tubular acidosis (RTA) - type II
3141	Pseudohypoaldosteronism type 1
3156	Pseudohypoaldosteronism type 2 (Gordon syndrome)
3658	Renal coloboma syndrome
3269	Rubinstein-Taybi syndrome
2787	Thin basement membrane disease
3346	Townes-Brocks syndrome
3276	Tuberous sclerosis
2917	Tubular disorder as part of inherited metabolic diseases
2827	Uromodulin-associated nephropathy (familial juvenile hyperuricaemic nephropathy)
3282	von Hippel-Lindau disease
3333	Williams syndrome
3248	Xanthinuria

V: MISCELLANEOUS RENAL DISORDERS**Code Primary renal disease**

3442	Acute cortical necrosis
3380	Acute kidney injury
3403	Acute kidney injury due to circulatory failure
3398	Acute kidney injury due to hypovolaemia
3435	Acute kidney injury due to nephrotoxicity
3426	Acute kidney injury due to rhabdomyolysis
3419	Acute kidney injury due to sepsis
3457	Acute pyelonephritis

V: MISCELLANEOUS RENAL DISORDERS (continued)**Code Primary renal disease**

3564	Chronic kidney disease (CKD) / chronic renal failure (CRF) - aetiology uncertain / unknown - histologically proven
3555	Chronic kidney disease (CKD) / chronic renal failure (CRF) - aetiology uncertain / unknown - no histology
3529	Chronic kidney disease (CKD) / chronic renal failure (CRF) caused by tumour nephrectomy
3540	Chronic kidney disease (CKD) / chronic renal failure (CRF) due to donor nephrectomy
3538	Chronic kidney disease (CKD) / chronic renal failure (CRF) due to traumatic loss of kidney
3708	Chronic renal failure
3643	Chronic renal failure due to systemic infection
3572	Haematuria and proteinuria - no histology
3712	Isolated haematuria - no histology
3720	Isolated proteinuria - no histology
3461	Kidney tumour
3501	Mesoblastic nephroma - histologically proven
3474	Renal cell carcinoma - histologically proven
3691	Renal failure
3517	Single kidney identified in adulthood
3488	Transitional cell carcinoma - histologically proven
3490	Wilms tumour - histologically proven

Appendix 3 - Grouping of causes of death

1994 code	1995 code	COD group	Cause of death
0	0	XI	Cause of death uncertain / not determined
11	11	I	Myocardial ischaemia and infarction
12	12	X	Hyperkalaemia
13	13	X	Haemorrhagic pericarditis
14	14	II	Other causes of cardiac failure
15	15	III	Cardiac arrest / sudden death; other cause or unknown
16	16	II	Hypertensive cardiac failure
17	17	X	Hypokalaemia
18	18	II	Fluid overload / pulmonary oedema
21	21	X	Pulmonary embolus
22	22	IV	Cerebro-vascular accident, other cause or unspecified
23	23	X	Gastro-intestinal haemorrhage
24	24	X	Haemorrhage from graft site
25	25	X	Haemorrhage from vascular access or dialysis circuit
26	26	X	Haemorrhage from ruptured vascular aneurysm (not code 22 or 23)
27	27	X	Haemorrhage from surgery (not code 23, 24 or 26)
28	28	X	Other haemorrhage (not codes 23-27)
29	29	X	Mesenteric infarction
31	31	V	Pulmonary infection (bacterial - not code 73)
32	32	V	Pulmonary infection (viral)
33	33	V	Pulmonary infection (fungal or protozoal; parasitic)
34		V	Infections elsewhere except virus hepatitis
35	35	V	Septicaemia
36	36	V	Tuberculosis (lung)
37	37	V	Tuberculosis (elsewhere)
38	38	V	Generalized viral infection
39	39	V	Peritonitis (all causes except for Peritoneal Dialysis)
41	41	X	Liver disease due to hepatitis B virus
42	42	X	Liver disease due to other viral hepatitis
43	43	X	Liver disease due to drug toxicity
44	44	X	Cirrhosis - not viral
45	45	X	Cystic liver disease
46	46	X	Liver failure - cause unknown
51	51	VI	Patient refused further treatment for ESRF
52	52	VI	Suicide
53	53	VII	ESRF treatment ceased for any other reason
	54	VII	ESRF treatment withdrawn for medical reasons
61		X	Uremia caused by graft failure
62	62	X	Pancreatitis
63	63	X	Bone marrow depression
64	64	VIII	Cachexia
66	66	IX	Malignant disease, possibly induced by immunosuppressive therapy
67	67	IX	Malignant disease: solid tumors except those of 66
	68	IX	Malignant disease: lymphoproliferative disorders except those of 66
69	69	X	Dementia
70	70	V	Peritonitis (sclerosing, with peritoneal dialysis)
71	71	X	Perforation of peptic ulcer
72	72	X	Perforation of colon
73	73	X	Chronic obstructive airways disease
81	81	X	Accident related to ESRF treatment (not code 25)
82	82	X	Accident unrelated to ESRF treatment
	100	V	Peritonitis (bacterial, with peritoneal dialysis)
	101	V	Peritonitis (fungal, with peritoneal dialysis)
	102	V	Peritonitis (due to other cause, with peritoneal dialysis)
99	99	X	Other identified cause of death

COD group: I: myocardial ischaemia and infarction; II: heart failure; III: cardiac arrest, other cause / unknown; IV: cerebrovascular accident; V: infection; VI: suicide / refusal treatment; VII: withdrawal; VIII: cachexia; IX: malignancies; X: miscellaneous; XI: unknown / unavailable

Appendix 4 - Treatment modalities

Event code

001	Home haemodialysis
002	Centre haemodialysis
003	Haemofiltration
004	Haemodiafiltration
009	Haemodialysis, type unknown
011	Continuous Ambulatory Peritoneal Dialysis (CAPD)
012	Intermittent Ambulatory Peritoneal Dialysis (CAPD)
013	Continuous Automated Peritoneal Dialysis (APD)
014	Intermittent Automated Peritoneal Dialysis (APD)
019	Peritoneal Dialysis, type unknown
090	Unknown dialysis
020	Transplantation, living donor
021	Transplantation, living related donor
022	Transplantation, living unrelated donor
023	Transplantation, deceased donor
029	Transplantation, donor type unknown
060	Transplantation follow-up (still functioning)
061	Graft failure
031	Treatment type unknown / unavailable
051	Recovery Renal Function
052	Death
053	Transfer out to other registry
054	Transfer in from other registry
055	Lost to follow-up
071	Limited care / stopped treatment (without recovery of renal function)

Appendix 5 - Renal registries contributing data for the different types of analyses

	Section A Individual patient data			Section B Aggregated data	Section Paediatric RRT Individual patient data
	Incidence and prevalence	Survival	Expected remaining lifetimes	Incidence and prevalence	Incidence and prevalence
Albania	-	-	-	+	-
Austria	+	+	+	-	+
Belgium, Dutch-speaking	+	+	+	-	-
Belgium, French-speaking	+	+	+	-	-
Bosnia and Herzegovina	+	-	-	-	+
Bulgaria	-	-	-	+	-
Croatia	-	-	-	+	-
Cyprus	-	-	-	+	-
Czech Republic	-	-	-	+	-
Denmark	+	+	+	-	+
Estonia	+	-	-	-	+
Finland	+	+	+	-	+
France	+	-	-	-	+
Georgia	-	-	-	+	-
Greece	+	+	+	-	+
Iceland	+	+	+	-	+
Israel	-	-	-	+	-
Latvia	-	-	-	+	-
Lithuania	-	-	-	+	-
Montenegro	-	-	-	+	-
Norway	+	+	+	-	+
Poland	-	-	-	+	-
Portugal	-	-	-	+	-
Romania	+	-	-	-	+
Russia	-	-	-	+	-
Serbia	+	-	-	-	+
Slovakia	-	-	-	+	-
Slovenia	+	-	-	-	+
Spain, Andalusia	+	+	+	+	+
Spain, Aragon	+	+	+	+	+
Spain, Asturias	+	+	+	+	+
Spain, Balearic Islands	-	-	-	+	-
Spain, Basque country	+	+	+	+	+
Spain, Cantabria	+	+	+	+	-
Spain, Castile and León	+	+	+	+	-
Spain, Castile-La Mancha	+	+	-	+	-
Spain, Catalonia	+	+	+	+	+
Spain, Ceuta	-	-	-	+	-
Spain, Community of Madrid	+	-	-	+	+
Spain, Extremadura	+	+	-	+	+
Spain, Galicia	+	-	-	+	+
Spain, La Rioja	-	-	-	+	-
Spain, Melilla	-	-	-	+	-
Spain, Navarre	-	-	-	+	-
Spain, Region of Murcia	+	-	-	+	+
Spain, Valencian region	+	+	+	+	+
Sweden	+	+	+	-	+
Switzerland	-	-	-	+	-
The Netherlands	+	+	+	-	+
Turkey	-	-	-	+	-
Ukraine	-	-	-	+	-
United Kingdom, England	+	+	+	-	-
United Kingdom, Northern Ireland	+	+	-	-	-
United Kingdom, Scotland	+	+	+	-	+
United Kingdom, Wales	+	+	+	-	-

www.era-edta-reg.org

ERA-EDTA Registry
Academic Medical Center
Department of Medical Informatics
PO Box 22700
1100 DE Amsterdam
The Netherlands

ISBN 978-90-817480-5-6

June 2015

